


CURRICULUM VITAE

A handwritten signature in black ink on a light gray rectangular background. The signature reads "Paul A. Bunn, Jr., M.D." in a cursive script.

Paul A. Bunn, JR, MD, FASCO
August 2019

PERSONAL DATA

Paul A. Bunn, JR, M.D., FASCO

Distinguished Professor
University of Colorado School of Medicine (UCSOM)
Department of Medicine
Division of Medical Oncology
Lung Cancer Research
Mail Stop 8117, 12801 East 17th Avenue, Room 8102
Aurora, CO 80045
Telephone: 303-724-4498; Fax: 303-724-3889
E-mail: Paul.Bunn@UCDenver.edu

Citizenship: United States
Marital Status: Divorced
Children: Three

EDUCATION AND TRAINING

1967	B.A. Amherst College, Amherst, Mass. (cum laude)
1971	Medical Degree Cornell University Medical Center, New York, NY
1971-1972	Medical Internship University of California, San Francisco, CA, H.C. Moffitt Hospital
1972-1973	Medical Residency University of California, San Francisco, CA, H.C. Moffitt Hospital

MILITARY SERVICE

1973-1984	U.S. Public Health Service
-----------	----------------------------

ACADEMIC APPOINTMENTS AND LEADERSHIP POSITIONS

1973-1976	Clinical Associate Medicine Branch National Cancer Institute, National Institute of Health, Bethesda, MD
1976-1981	Senior Investigator Medical Oncology Branch National Cancer Institute, Washington VA Hospital, Washington, D.C.
1978-1981	Assistant Professor of Medicine Georgetown University Medical School, Washington D.C.
1981-1984	Head Cell Kinetic Section, Navy Medical Oncology Branch National Cancer Institute, Bethesda, MD
1981-1984	Associate Professor of Medicine Uniformed Services University of Health Sciences, Bethesda, MD
1984-1994	Head, Division of Medical Oncology University of Colorado Health Sciences Center, Denver, CO

FASCO

1987-2009	Director, University of Colorado Cancer Center, Denver, CO
1996-1999	Acting Chairman Department of Radiation Oncology University of Colorado Health Sciences Center, Denver, CO
1998-2006	Grohne/Stapp endowed Chair of Cancer Research
2003-2013	Executive Director International Association for the Study of Lung Cancer
2004-2006	Acting Division Head Division of Medical Oncology
1984-present	Professor of Medicine University of Colorado Health Sciences Center, Denver, CO
2005-present	Fellow of the American Society of Clinical Oncology
2006-present	James Dudley endowed Professor of Lung Cancer
2013-present	Distinguished Professor University of Colorado Health Sciences Center, Denver, CO

HONORS, SPECIAL RECOGNITIONS, AND AWARDS

1967	Howard Hill Mossman Award, Amherst College
1971	Alpha Omega Alpha, Cornell University Medical College
1971	Sondra Lee Shaw Research Award, Cornell University Medical College
1984	PHS Medal of Commendation
1988	Commonwealth of Kentucky, Kentucky Colonel Award
1992	Scientist of the Year Award, ARCS - Denver Chapter
1996	UCHSC Faculty Council, Award for Excellence
1998	James F. Mitchell-Paul C. Kieman Foundation Scholar Award
2001	James Addison Sewall Award, University of Colorado
2002	American Italian Cancer Research Foundation Award
2003	IASLC Merit Award
2004	SPORE Outstanding Leadership Award
2004	Claude Jacquillat Award
2006	American Association for the Advancement of Science Fellow
2008	Colorado Pulmonary Hall of Fame
2008	Australian Lung Foundation Life Achievement Award
2008	Inventor of the Year Award, UCD Technology Transfer
2012	University of Colorado Hospital President's Award
2013	Distinguished Professor, Univ. of Colorado
2014	Giants in Cancer Care Award
2016	University of Athens 4 th Lung Cancer Network Award for Distinguished Education and Research (January 2016)

FASCO

2016	ASCO Karnofsky Award (June 2016)
2018	Honoary Membership, Hungarian Respiratory Society
1991-present	The 400 Best Doctors in America, Good Housekeeping
2005-present	America's Top Doctors for Cancer, Castle Connolly Medical Ltd.

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

1976-1986	Cell Kinetic Society Nominating Committee 1981-1983, Chair 1983 Finance Committee 1983-1984
1976-2005	American Society of Hematology Scientific Subcommittee on Neoplasia 1989-1992
1985-1990	Lung Cancer Study Group
1987-2009	American Association of Cancer Institutes (AACI) Board of Directors 1994-1997, 2000-2003 President-Elect 1994-1995 President 1995-1996 Past President 1996-1997
1994-1998	International Society for Cutaneous Lymphomas
1977-present	American Society of Clinical Oncology (ASCO) Board of Directors 1995-1999 President-Elect 2001-2002 President 2002-2003 Past President 2003-2004 Chair, Program Subcommittee 1985, 1990 ACRA (Advanced Clinical Research Award) Subcommittee, 2006-present Real Estate Task Force Committee, 2005-2006 ASCO Foundation, Board of Directors 2004-2010, Chair 2006-2007
1977-present	American Association for Cancer Research (AACR) Grants Review Committee, 2006-2007
1978-present	American Federation for Clinical Research
1979-present	International Association for the Study of Lung Cancer (IASLC) Board of Directors 1988-2000 President-Elect 1991-1994 President 1994-1997 Past President 1997-2000 Executive Director 2003-2013
1983-present	American Association for the Advancement of Science
1985-present	Western Association of Physicians
1986-present	Southwest Oncology Group
1998-present	American College of Physicians Fellow
2002-present	National Dialogue on Cancer Collaborating Partner
2003-present	European Society of Medical Oncology

MAJOR COMMITTEES AND SERVICE RESPONSIBILITIES

Local Committees/Service

1982-1984	NIH, NCI, Institutional Review Board
1982-1984	NCI Intramural Support Contract Review Committee
1985-1996	Faculty Senate UCHSC
1985-1989	Board of Directors, Hospice of St. John
1986-1991	Finance Committee, University Physicians, Inc.
1986-1990	Board of Directors, University Physicians, Inc.
1987-2009	Executive Committee, University of Colorado School of Medicine
1989-2003	Board of Directors, American Cancer Society, Colorado Division
1991-1995	Board of Directors, Leukemia Society of America, Colorado Division
1991-1995	Vice Chair, UCHSC Indirect Cost Committee
1992-1996	Board of Directors, The University Hospital Resource Council
1993-1994	Board of Directors, The Cancer Venture
1993-1994	Board of Directors, Fair Share for Colorado (cigarette tax initiative)
1987-1995	Medical Board, University Hospital
1996	Chairman, UCHSC Facilities Committee
1997-2000	Board of Directors, QualLife Wellness Community
1998-2000	UCHSC Research Facilities
1999-2000	Chair Core Laboratory Committee, UCHSC Research Facilities
1999	Medicine Search Committee Chair, School of Medicine, Department of Prevention
2000-2003	Cancer League of Colorado Scientific Advisory Board
2000-2003	Governor's Tobacco-Related Research Scientific Advisory Committee
2005	Pathology Chair Search Committee, School of Medicine
1984-2006	Cancer Committee, University of Colorado
2012	Chair, Department of Medicine, Division of Hematology Search Committee

National Committees/Service

1978	Co-Chairman, National Cancer Institute Workshop on Cutaneous T-Cell Lymphomas
1978	Co-Chairman, National Cancer Institute Workshop on Multiple Myeloma
1992-1996	Oncology Drugs Advisory Committee, US Food and Drug Administration (FDA)
1995-1996	Chairman
1996-1997	Member, NCI Cancer Clinical Trials Committee
1996-2002	Chairman, Solid Tumor Oncology Education Foundation
1997-2207	Medical Advisory Board, Salick Health Care / Aptium Oncology, Inc.
1998-2008	Cancer Research Foundation of America Medical Advisory Board Member

FASCO

1999-2007	CBCE (Center for Biomedical Continuing Education)
2000-2007	Lung Cancer Alliance, Board of Directors
2001-2004	NCI Lung Cancer Progress Review Group
2005-2009	National Cancer Prevention Fund, Board of Directors
2009-2016	NCI Thoracic Malignancy Steering Committee

Grant Review Committees

2001 & 2007	Chair, Cancer League of Colorado Grant Review Committee
2003-2008	Italian American Cancer Research Foundation Grant Review Committee
2009-2011	AACR Rosenthal Award selection committee
2010	Lungevity Grant Review Committee
2010, 2013, 2018	NCI-SPORE Grant Review subcommittee
2016-present	CRPIT Review Committee

Data and Safety Monitoring Boards

2012-2014	Boehringer-Ingelheim Nintedanib phase 3 study
2013-2014	Daiichi-Sankyo tivantinib MARQUEE study
2013-2015	Immunogen anti CD56 immunoconjugate study
2013-2015	Merrimack MM121 studies
2014-2016	Genentech OAK study of MPDL280A
2014-present	Merck Keynote studies of pembrolizumab in Lung and Head and Neck Cancers
2017-present	Merck-Serono Clinical Review Committee of studies of avelumab in multiple cancers
2017-present	Astra-Zeneca/Medimmune DMC of studies with Medi 9447
2017-present	Juno DSMB for CAR/TCR clinical trials

Editorial Boards

1976-1980	Associate Editor, Cancer Treatment Reports
1984-1994	Associate Editor, Medical and Pediatric Oncology
1990-1994	Associate Editor, Contemporary Oncology
1991-1994	Associate Editor, Journal of Clinical Oncology
1992-1996	Associate Editor, Cancer Research
1995-1999	Advisory Board, Clinical Cancer Research
2003-2006	Editorial Board, Annals of Surgical Oncology
1988-present	Associate Editor, Lung Cancer
1988-present	Associate Editor, Physician Data Query (PDQ)
1990-present	Associate Editor, Oncology Times
1995-present	Associate Editor, International Journal of Cancer Research

FASCO

- 1997-present Editorial Board, Drug Resistance Updates
- 1997-present Honorary Editor, Chinese Assn. for the Study of Lung Cancer
- 2001-present Member of Editorial Board, Chinese Journal of Lung Cancer

External Scientific Advisor

- 1988-1992 University of Miami Cancer Center
- 1989-1993 University of Florida Cancer Center
- 1989-1994 University of Arkansas Cancer Center
- 1991-1994 University of Virginia Cancer Center
- 1993-2002 Fox Chase Cancer Center
- 1994-2002 H. Lee Moffitt Cancer Center
- 1996-2006 University of Arizona Cancer Center
- 2013-2015 MAYO Clinic Lung SPORE
- 2014-2015 UCLA/BU Lung Cancer SPORE
- 1994-present Vanderbilt-Ingram Cancer Center
- 2004-present MD Anderson Cancer Center
- 2013-present Yale University Lung Cancer SPORE
- 2014-present UT Southwestern MD Anderson Lung Cancer SPORE

Media and Public Awareness

- 2008 Mentioned in The Denver Post, "CU Cancer Center bids farewell to Dr. Bunn". June 9, 2008.
<http://www.denverpost.com/2008/06/09/cu-cancer-center-bids-farewell-to-dr-bunn/>
- 2011 Interview and Quotations in MLive, "Pfizer: New cancer pill Xalkori gives hope, shows new strategy for major drugmaker". August 31, 2011.
http://www.mlive.com/business/west-michigan/index.ssf/2011/08/pfizer_new_cancer_pill_gives_h.html
- 2013 Interview and Quotations in The ASCO Post, "Paul A. Bunn, JR, MD, Offers Insights About a Hopeful Era in Lung Cancer Treatment". September 1, 2013.
<http://www.ascopost.com/issues/september-1-2013/paul-a-bunn-jr-md-offers-insights-about-a-hopeful-era-in-lung-cancer-treatment/>
- 2013 Interview and Quotations in OncLive, "Expanding TKI Therapy in Advanced Lung Cancer". October 9, 2013.
<http://www.onclive.com/publications/oncology-live/2013/september-2013/expanding-tki-therapy-in-advanced-lung-cancer>
- 2013 Mentioned in CU Denver Today, "Leaders in health care, economics recognized as Distinguished Professors". November 5, 2013.
<http://www.cudenvertoday.org/bunn-medema-recognized-as-distinguished-professors/>

FASCO

- 2014 Mentioned in Colorado Cancer Blogs by University of Colorado Cancer Center, "Paul A. Bunn, Jr, MD earns 2014 'Giants of Cancer Care' Award". June 11, 2014.
<http://www.coloradocancerblogs.org/paul-bunn-jr-md-earns-2014-giants-cancer-care-award/>
- 2014 Mentioned in Cancer Progress, "Oncology Luminaries: Dr. Paul A. Bunn, Jr.". October 27, 2014.
<http://www.cancerprogress.net/node/2631>
- 2015 Interview and Quotations in OncLive, "Translational Advances Deliver Precision Medicine to NSCLC". July 31, 2015.
<http://www.onclive.com/web-exclusives/translational-advances-deliver-precision-medicine-to-nsclc>
- 2016 Interview and Quotations in Cancer Action Now, "Cancer Action Now Launches Online Cancer Information Service, Offering Early and Direct Access to Top Oncology Experts". March 16, 2016.
<http://www.prnewswire.com/news-releases/cancer-action-now-launches-online-cancer-information-service-offering-early-and-direct-access-to-top-oncology-experts-300237090.html>
- 2016 Interview and Quotations in Newswise, "CU Cancer Center's Paul Bunn, Jr., MD, FASCO, Earns ASCO David A. Karnofsky Memorial Award". June 2, 2016.
<http://www.newswise.com/articles/cu-cancer-center-s-paul-bunn-jr-md-fasco-earns-asco-david-a-karnofsky-memorial-award>
- 2016 Interview and Quotations in MedPage Today, "Novel App Seems to Extend Lung Cancer Survival". June 7, 2016
<http://www.medpagetoday.com/MeetingCoverage/ASCO/58350>
- 2016 Interview for OncLiv, "Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC". August 5, 2016.
<http://www.onclive.com/conference-coverage/ilc-2016/dr-bunn-on-missed-endpoint-in-checkmate026-for-nsclc>
- 2016 Interview and Quotations in OncLive, "Combination of Immunotherapy and Lung Cancer Therapies Potential Game-Changer, But Needs Further Research". August 9, 2016.
<http://www.onclive.com/conference-coverage/ilc-2016/combination-of-immunotherapy-and-lung-cancer-therapies-potential-gamechanger-but-needs-further-research>
- 2016 Interview and Quotations in OncLive, "Bunn Discusses Frontline Nivolumab NSCLC Results, Issues With PFS EndPoint". August 11, 2016.
<http://www.onclive.com/web-exclusives/bunn-discusses-frontline-nivolumab-nsclc-results-issues-with-pfs-endpoint>
- 2016 Interview and Quotations in Cure, "Physician Explains Why Frontline Opdivo Fell Short in Lung Cancer". August 16, 2016.
<http://www.curetoday.com/articles/physician-explains-why-frontline-opdivo-fell-short-in-lung-cancer>
- 2016 Mentioned in OncLive, "A Man With Many Mentors Makes His Own Mark in Lung Cancer". September 4, 2016.
<http://www.onclive.com/publications/oncology-live/2016/vol-17-no-17/a-man-with-many-mentors-makes-his-own-mark-in-lung-cancer?p=1>
- 2016 Interview and Quotations in Targeted Oncology, "Immunotherapies Combined With Lung Cancer Treatments Could Be Practice Changing". October 6, 2016.

<http://www.targetedonc.com/publications/targeted-therapy-news/2016/september-2016/immunotherapies-combined-with-lung-cancer-treatments-could-be-practice-changing>

2017 Interview and Quotations in Ecumenical News, "Cancer cure news 2017: Breakthrough in genetics may be the cure to cancer". February 17, 2017.
<http://www.ecumenicalnews.com/article/cancer-cure-news-2017-breakthrough-in-genetics-may-be-the-cure-to-cancer/58968.htm>

LICENSURE AND BOARD CERTIFICATION

Licensure

1974, Maryland - D15980

1984, Colorado – 26328

Board Certification

July 1972 Diplomat, National Board of Medical Examiners

June 1974 Diplomat, American Board of Internal Medicine

October 1975 Diplomat, American Board of Internal Medicine, Medical Oncology

INVENTIONS, INTELLECTUAL PROPERTY, AND PATENTS HELD OR PENDING

Filing Date	Patent Title	Application Type	Patent Number
07/20/1993	Magnetic Microparticles	US Utility	5,411,730
05/15/1996	Cationic Lipid and Methods for Use Therefor	US Utility	5,980,935
10/02/1997	Hydrophilic microparticles and methods to prepare same	US Utility	6,048,550
08/19/1999	Anti-Cancer Compounds	US Utility	6,388,054
12/28/2001	Anti-Cancer Compounds and Methods Related Thereto		7,071,168
08/14/2005	Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto	PCT - Patent Cooperation Treaty	Pending, 11/781,946
12/15/2005	Methods For Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients	PCT - Patent Cooperation Treaty	Pending
12/14/2005	Anti-Cancer Compounds	US Utility	Pending 10/035,662
03/13/2006	Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors	PCT - Patent Cooperation Treaty	Pending Prov. # 60/951,445
08/09/2007	Methods and Compositions for Treating Cancer	Provisional	Pending

GRANT SUPPORT

Active

Title: SPORE in Lung Cancer
Project 2: Growth Factor Inhibitors for Lung Cancer Therapy and Prevention (Project Principal Investigator)
Core 5: Administration (Core Director)

Sponsor: National Institute of Health/National Cancer Institute; P50 CA058187

Role: Principal Investigator

Period: 05/01/2008 – 04/30/2019

Amount: \$1,616,546

Percent Effort: 30%

Title: Training in Translational Research of Lung, Head and Neck Cancers

Sponsor: National Institute of Health/National Cancer Institute; T32 CA174648-01

Role: Co-PI

Period: 04/01/2013 – 03/31/18

Amount: \$200,774

Percent Effort: 0%

Title: Evaluation of the activity of derivations of the histone deacetylase inhibitor (HDACi) largazole (developed by Cetya Therapeutics) in combination with EGFR and Hedgehog inhibitors in non-small cell lung cancer (NSCLC) cell lines and their effect on epithelial-mesenchymal transition (EMT)

Sponsor: Colorado Cancer Translational Research Accelerator (CCTRA), Pilot grant CTGG2 2017-1386 (Colorado Office of Economic Development)

Role: Co-PI (Hendrick, Witta, Bunn)

Period: 07/01/2017 – 12/31/2019

Amount: \$56,200

Percent Effort: 0%

Completed

Title: Lung Cancer Mutation Consortium

Sponsor: Free to Breathe

Role: Principal Investigator

Period: 08/01/2012-06/30/2015

Amount: \$2,600,000

Percent Effort: 5%

Title: Lung Cancer Mutation Consortium

Sponsor: National Institute of Health/National Cancer Institute; 5 RC2 CA148394-02

Role: Principal Investigator

Period: 09/29/2009 – 08/31/2012

Percent Effort: 10%

Title: RAID

Sponsor: National Cancer Institute

Role: Principal Investigator

Period: 1999-03/31/2007

FASCO

Percent Effort: <1%

Title: LCBCC: Iloprost Chemoprevention Trial - P50 CA070907-06 (Minna, PI)

Sponsor: UT Southwestern/NCI

Role: Subcontract Principal Investigator

Period: 05/01/2004 to 04/30/2006

Amount: \$492,371

Percent Effort: <5%

Title: Phase II trial of induction paclitaxel/carboplatin in clinical stage IB (T2N0), II (T12N1) and selected IIIA (T3N0-1) non-small cell lung cancer (NSCLC).

Sponsor: Bristol-Myers Sq (IRB# 95-582)

Period: 02/12/1996-02/11/2000

Amount: \$36,507.00

Title: Sulindac sulfone as a chemoprevention agent for human lung cancers: in vitro and in vivo study.

Sponsor: Cell Pathways

Period: 02/19/1998-03/31/2001

Amount: \$15,523

Title: Postgraduate Training in Cancer Research T32 CA09331

Sponsor: NIH/NCI

Period: 07/01/1992-06/30/1996

Amount: \$460,358

Title: Post Graduate Training in Cancer Research T32 CA09331

Sponsor: NIH/NCI

Period: 09/01/1986-06/30/1992

Amount: \$381,087

Title: Core Grant Supplement - High Dose Radiolabeled Antibody Therapy in Metastatic Breast Cancer Patients P30 CA46934

Sponsor: NIH/NCI

Period: 03/01/1992-02/28/1993

Amount: \$50,000

Title: Targeted Therapy for Lung Cancer (Project 2) U01 CA46088

Sponsor: NIH/NCI

Period: 06/01/1988-05/31/1992

Amount: \$148,732

Title: Southwest Oncology Group

Sponsor: NIH/NCI

Period: 01/01/1988-02/31/1992

Amount: \$123,403

Title: Monoclonal Antibody Treatment of Breast Cancer (Project 1) P01 CA42767

Sponsor: NIH/NCI

Period: 09/01/1988-08/31/1991

Amount: \$372,324

Title: Cancer Center Core Grant P30 CA46934

Sponsor: NIH/NCI

Period: 03/01/1988-02/28/1991

Amount: \$2,831,595

Title: A Phase I Study of the Toxicity, Pharmacokinetics, Imaging, Dosimetry, and Efficacy of 131I-Labeled Monoclonal Antibody LL2 in Patients with B-Cell Lymphoma

FASCO

Sponsor: Immunomedics
Period: 09/12/1991-1995
Amount: \$16,000

Title: Effects and Tolerance of Dexniguldipine-HCL Combined with VAD/VADP in Patients with Resistant Multiple Myeloma

Sponsor: Byk Gulden
Period: 12/01/1993-1995
Amount: \$25,050

Title: A Phase II Study of Dexniguldipine in Relapsed Small Cell Lung Cancer

Sponsor: Byk Gulden
Period: 05/01/1993-1995
Amount: \$23,322

Title: A Multi-Centre Phase II Study of Campath-IH in Patients with Non-Bulky Non-Hodgkin's Lymphoma

Sponsor: Burroughs Wellcome
Period: 04/01/1993-1995
Amount: \$36,187

Title: Follow-on Protocol for Phase I-II Studies of Campath-IH Given to Patients with Non-Hodgkin's Lymphoma (including chronic lymphocytic leukemia)

Sponsor: Burroughs Wellcome
Period: 04/16/1992-03/17/1993
Amount: \$10,000

Title: A Multi-Centre Phase I-II Study of Campath-IH Given Five Times a Week to Patients with Non-Hodgkin's Lymphoma (including chronic lymphocytic leukemia)

Sponsor: Burroughs Wellcome
Period: 01/15/1992-03/17/1993
Amount: \$33,750

Title: A Clinical Trial of Oral Navelbine for the Treatment of Women with Advanced Breast Cancer

Sponsor: Burroughs Wellcome
Period: 09/03/1991-10/15/1992
Amount: \$7,778

Title: Investigation of a New Device for Extracorporeal Removal of Circulating Radiolabeled Mouse Antibody

Sponsor: Cobe Laboratories, Inc.
Period: 10/20/1989-09/25/1992
Amount: \$12,600

Title: A Phase I Oral Ascending Multiple Dose Tolerability Study of B859-35 in Patients with Cancer

Sponsor: Byk Gulden
Period: 03/23/1992-09/23/1992
Amount: \$26,884

Title: A Clinical Trial of Intravenous Navelbine in First and Second-line Therapy of Metastatic Breast Cancer

Sponsor: Burroughs Wellcome
Period: 07/11/1991-06/05/1992
Amount: \$7,500

Title: A Trial of Oral Navelbine for the Treatment of Inoperable, Previously Untreated, Stage IV Non-Small Cell Lung Cancer.

Sponsor: Burroughs Wellcome

FASCO

Period: 09/03/1991-03/13/1992

Amount: \$7,500

Title: Sanchez - Audrey Meyer Mars Fellowship

Sponsor: American Cancer Society

Award Period: 07/01/1990-06/30/1991

Amount: \$40,000

Title: Development of Ferromagnetic Partides

Sponsor: Ferrotherm

Period: 04/05/1990-06/30/1991

Amount: \$5,779

Title: Imaging and Treatment of Lung Cancer with Monoclonal Antibody KC4

Sponsor: Coulter Immunology, Inc.

Period: 10/01/1985-09/30/1990

Amount: \$375,000

Title: Phase I-II Study of Patients with Small Cell Carcinoma of the Lung Utilizing Dose Intensification
CEP + GMCSF

Sponsor: Schering Plough

Period: 04/06/1988-09/15/1989

Amount: \$2,287

Title: Pilot Study of Trimetrexate Administered in Combination with Cisplatin or Etoposide in Patients
with Non-Small Cell Lung Cancer

Sponsor: Warner/Lambert/Parke Davis

Period: 09/09/1987-09/23/1988

Amount: \$8,750

Title: Phase I-II Ascending Dose Study of Monoclonal Antibody B72.3 GYK-DPTA III-in in Patients with
Colorectal Carcinoma

Sponsor: Cytogen

Period: 09/23/1987-03/14/1988

Amount: \$10,000

Title: Treatment of Patients with Recombinant Gamma Interferon

Sponsor: Genentech, Inc.

Period: 01/01/1987-12/31/1987

Amount: \$5,000

Title: ACS Institutional Research Grant

Sponsor: American Cancer Society

Period: 09/01/1986-08/31/1987

Amount: \$50,000

Title: Adjunctive Laboratory Investigations for Patients on Clinical Research Studies Involving
Monoclonal Antibodies Kc4 and B1

Sponsor: Cancer League of Colorado

Period: 10/01/1986-06/30/1987

Amount : \$15,000

Title: Molecular Biology of Cell Proliferation (sub-project)

Sponsor: Markey Foundation

Period: 10/1991-09/1996

Amount: \$50,000/year

FASCO

- Title: A Phase I-II Study of Daily Carboplatin and Simultaneous Accelerated, Hyperfractionated Chest Irradiation Followed by Single Agent Carboplatin in Patients with Regionally Inoperable (Stages IIIA and B) Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Bristol-Myers Squibb
 Period: 12/25/1992-1997
 Amount: \$85,555
- Title: A Phase I-II Trial of Carboplatinum and Taxol in Untreated Patients with Metastatic Non-Small Cell Lung Cancer
- Sponsor: Bristol-Myers Squibb
 Period: 04/20/1993-1997
 Amount: \$30,555
- Title: A Phase I-II Trial of Cisplatin, VP-16, and Taxol in Untreated Patients with Extensive Stage Small Cell Lung Cancer
- Sponsor: Bristol-Myers Squibb
 Period: 06/01/1993-1998
 Amount: \$21,825
- Title: A Pilot Phase II Study of Induction Therapy with Daily Etoposide, Daily Cisplatin and Simultaneous Chest Irradiation Followed by 4 Cycles of Consolidation Cisplatin/Etoposide Therapy in Limited Stage Small Cell Lung Cancer
- Sponsor: Bristol-Myers Squibb
 Period: 12/25/1992-1998
 Amount: \$21,492

BIBLIOGRAPHY**Original Articles in Refereed Journals**

1. Bunn, P.A., Jr., Okamoto, M., Riker, W.F., Jr.: Further observations on subacute denervation and mammalian motor nerve terminal function. *Neurology* 23:12-20, 1973.
2. Richman, S.D., Levenson, S.M., Bunn, P.A., Jr., Flinn, G.S., Johnston, G.S., DeVita, V.T.: 67-Ga accumulation in pulmonary lesions associated with bleomycin toxicity. *Cancer* 36:1966- 1972, 1975.
3. Bunn, P.A., Jr., Schein, P.S., Banks, P.M., DeVita, V.T.: Central nervous system complications in patients with diffuse histocytic and undifferentiated lymphoma: Leukemia revisited. *Blood* 47:3-10, 1976.
4. Shackney, S.E., Bunn, P.A., Jr., Ford, S.S.: Effects of colcemid on mouse one marrow. *Cell Tissue Kinet.* 9:363-370, 1976.
5. Bunn, P.A., Jr., Shackney, S.E., Ford, S.S.: Effects of colcemid on hematopoiesis in the mouse. *J. Clin. Invest.* 58:1280-1285, 1976.
6. Bunn, P.A., Jr., Ford, S.S., Shackney, S.E.: Rapid grain and cell counting for cell kinetic studies: bried communication. *J. Natl. Cancer Inst.* 59:285-287, 1977.
7. Bunn, P.A., Jr., Cohen, M.H., Ihde, D.C., Fossieck, B.E., Jr., Matthews, M.J., Minna, J.D.: Advances in small cell bronchogenic carcinoma: A commentary. *Cancer Treat. Rep.* 61:333-342, 1977.
8. Ihde, D.C., Cohen, M.H., Bunn, P.A., Jr., Bernath, A.M., Broder, E., Minna, J.D.: Bleomycin, Methotrexate, and Streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity. *Cancer Treat. Rep.* 62:155- 157, 1978.
9. Bunn, P.A., Jr., Ihde, D.C., Cohen, M.H., Shackney, S.E., Minna, J.D.: Streptozotocin in advanced small cell bronchogenic carcinoma: An ineffective non-myelosuppressive agent. *Cancer Treat. Rep.* 62:479-481, 1978.
10. Brigham, B., Bunn, P.A., Jr., Minna, J.D., Cohen, M.H., Ihde, D.C., Shackney, S.E.: Growth rates of small cell bronchogenic carcinoma. *Cancer* 42:2880-2886, 1978.
11. Ihde, D.C., Cohen, M.H., Bernath, A.M., Matthews, M.J., Bunn, P.A., Jr., Minna, J.D.: Serial fiberoptic bronchoscopy during chemotherapy of small cell carcinoma of the lung. *Chest* 74: 531- 536, 1978.

FASCO

12. Bunn, P.A., Jr., Nugent, J.L., Ihde, D.C., Cohen, M.H., Eddy, J.L., Minna, J.D.: 5-Fluorouracil, methyl CCNU, adriamycin and mitromycin C (FM-AM) in the treatment of advanced gastric cancer. *Cancer Treat. Rep.* 62: 1287-1293, 1978.
13. Bunn, P.A., Jr., Cohen, M.H., Nugent, J.L., Matthews, M.J., Minna, J.D., Widerlite, L.: Simultaneous gastric and plasma carcinoembryonic antigen (CEA) in 117 patients undergoing gastroscopy. *Gastroenterology* 76: 734-741, 1979.
14. Ihde, D.C., Simms, E.B., Matthews, M.J., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D.: Bone marrow metastases in small cell carcinoma of the lung: Frequency, description, and influence on chemotherapeutic toxicity and prognosis. *Blood* 53: 677-686, 1979.
15. Nugent, J.L., Bunn, P.A., Jr., Matthews, M.J., Cohen, M.H., Ihde, D.C., Minna, J.D.: Central nervous system metastases in small cell bronchogenic carcinoma: Increased frequency and changing pattern with lengthening survival. *Cancer* 44: 1885-1893, 1979.
16. Cohen, M.H., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Jr., Matthews, M.J., Shackney, S.E., Johnston-Early, A.V., Makuch, R., Minna, J.D.: Cyclic alternating combination chemotherapy of small cell bronchogenic carcinoma. *Cancer Treat. Rep.* 63: 163- 170, 1979.
17. Cohen, M.H., Chretien, P.B., Ihde, D.C., Makuch, R., Fossieck, B.E., Jr., Bunn, P.A., Jr., Johnston, A.V., Shackney, S.E., Lipson, S.D., Kenady, D.E., Minna, J.D.: Thymosin fraction V prolongs the survival of small cell lung cancer patients treated with intensive combination chemotherapy. *JAMA* 241: 1813-1815, 1979.
18. Ihde, D.C., Bilek, F.S., Cohen, M.H., Bunn, P.A., Jr., Eddy, J., Minna, J.D.: Response to thoracic radiotherapy in patients with small cell carcinoma of the lung after failure of combination chemotherapy. *Radiology* 132: 443-446, 1979.
19. Whang-Peng, J., Bunn, P.A., Jr., Knutsen, T., Schechter, G.P., Gazdar, A.F., Matthews, M.J., Minna, J.D.: Cytogenetic abnormality in patients with cutaneous T-cell lymphomas. *Cancer Treat. Rep.* 63: 575-580, 1979.
20. Gazdar, A.F., Carney, D.N., Russell, E.K., Schechter, G.P., Bunn, P.A., Jr.: In vitro growth of cutaneous T-cell lymphomas. *Cancer Treat. Rep.* 63: 587- 590, 1979.
21. Guccion, J.G., Fischmann, B.A., Bunn, P.A., Jr., Schechter, G.P., Patterson, R.H., Matthews, M.J.: The ultrastructural appearance of cutaneous T-cell lymphomas in skin, lymph nodes and peripheral blood. *Cancer Treat. Rep.* 63:565-570, 1979.
22. Schechter, G.P., Bunn, P.A., Jr., Fischmann, A.B., Matthews, M.J., Guccion, J., Soehnen, F., Munson, D., Minna, J.D.: Blood and lymph node T lymphocytes in cutaneous T-cell lymphomas: Evaluation by light microscopy. *Cancer Treat. Rep.* 63:571-574, 1979.
23. Fischmann, A.B., Bunn, P.A., Jr., Guccion, J.C., Matthews, M.J., Minna, J.D.: Exposure to chemicals, physical and biologic agents in cutaneous T- cell lymphomas. *Cancer Treat. Rep.* 63:591-596, 1979.
24. Bunn, P.A., Jr., Fischmann, A.B., Schechter, G.P., Kumar, P.D., Ihde, D.C., Cohen, M.H., Fossieck, B.E., Gazdar, A.F., Matthews, M.J., Eddy, J.E., Minna, J.D.: Combined modality therapy with electron beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. *Cancer Treat. Rep.* 63:713-717, 1979.
25. Shackney, S.E., Edelson, R., Bunn, P.A., Jr.: The kinetics of Sezary cell production. *Cancer Treat. Rep.* 63:659-661, 1979.
26. Shackney, S.E., Bunn, P.A., Jr., Ford, S.S., Erickson, B., Ross, W.E.: A study of drug induced kinetic perturbations in the marrow of a patient with neuroblastoma. *Cancer* 45: 882-892, 1980.
27. Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Dunnick, N.R., Eddy, J.L., Minna, J.D.: Effective treatment of hormonally unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: Methods of documenting tumor response and progression. *Cancer* 45:1300-1310, 1980.
28. Ihde, D.C., Cohen, M.H., Simms, E.B., Matthews, M.J., Bunn, P.A., Jr., Minna, J.D.: Evaluation of response to chemotherapy with fiberoptic bronchoscopy: Results in non-small cell carcinoma of the lung. *Cancer* 45:1693-1696, 1980.
29. Huberman, M., Bunn, P.A., Jr., Matthews, M.J., Gazdar, A.F., Ihde, D.C., Cohen, M.H., Minna, J.D.: Hepatic involvement in the cutaneous T-cell lymphomas: Results of percutaneous biopsy and peritoneoscopy. *Cancer* 45:1683-1688, 1980.
30. Huberman, M., Fossieck, B.E., Bunn, P.A., Jr., Cohen, M.H., Ihde, D.C., Minna, J.D.: Herpes-Zoster and small cell bronchogenic carcinoma. *Am. J. Med.* 68:214-218, 1980.

FASCO

31. Levine, R.F., Bunn, P.A., Jr., Hazzard, K.C., Schlam, M.L.: Flow cytofluorometric analysis of megakaryocyte ploidy. Validation of method and discovery that 8N are the predominant ploidy class in guinea pig and monkey marrow. *Blood* 56:210-217, 1980.
32. Gazdar, A.F., Carney, D.N., Bunn, P.A., Jr., Russell, E.K., Schechter, G.P., Guccion, J.G.: Mitogen requirements for the in vitro propagation of cutaneous T cell lymphomas. *Blood* 55: 409- 417, 1980.
33. Bunn, P.A., Jr., Whang-Peng, J., Carney, D.N., Schlam, M.L., Knutsen, T., Gazdar, A.F.: Correlation of DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sezary syndrome: Diagnostic and prognostic implications. *J. Clin. Invest.* 65: 1440-1448, 1980.
34. Bunn, P.A., Jr., Huberman, M.S., Whang-Peng, J., Schechter, G.P., Guccion, J.G., Matthews, M.J., Gazdar, A.F., Dunnick, N.R., Fischmann, A.B., Ihde, D.C., Cohen, M.H., Fossieck, B.E., Jr., Minna, J.D.: Prospective staging evaluation of patients with cutaneous T-cell lymphomas: Demonstration of a high frequency of extracutaneous dissemination. *Ann. Int. Med.* 93: 223-230, 1980.
35. Johnston-Early, A.V., Cohen, M.H., Paxton, T., Fossieck, B.E., Jr., Minna, J.D., Ihde, D.C., Bunn, P.A., Jr., Matthews, M.J., Makuch, R.: Smoking abstinence prolongs the survival of treated small cell bronchogenic carcinoma patients. *J. Am. Med. Assoc.* 244: 2175-2179, 1980.
36. Carney, D.N., Matthews, M.J., Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Makuch, R.W., Gazdar, A.F., Minna, J.D.: Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy and survival. *J. Natl. Cancer Inst.* 65: 1225-1230, 1980.
37. Gazdar, A.F., Carney, D.N., Russell, E.K., Simms, H.L., Baylin, S.B., Bunn, P.A., Jr., Minna, J.D.: Establishment of continuous, clonable, cultures of small cell carcinoma of the lung having amine precursor uptake and decarboxylation properties. *Cancer Res.* 40: 3502-3507, 1980.
38. Poesz, B.J., Ruscetti, F.M., Gazdar, A.F., Bunn, P.A., Jr., Minna, J.D., Gallo, R.C.: Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. (USA)* 77: 7415-7419, 1980.
39. Carney, D.N., Bunn, P.A., Jr.: Manifestations of cutaneous T-cell lymphomas. *J. Surg. Dermat. Oncol.* 6: 369-377, 1980.
40. Bunn, P.A., Jr., Carney, D.N.: Treatment of cutaneous T-cell lymphomas. *J. Surg. Dermat. Oncol.* 6: 383-388, 1980.
41. Carney, D.N., Bunn, P.A., Jr., Schechter, G.P., Gazdar, A.F.: Lymphocyte Transformation in patients with cutaneous T-cell lymphomas. *Int'l. J. Cancer* 26: 534-542, 1980.
42. Cohen, M.H., Makuch, R., Johnston-Early, A., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Jr., Minna, J.D.: Laboratory parameters as an alternative to performance status in prognostic stratification of small cell lung cancer patients. *Cancer Treat. Rep.* 65: 187-195, 1981.
43. Bunn, P.A., Jr., Edelson, R.L., Ford, S.S., Shackney, S.E.: Patterns of cell proliferation and migration in patients with the Sezary syndrome. *Blood* 57: 452-463, 1981.
44. Carney, D.N., Bunn, P.A., Jr., Gazdar, A.F., Pagan, J.A., Minna, J.D.: Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. *Proc. Natl. Acad. Sci. (USA)* 78: 3185- 3189, 1981.
45. Levenson, R.M., Jr., Ihde, D.C., Huberman, M.S., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D.: Phase II trial of cisplatin in small cell carcinoma of the lung. *Cancer Treat. Rep.* 65: 905-907, 1981.
46. Posner, L.E., Fossieck, B.E., Jr., Eddy, J.L., Bunn, P.A., Jr.: Septicemic complications of the cutaneous T-cell lymphomas. *Am. J. Med.* 71: 210-216, 1981.
47. Haynes, B.F., Bunn, P.A., Jr., Mann, D., Thomas, C., Eisenbarth, G.S., Minna, J.D., Fauci, A.S.: Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. *J. Clin. Invest.* 67: 523-530, 1981.
48. Ihde, D.C., Makuch, R.W., Carney, D.N., Bunn, P.A., Jr., Cohen, M.H., Matthews, M.J., Minna, J.D.: Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. *Am. Rev. Resp. Dis.* 123:500-507, 1981.
49. Haynes, B.I., Metzgar, R.S., Minna, J.D., Bunn, P.A., Jr.: Phenotypic characterization of cutaneous T-cell lymphoma: Comparison with other malignant T cells with the use of monoclonal antibodies. *N. Engl. J. Med.* 304: 1319-1323, 1981.

50. Levenson, R.M., Ihde, D.C., Matthews, M.J., Cohen, M.H., Gazdar, A.F., Bunn, P.A., Jr., Minna, J.D.: Small cell carcinoma presenting as an extrapulmonary neoplasm: Sites of origin and response to chemotherapy. *J. Natl. Cancer Inst.* 67: 607-612, 1981.
51. Levenson, R.M., Sauerbrunn, B.J.L., Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Small cell lung cancer: radonucleide bone scans for assessment of tumor extent and response. *Am. J. Roent.* 137:31-35, 1981.
52. Posner, L.E., Guroff, M.R., Kalyanaraman, V.S., Poiesz, B.J., Ruscetti, F.W., Bunn, P.A., Jr., Minna, J.D., Gallo, R.C.: Natural antibodies to the human T-cell lymphoma virus in patients with cutaneous T-cell lymphomas. *J. Exp. Med.* 154: 333-346, 1981.
53. Carney, D.N., Gazdar, A.F., Bunn, P.A., Jr., Guccion, J.G.: Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. *Stem Cells* 1: 149-164, 1981.
54. Earle, M.F., Fossieck, B.E., Cohen, M.H., Ihde, D.C., Bunn, P.A., Jr., Minna, J.D.: Perirectal infections in patients with small cell lung cancer. *JAMA* 246: 2464-2466, 1981.
55. Minna, J.D., Cuttitta, F., Rosen, S., Bunn, P.A., Jr., Carney, D.N., Gazdar, A.F., Krasnow, S.: Methods for production of monoclonal antibodies with specificity for human lung cancer cells. *In Vitro* 17: 1058-1070, 1981.
56. Kalyanaraman, V.S., Sarngadharan, M.G., Bunn, P.A., Jr., Minna, J.D., Gallo, R.C.: Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus. *Nature* 294: 271-273, 1981.
57. Bradley, E.C., Schechter, G.P., Matthews, M.J., Whang-Peng, J., Cohen, M.H., Bunn, P.A., Jr., Ihde, D.C., Minna, J.D.: Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. *Cancer* 49: 221-223, 1982.
58. Ihde, D.C., Dunnick, N.R., Johnston-Early, A., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Abdominal computed tomography in small cell lung cancer: Assessment of extent of disease and response to therapy. *Cancer* 49: 1485- 1490, 1982.
59. Brigham, B.A., Bunn, P.A., Jr., Horton, J.E., Schechter, G.P., Wahl, L.M., Bradley, E.C., Dunnick, N.R., Matthews, M.J.: Skeletal manifestations in cutaneous T-cell lymphomas. *Arch. Dermatol.* 118: 461-467, 1982.
60. Whang-Peng, J., Bunn, P.A., Jr., Knutsen, T., Matthews, M.J., Schechter, G.P., Minna, J.D.: Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma. *Cancer* 50: 1539-1553, 1982.
61. Bunn, P.A., Jr., Krasnow, S., Makuch, R.W., Schlom, M.L., Schechter, G.P.: Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: Clinical implications. *Blood* 59: 528-535, 1982.
62. Munson, D., Bunn, P.A., Jr., Schechter, G.P.: Fc receptor-defined T-lymphocyte subpopulations in patients with cutaneous T-cell lymphoma. *J. Invest. Dermatol.* 79: 317-321, 1982.
63. Whang-Peng, J., Bunn, P.A., Jr., Kao Shan, S.C., Lee, E.C., Carney, D.N., Gazdar, A.F., Minna, J.D.: A non-random chromosomal abnormality, del 3p (14- 23), in human small cell lung cancer. *Cancer Gen. Cytogen.* 6: 119-134, 1982.
64. Krasnow, S., Bunn, P.A., Jr., Ihde, D.C., Matthews, M.J., Cohen, M.H., Eddy, J.N., Minna, J.D.: ICFR-159 in advanced gastric cancer: Absence of activity. *Am. J. Clin. Oncol. (CCT)* 5: 635- 639, 1982.
65. Rosen, S.T., Aisner, J., Makuch, R.W., Matthews, M.J., Ihde, D.C., Whitacre, M., Glatstein, E., Wiernik, P., Lichter, A.S., Bunn, P.A. Jr.: Carcinomatous leptomeningitis in small cell lung cancer. A clinicopathologic review of the National Cancer Institute experience. *Medicine* 61,1: 45-53, 1982.
66. Whang-Peng, J., Kao-Shan, C.S., Lee, E.C., Bunn, P.A., Jr., Carney, D.N., Gazdar, A.F., Minna, J.D.: A specific chromosome defect associated with human small cell lung cancer: Deletion 3p (14-23). *Science* 215: 181-182, 1982.
67. Radice, P.A., Matthews, M.J., Ihde, D.C., Gazdar, A.F., Carney, D.N., Bunn, P.A., Jr., Cohen, M.H., Fossieck, B.E., Makuch, R.M., Minna, J.D.: The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. *Cancer* 50: 2894-2902, 1982.
68. Blatt, J., Bunn, P.A., Jr., Carney, D.N., Reaman, G., Soprey, P., Poplack, D.G.: Purine pathway enzymes in the circulating malignant cells of patients with cutaneous T-cell lymphoma. *Brit. J. Haematol.* 52: 97-104, 1982.
69. Carney, D.N., Marangos, P.J., Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D., Gazdar, A.F.: Serum neuron specific enolase: A marker for disease extent and response to therapy in patients with small cell carcinoma of the lung. *Lancet* 1: 583-585, 1982.
70. Thant, M., Hawley, R.J., Smith, M.T., Cohen, M.H., Minna, J.D., Bunn, P.A., Jr., Ihde, D.C., West, W., Matthews, M.J.: Possible enhancement of vincristine neuropathy by VP-16. *Cancer* 49: 859- 864, 1982.

71. Minna, J.D., Bunn, P.A., Jr., Carney, D.N., Cohen, M.H., Cuttitta, F., Fossieck, B.E., Gazdar, A.F., Ihde, D.C., Johnston- Early, A., Matthews, M.J., Makuch, R., Oie, H., Rosen, S., Lichter, A., Glatstein, E.: Experience of the National Cancer Institute (USA) in the treatment and biology of small cell carcinoma of the lung. *Bulletin du Cancer* 69: 83-93, 1982.
72. Morstyn, G., Ihde, D.C., Eddy, J.L., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. *Am. J. Clin. Onc. (CCT)* 6: 547-551, 1983.
73. Rosen, S.T., Makuch, R.W., Lichter, A.S., Ihde, D.C., Matthews, M., Jr., Minna, J.D., Glatstein, E., Bunn, P.A., Jr.: The role of prophylactic cranial irradiation in preventing central nervous system metastases in small cell lung cancer: Potential benefit restricted to patients in complete response. *Amer. J. Med.* 74: 615-624, 1983.
74. Johnston-Early, A., Cohen, M.H., Fossieck, B.E., Jr., Harwood, S., Ihde, D.C., Bunn, P.A., Jr., Matthews, M.J., Minna, J.D., Makuch, R.: Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. *Cancer* 52:1395-1400, 1983.
75. Gallo, R.C., Kalyanaraman, V.S., Sarngadharan, M.G., Sliiski, A., Vonderheid, E.C., Maeda, M., Nakao, Y., Yamada, K., Ito, Y., Gutensohn, N., Murphy, S., Bunn, P.A., Jr., Catovsky, D. Greaves, M.F., Blayney, D., Blattner, W., Jarrett, W.F.H., zur Hausen, H., Seligmann, M., Brouet, J.C., Haynes, B.F., Jegasothy, B.V., Jaffe, E., Cossman, J., Broder, S., Fisher, R.I., Golde, D.W., Robert-Guroff, M.: Association of human type C retrovirus with a subset of adult T-cell cancers. *Cancer Research* 43: 3892-3899, 1983.
76. Batist, G., Ihde, D.C., Zabell, A., Lichter, A., Veach, S.R. Cohen, M.H., Carney, D.N., Bunn, P.A., Jr.: Small cell carcinoma of lung: reinduction therapy after late relapse. *Ann. Int. Med.* 98: 472-474, 1983.
77. Robert-Guroff, M., Kalyanaraman, V.S., Blattner, W.A., Popovic, M., Sangadharan, M.G., Maeda, M., Blayney, D., Catovsky, D., Bunn, P.A., Jr., Shibita, A., Nakao, Y., Ito, Y., Aoki, T., Gallo, R.C.: Evidence for HTLV-infection of family members of HTLV positive T-cell leukemia-lymphoma patients. *J. Exp. Med.* 157: 248-258, 1983.
78. Blayney, D.W., Blattner, W.A., Robert-Guroff, M.R., Jaffe, E., Fisher, R.I., Bunn, P.A., Jr., Patton, M.G., Rarick, H.R., Gallo, R.C.: The human T-cell leukemia/lymphoma virus (HTLV) in the Southeastern United States. *JAMA* 250: 1048-1052, 1983.
79. Blayney, D.W., Jaffe, E.S., Blattner, W.A., Cossman, J., Robert- Guroff, M., Longo, D., Bunn, P.A., Jr., Gallo, R.C.: The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphomas (ATL). *Blood* 62: 401-405, 1983.
80. Bunn, P.A., Jr., Schechter, G.P., Blayney D., Young, R.C., Matthews, M.J., Blattner, W., Broder, S., Robert-Guroff, M., Gallo, R.C.: Clinical course of retrovirus-associated adult T- cell lymphoma in the United States. *New Engl. J. Med.* 309: 257- 264, 1983.
81. Bunn, P.A., Jr., Carney, D.N., Gazdar, A.F., Whang-Peng, J., Matthews, M.J.: Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer. *Cancer Res.* 43: 5026-5032, 1983.
82. Brower, M., Ihde, D.C., Johnston-Early, A., Bunn, P.A., Jr., Cohen, M.H., Carney, D.N., Makuch, R.W., Matthews, M.J., Radice, P.A., Minna, J.D.: Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy. *Am. J. Med.* 75: 993-1000, 1983.
83. Mitsuya, H., Matis, L.A., Megson, M., Bunn, P.A., Jr., Murray, C., Mann, D.L., Gallo, R.C., Broder, S.: Generation of an HLA- restricted cytotoxic T- cell line reactive against cultured tumor cells from a patient with human T- cell leukemia/lymphoma virus. *J. Exp. Med.* 158: 994-999, 1983.
84. Brower, S., Carney, D.N., Ihde, D.C., Eddy, J., Bunn, P.A., Jr., Cohen, M.H., Pelsor, F.R., Matthews, M.J., Minna, J.D.: High dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. *Cancer* 52:1778-1782, 1983.
85. Morstyn, G., Ihde, D.C., Lichter, A.S., Bunn, P.A., Jr., Carney, D.N., Glatstein, E., Minna, J.D.: Small cell lung cancer 1973- 1983: Early progress and recent obstacles. *Int. Journal. Rad. Oncol. Biol. Phys.* 10:515-539, 1984.
86. Averbuch, S.D., Austin, H.A., III, Sherwin, S.A., Antonovyeh, T., Bunn, P.A., Jr., Longo, D.L.: Acute interstitial nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. *New Engl. J. Med.* 310:32-35, 1984.
87. Doyle, L.A., Ihde, D.C., Carney, D.N., Bunn, P.A., Jr., Cohen, M.H., Matthews, M.J., Puffenbarger, R., Cordes, R.S., Minna, J.D.: Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic

- carcinoma: Severe pulmonary toxicity from q 3 weekly mitomycin C. *Am. J. Clin. Oncol. (CCT)*, 7:719-724, 1984.
88. Broder, S., Bunn, P.A., Jr., Jaffe, E.S., Blattner, W.A., Gallo, R.C., Wong- Staal, F., Waldmann, T.A., DeVita, V.T.: T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. *Ann. Int. Med.* 100:543-557, 1984.
89. Mulshine, J.L., Makuch, R.W., Johnston-Early, A., Matthews, M.J., Carney, D.N., Ihde, D.C., Cohen, M.H., Bates, H.R., Dunnick, N.R., Minna, J.D., Bunn, P.A., Jr.: Diagnosis and significance of liver metastases in small cell carcinoma of the lung. *J. Clin. Oncol.* 2:733-741, 1984.
90. Jaffe, E.S., Blattner, W.A., Blayney, D.W., Bunn, P.A., Jr., Robert-Guroff, M., Gallo, R.C.: The pathologic spectrum of HTLV associated leukemia/lymphoma in the United States. *Am. J. Surg. Path.* 8:263-275, 1984.
91. Foon, K.A., Schroff, R.W., Bunn, P.A., Jr., Mayer, D., Abrams, P.G., Fer M., Ochs, J., Bottino, G.C., Sherwin, S.A., Carlo, D.J., Herberman, R.B., Oldham, R.K.: Effects of monoclonal antibody serotherapy in patients with chronic lymphocytic leukemia. *Blood* 64:1085-1093, 1984.
92. Crane, J.M., Nelson, M.J., Ihde, D.C., Makuch, R.W., Glatstein, E., Zabell, A., Johnston-Early, A., Bates, H.R., Saini, N., Cohen, M.H., Bunn, P.A., Jr.: A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. *J. Clin. Oncol.* 2:1017- 1024, 1984.
93. Schupbach, J., Sarngadharan, M.G., Blayney, D.W., Kalanaraman, V.S., Bunn, P.A., Jr., Gallo, R.C.: Demonstration of vial antigen p24 in circulating immune complexes of two patients with human T-cell leukemia/lymphoma virus (HTLV) positive lymphoma. *Lancet* I: 302-304, 1984.
94. Bunn, P.A., Jr., Foon, K.A., Ihde, D.C., Longo, D.L., Eddy, J., Winkler, C.F., Zeffern, J., Sherwin, S.A., Oldham, R.: Recombinant leukocyte A interferon: An active agent in advanced refractory cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). *Ann. Int. Med.* 101:484- 488, 1984.
95. Morstyn, G., Schechter, G.P., Ihde, D.C., Carney, D.N., Eddy, J.L., Cohen, M.H., Minna, J.D., and Bunn, P.A., Jr.: Therapy for multiple myeloma with alternating non-cross resistant chemotherapy combinations: Heterogeneity of tumor responsiveness. *Cancer Treat. Rep.* 68: 1439-1446, 1984.
96. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., Bunn, P.A., Jr.: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. *J. Immunol. Methods* 72:77- 89, 1984.
97. Bunn, P.A., Jr., Carrasquillo, J.A., Keenan, A.M., Schroff, R.W., Foon, K.A., Hsu, S.M., Gazdar, A.F., Reynolds, J.C., Perentesis, P., Larson, S.M.: Imaging of T-cell lymphoma by radiolabelled monoclonal antibody. *Lancet* II: 1219-1222, 1984.
98. Ihde, D.C., Johnston-Early, A., Carney, D.N., Cohen, M.H., Bunn, P.A., Jr., Pelsor, F.R., Minna, J.D.: Lack of efficacy of high dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung. *Cancer Treat. Rep.* 66:1223-1225, 1985.
99. Whang-Peng, J., Bunn, P.A., Jr., Knutsen, T., Kao-Shan, C.S., Broder, S., Gelman, E., Jaffe, E.S., Blattner, W., Lofters, W., Young, R.C., Gallo, R.C.: Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States. *J Natl. Cancer Inst.* 74:357-369, 1985.
100. Doyle, A., Martin, J., Funa, K., Gazdar, A., Carney, D., Martin, S., Linnoila, I., Cuttitta, F., Mulshine, J., Bunn, P.A., Jr., Minna J.D: Markedly decreased expression of class I histocompatibility antigens proteins in mRNA in human small cell lung cancer. *J. Exp. Med.* 161:1135-1151, 1985.
101. Lichter, A.S., Bunn, P.A., Jr., Ihde, D.C., Cohen, M.H., Makuch, R.W., Carney, D.N., Johnston-Early, A., Minna, J.D., Glatstein, E.: The role of radiation therapy in the treatment of small cell lung cancer. *Cancer* 55:2163-2175, 1985.
102. Dodd, R.C., Newman, S.L., Bunn, P.A., Jr., Winkler, C.F., Cohen, M.S., Gray, T.K.: Lymphokine induced monocytic differentiation as a possible mechanism for the hypercalcemia associated with adult T-cell lymphoma. *Cancer Res.* 45:2501-2506, 1985.
103. Johnson, B.E., Ihde, D.C., Bunn, P.A., Jr., Becker, B., Walsh, T., Weinstine, Z.R., Matthews, M.J., Whang-Peng, J., Makuch, R.W., Johnston- Early, A., Lichter, A.S., Carney, D.N., Cohen, M.H., Glatstein, E., Minna, J.D.: Small-cell lung cancer patients treated with combination chemotherapy with or without irradiation: Data on potential cures, chronic toxicities, and late relapses from a five to eleven year follow-up. *Ann. Int. Med.* 103:430-438, 1985.

104. Rosen, S.T., Radvany R., Roenigk, H., Jr., Terasaki, P., and Bunn, P.A., Jr.: HLA antigens in cutaneous T-cell lymphoma. *J. Amer. Acad. Derm.* 12:531-534, 1985.
105. Bunn, P.A., Jr., Linnoila, I., Minna, J.D., Carney, D., Gazdar, A.F.: Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. *Blood* 65:764-768, 1985.
106. Bertness, V., Kirsch, I., Hollis, G., Johnson, B., Bunn, P.A., Jr.: T-cell receptor gene rearrangements are clinical markers of human T-cell lymphomas. *New Engl. J. Med.* 313:534-538, 1985.
107. Lindmo, T., Boven, E., Mitchell, J.B., Morstyn, G., Bunn, P.A. Jr.: Specific killing of human melanoma cells by 125I-labelled 9.2.27 monoclonal antibody. *Cancer Res.* 45:5080-5087, 1985.
108. Sausville, E.A., Worsham, G.F., Matthews, M.J., Makuch, R.W., Fischmann, A.B., Schechter, G.P., Gazdar, A.F., Bunn, P.A., Jr.: Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system. *Human Pathol.* 16:1098-1109, 1985.
109. Gazdar, A.F., Bunn, P.A., Jr., Minna, J.D., Baylin, S.B.: Origin of small cell lung cancer. *Science* 229:679-680, 1985.
110. Sidi, Y., Edwards, N.L., Winkler, C., Bunn, P.A., Jr., Mitchell, B.S.: Differential metabolism of deoxyribonucleosides by leukemia T-cells of immature and mature phenotype. *Brit. J. Haematol.* 61:125-134, 1985.
111. Fargion, S., Carney, D.N., Mulshine, J., Rosen, S., Bunn, P.A., Jr., Jewett, P., Cuttitta F., Gazdar, A.F., Minna, J.D.: Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. *Cancer Res.* 46:2633-2638, 1986.
112. Dodd, R.C., Winkler, C.F., Bunn, P.A., Jr., Williams, M.E., Gray, T.K.: Calcitriol levels in hypercalcemic patients with adult T- cell lymphoma. *Arch. Intern. Med.* 146:1971-1972, 1986.
113. Johnson, B.E., Ihde, D.C., Matthews, M.J., Bunn, P.A., Jr., Zabell, A., Johnston-Early, A., Makuch, R.W., Cohen, M.H., Glatstein, E., Minna, J.D.: Non-small cell lung cancer: A major cause of late mortality in small cell lung cancer patients. *Am. J. Med.* 80:1103-1110, 1986.
114. Boven, E., Lindmo, T., Mitchell, J.B., Bunn, P.A., Jr.: Selective cytotoxicity of 125I-labeled monoclonal antibody T101 in human malignant T- cell lines. *Blood* 67:429-435, 1986.
115. Bunn P.A. Jr., Ihde, D.C., Foon, K.A.: The role of interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. *Cancer* 57:1689-1695, 1986.
116. Brooks, B.J., Jr., Seifter, E.J., Walsh, T.E., Lichter, A.S., Bunn, P.A., Jr., Zabell, A., Early-Johnston, A., Edison, M., Makuch, R.W., Cohen, M.W., Glatstein, E., Ihde, D.C.: Pulmonary toxicity with combined modality therapy for limited stage small cell lung cancer. *J. Clin. Oncol.* 4:200-209, 1986.
117. Batist, G., Carney, D.N., Cowan, K.H., Veach, S., Gilliam, M., Bunn, P.A., Jr. Idhe, D.C.: Etoposide (VP-16) and cisplatin in previously treated small cell lung cancer; Clinical trial and in vitro correlates. *J. Clin. Oncol.* 4:982-986, 1986.
118. Winkler, C.F., Sausville, E.A., Ihde, D.C., Fischmann, A.B., Schechter, G.P., Kumar, P.P., Minna, J.D., Makuch, R.W., Gazdar, A.F., Matthews, M.J., Eddy, J.L., Bunn, P.A., Jr.: Combined modality treatment of cutaneous T-cell lymphomas: Results of 6 year follow-up. *J. Clin. Oncol.* 4:1094-1100, 1986.
119. Ihde, D.C., Deisseroth, A.B., Lichter, A.S., Bunn, P.A., Jr., Carney, D.N., Cohen, M.H., Veach, S.R., Makuch, R.W., Johnston- Early, A., Abrams, R.A., Messerschmidt, G.L., Matthews, M.J. and Minna, J.D.: Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small cell lung cancer. *J. Clin. Oncol.* 10:1443-1454, 1986.
120. Carrasquillo, J.A., Bunn, P.A., Jr.: Keenan, A.M., Reynolds, J.C., Schroff, R.W., Foon, K.A., Hsu, S.M., Gazdar, A.F., Mulshine, J.L., Oldham, R.K., Parentesis, P., Horowitz, M., Eddy, J., James, P., Larson, S.M.: Radioimmunodetection of cutaneous T-cell lymphoma with 111In-T101 monoclonal antibody. *New Engl. J. Med.* 315 (11):673-680, 1986.
121. Seifter, E.J., Bunn, P.A., Jr., Cohen, M.H., Makuch, R.W., Dunnick, N.R., Javadpoor, N., Bensimon, H., Eddy, J.L., Minna, J.D., Ihde, D.C.: A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. *J. Clin. Oncol.* 4:1365- 1373, 1986.

FASCO

122. Pedersen, A.G., Becker, K.L., Bach, F., Snider, R.H., Gazdar, A.F., Sorensen, P.S., Bunn, P.A. Jr., Hansen, H.H.: Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer. *J. Clin. Oncol.* 4:1620-1627, 1986.
123. Funa, K., Dawson, N., Jewett, P.B., Agren, H., Ruckdeschel, J.C., Bunn, P.A., Jr., Gazdar, A.F.: Automated fluorescent analysis for drug induced cytotoxicity assays. *Cancer Treat. Rep.* 70:1147-1151, 1986.
124. Bunn, P.A., Jr., Greco, F.A., and Einhorn, L.: Cyclophosphamide, Doxorubicin and Etoposide as first line therapy in the treatment of small-cell lung cancer. *Semin. Oncol.* 13:45-53, 1986.
125. Schechter, G.P., Sausville, E., Fischmann, B.A., Soehnen, F., Eddy, J., Matthews, M.A., Munsen, D., Makuch, R., Bunn, P.A., Jr.: Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. *Blood* 69:841-849, 1987.
126. Dmitrovsky, E., Bunn, P.A., Jr., Matthews, M.J., Schechter, G.P., Makuch, R.W., Winkler, C., Eddy, J., Sausville, E., Ihde, D.C.: Cytologic transformation in cutaneous T-cell lymphoma: A clinicopathologic entity associated with poor prognosis. *J. Clin. Oncol.* 5:208-215, 1987.
127. Carrasquillo, J.A., Mulshine, J.L., Bunn, P.A., Jr. Reynolds, J.C., Foon, K.A., Schroff, R.W., Perentesis, P., Steis, R.G., Keenan, A.M., Horowitz, M., Larson, S.M.: ¹¹¹In T101 monoclonal antibody is superior to ¹³¹I-T101 in imaging of cutaneous T-cell lymphoma. *J. Nucl. Med.* 3:281-287, 1987.
128. Keenan, A.M., Weinstein, J.N., Mulshine, J.L., Carrasquillo, J.A., Bunn, P.A., Jr., Reynolds, J.C., Larson, S.M.: Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of ¹¹¹Indium-labeled T- 101 monoclonal antibody. *J. Nucl. Med.* 28:42-46, 1987.
129. Mulshine, J.L., Keenan, A.M., Carrasquillo, J.A., Walsh, T., Linnoila, R.I., Holton, H.D., Harwell, J., Bunn, P.A., Jr., Weinstein, J.N.: Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes. A new approach to lung cancer imaging. *Cancer Res.* 47:3572-3576, 1987.
130. Doyle, L.A., Cuttitta, F., Mulshine, J.L., Bunn, P.A., Jr., Minna, J.D.: Markedly different antibody responses to immunized small cell and non-small cell lung cancer cells. *Cancer Res.* 47:5009-5013, 1987.
131. Bunn, P.A., Jr., Lichter, A.S., Makuch, R.W., Cohen, M.H., Matthews, M.J. Veach, S., Johnston-Early, A., Edison, M., Glatstein, E., Minna, J.D., Idhe, D.C.: Chemotherapy alone or chemotherapy with chest radiotherapy in limited stage Small cell lung cancer. A prospective, randomized trial. *Ann. Int. Med.* 106:655-662, 1987.
132. Keenan, A.M., Weinstein, J.N., Carrasquillo, J.A., Bunn, P.A., Jr., Reynolds, J.C., Foon, K.A., Smarte, N.C., Ghosh, B., Fejka, R.M., Larson, S.M., Mulshine, J.L.: Immunolymphoscintigraphy and the dose-dependence of Indium-111-labeled T101 monoclonal antibody in patients with cutaneous T- cell lymphoma. *Cancer Res.* 47:6093-6099, 1987.
133. Bunn, P.A., Jr., Ihde, D.C., Foon, K.A.: Recombinant Alfa-2a interferon (Roferon-A) is an active agent in advanced cutaneous T- cell lymphomas. *Int. J. Cancer* 1:9-13, 1987.
134. Carmichael, J., Crane, J.M., Bunn, P.A., Jr., Glatstein, E., Idhe, D.C.: Results of therapeutic cranial irradiation in small cell lung cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 14:455-459, 1988.
135. Sausville, E.A., Eddy, J.L., Makuch, R.W., Fischmann, A.B., Schechter, G.P., Matthews, M., Minna, J.D., Glatstein, E., Ihde, D.C., Kaye, F., Veach, S.R., Gazdar, A.F., Phelps, R., O'Connor, T., Trepel, J.B., Cotelingham, J, Bunn, P.A., Jr.: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary Syndrome: Definition of three distinctive prognostic groups. *Ann. Int. Med.* 109:372-382, 1988.
136. Beck, L., Kane, M., Bunn, P.A., Jr.: Innovative and future approaches to small cell lung cancer treatment. *Semin. Oncol.* 15:300-314, 1988.
137. Frontiera, M., Murray, J.L., Thomas, J., Satterlee, W., Schmelter, R., Lamki, L., Rosenblum, M., Unger, M., Robinson, W.A., Bunn, P.A., Jr.: Sequential use of ¹¹¹Indium-labeled monoclonal antibodies 96.5 and ZME018 does not increase detection sensitivity for metastatic melanoma. *Clin. Nucl. Med.* 14:357-366, 1989.
138. Graham, M. L., Bunn, P.A., Jr., Jewett, P.B., Gonzalez-Aller, C., Horwitz, K.B.: Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: Characterization of an assay in breast cancer cell lines. *Cancer Res.* 49:3934-3942, 1989.
139. Kaye, F.J., Bunn, P.A., Jr., Steinberg, S.M., Stocker, J.L., Ihde, D.C., Fischmann, A.B., Glatstein, E.J., Schechter, G.P., Phelps, R.M., Foss, F.M., Parlett III, H.L., Anderson, M.J., Sausville, E.A.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. *New Engl. J Med.* 321:1784-1790, 1989.

140. Kohn, E.C., Steis, R.G., Sausville, E.A., Veach, S.R., Stocker, J.L., Phelps, R., Franco, S., Longo, D.L., Bunn, P.A., Jr., Ihde, D.C.: Phase II trial of intermittent high dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. *J. Clin. Oncol.* 8:155-160, 1990.
141. Kaplan, E.H., Rosen, S.T., Norris, D.B., Roenigk, H.H., Jr., Saks, S.R., Bunn, P.A. Jr.: Phase II study of recombinant human interferon-gamma for treatment of cutaneous T-cell lymphoma. *J Natl. Cancer Inst.* 82:208-212, 1990.
142. Kuzel, T.M., Gilyon, K., Springer, E., Variakojis, D., Kaul, K., Bunn, P.A. Jr., Evans, L., Roenigk, H.H., Rosen, S.T.: Interferon alpha-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma, *J Natl. Cancer Inst.* 082:203-207, 1990.
143. Bunn, P.A., Jr., Dienhart, D.G., Chan, D., Puck, T.T., Tagawa, M., Jewett, P.B., Braunschweiger, E.: Neuropeptide stimulation of calcium flux in human lung cancer cells: Delineation of alternative pathways. *Proc. Natl. Acad. Sci.* 87:2162-2166, 1990.
144. Longley, C., Furmanski, P., Dienhart, D., Lear, J., Bloedow, D., Kasliwal, R., Bunn, P.A. Jr.: Pharmacokinetics, biodistribution and gamma camera imaging of ¹¹¹In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts. *Cancer Res.* 50:5954-5961, 1990.
145. Dienhart, D.G., Schmelter, R.F., Lear J.L., Miller, G.J., Glenn, S., Bloedow, D.C., Seligman, P., Kortright, K., Bunn, P.A. Jr.: Imaging of non-small cell lung cancers with a monoclonal antibody, KC4G3, which recognizes a human milk globule antigen. *Cancer Res.* 50:7068-7076, 1990.
146. Lamb, R., Gonzalez, R., Myers, A., Bunn, P. Jr., Robinson, W. Aggressive non-Hodgkin's lymphomas in AIDS: The University of Colorado experience. *Am. J. Med. Sci.* 300:345-349, 1990.
147. Mulshine, J.L., Carrasquillo, J.A., Weinstein, J.N., Keenan, A.M., Reynolds, J.C., Herdt, J., Bunn, P.A., Jr., Sausville, E., Eddy, J., Cotelingam, J.D., Perentesis, P., Pinsky, C., Larson, S.M.: Direct intralymphatic injection of radiolabeled ¹¹¹In-T101 in patients with cutaneous T-cell lymphoma. *Cancer Res.* 51:688-695, 1991.
148. Lear, J.L., Kasliwal, R., Feyerabend, A.J., Pratt, J.P., Bunn, P.A., Dienhart, D.G., Gonzalez, R., Johnson, T.K., Bloedow, D., Maddock, S.W., Glenn, S.D.: Improved monoclonal antibody imaging of tumors by clearance of unbound antibodies from the plasma with an anti-antibody column. *Radiology* 179:509-512, 1991.
149. Hartmann, C., Bloedow, D.C., Dienhart, D.G., Kasliwal, R., Johnson, T.K., Maddock, S.W., Glenn, S.D., McAteer, M.J., Feyerabend, A., Gonzalez, R., Lear, J.L., Bunn, P.A., Jr.: A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal radioimmunoabsorption. *J. of Pharm. and Biopharm.* 19:385-403, 1991.
150. Howard, R.B., Chu, H., Zeligman, B.E., Marcell, T., Bunn, P.A., McLemore, T.L., Mulvin, D.W., Cowen, M.E., Johnston, M.R.: Irradiated nude rat model for orthotopic human lung cancers. *Cancer Res.* 51:3274-3280, 1991.
151. Johnson, T.K., Maddock, S., Kasliwal, R., Dienhart, D.G., Bloedow, D., Hartmann, C., Feyerabend, A., Thickman, D., Glenn, S., Gonzalez, R., Lear, J., Bunn, P.A., Jr.: Radioimmunoabsorption of KC-4G3 antibody in peripheral blood: Implications for radioimmunotherapy. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 4:885-893, 1991.
152. Kelly, K., Kane, M., Bunn, P.A., Jr.: Growth factors in lung cancer: Possible etiologic role and clinical target. *Med.& Pediat. Oncology* 19:449-458, 1991.
153. Gonzalez, R., Salem, P., Bunn, P.A., Jr., Zukiwski, A., Lamb, R., Spittler, L., Wedel, N., Robinson, W.A.: Single dose murine monoclonal antibody-ricin A chain immunotoxin in the treatment of metastatic melanoma: A phase I trial. *Mol. Biother.* 3:192-196, 1991.
154. Bunn, P.A., Jr., Chan, D., Dienhart, D.G., Tolley, R., Tagawa, M., Jewett, P.B.: Neuropeptide signal transduction in lung cancer: Clinical implications of bradykinin sensitivity and overall heterogeneity. *Cancer Res.* 52:24-31, 1992.
155. Johnson, T.K., Gonzalez, R., Kasliwal, R., Lear, J., Feyerabend, A., Dienhart, D.G., Ceriani, R., Bunn, P.A., Jr.: Distribution of a breast directed ¹³¹I radiolabeled monoclonal antibody in blood and bone marrow: Implications for radioimmunotherapy. *Radiology* 182:107-114, 1992.
156. Mulvin, D.W., Howard, R.B., Mitchell, D.H., Noker, P.E., Kruse, C.A., Chu, H.D., Bunn, P.A., Johnston, M.R.: A secondary screening system for preclinical testing of human lung cancer therapies. *J. National Cancer Instit.* 84:31-37, 1992.

157. Taylor, C.W., Chase, E.M., Whitehead, R.P., Rinehart, J.J., Neidhart, J.A., Gonzalez, R., Bunn, P.A., Hersh, E.M.: A Southwest Oncology Group phase I study of the sequential combination of recombinant interferon- γ and recombinant interleukin-2 in patients with cancer. *Journ Immunother.* 11:176-183, 1992.
158. Bunn, P.A., Jr., Dienhart, D.G., Chan, D., Tagawa, M., Jewett, P.: Effects of neuropeptides on human lung and breast cancer cells. *Journ Nat'l. Cancer Instit.* 13:145-152, 1992.
159. Malkinson, A.M., Siegel, D., Forrest, G.L., Gazdar, A.F., Oie, H.K., Chan, D.C., Bunn, P.A., Mabry, M., Dykes, D.J., Harrison, S.D., Jr., Ross, D.: Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin c1. *Cancer Res.* 52:4752-4757, 1992.
160. Hazuka, M.B., Bunn, P.A., Jr.: Controversies in the non-surgical treatment of stage III non-small cell lung cancer. *Am. Rev. Respir Dis.* 145:967-977, 1992.
161. Bunn, P.A., Jr., Kelly, K.: Antigens in lung cancer: clinical radioimmunolocalization in lung cancer. *Lung Cancer.* 9:171-178, 1993.
162. Chan, D.G., Kirpotin, D.B., Bunn, P.A., Jr.: Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer. *J. Magnes and Magn Mat'l* 122:374-378, 1993.
163. Franklin, W.A., Waintrub, M., Edwards, D., Christensen, K., Prendegast, P., Woods, J., Bunn, P.A., Jr., Kolhouse, F.: New anti-lung cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. *Int J Cancer (Suppl 8)*:89-95, 1994.
164. Bunn, P.A., Jr., Chan, D., Stewart, J., Dienhart, D., Tolley, R., Jewett, P., Tagawa, M.: Effects of neuropeptides analogues on calcium flux and proliferation in lung cancer cell lines. *Cancer Res.* 54:3602-3610, 1994.
165. Hazuka, M.B., Crowley, J.J., Bunn, P.A., Jr., O'Rourke M., Braun, T.J., Livingston, R.B.: Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small cell lung cancer: Results of phase II Southwest Oncology Group Study. *J Clin. Oncol.* 12:1814-1820, 1994.
166. Haugen, B.R., Nawaz, S., Cohn, A., Shroyer, K., Bunn, P.A., Jr., Liechty, D.R., Ridgway, E.C.: Secondary Malignancy of the thyroid gland: A case report and review of the literature. *Thyroid* 4:297-300, 1994.
167. Bunn, P.A., Jr., Hoffman, S.J., Norris, D., Golitz, L.E., Aeling, J.L.: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). *Ann Int Med* 121:592-602, 1994.
168. Dienhart, D.G., Kasliwal, R., Lear, J.L., Johnson, T.K., Bloedow, D.C., Hartmann, C., Seligman, P., Miller, G.J., Glenn, S.D., McAtter, M.J., Thickman, D., Feyerabend, A., Maddock, E.N., Maddock, S., Bunn, P.A., Jr.: Extracorporeal immunoabsorption of radiolabeled monoclonal antibody: A method for reduction of background radioactivity and its potential role during the radioimmunodetection and radioimmunotherapy of cancer. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 7:225-252, 1994.
169. Bunn, PA, Jr., Van Zandwijk N, Pastorino U, Aisner J, Alberto P, Arriagada R, Carney D, Cornis R, Dittrich C, Gatzemeier U et al. European School of Oncology. First Euro-American Forum on Lung Cancer Treatment. *Eur J Cancer* 30A (5): 710-13, 1994.
170. Bunn, P.A., Jr., Crowley, J., Kelly, K., Hazuka, M., Beasley, K., Upchurch, C., Weiss, G.R., Hicks, W.J., Gandara, D.R., Rivkin, S., Livingston, R.: Chemoradiotherapy with or without GM-CSF in the treatment of limited stage small cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. *J Clin Oncol* 13:1632-1641, 1995.
171. Bunn, P.A., Jr., Kelly, K.: A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: A University of Colorado Cancer Center Study. *Semin. Oncol.* 22:54-58, 1995.
172. Schrier, D.M., Stemmer, S., Johnson, T., Kasliwal, R., Lear, J., Matthes, S., Taffs, S., Dufton, C., Glenn, S., Butchko, G., Ceriani, R., Rovira, D., Bunn, P.A., Jr., Shpall, E.J., Bearman, S., Purdy, M., Cagnoni, P., Jones, R.B.: High-dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial. *Cancer Res.* 55:5921s-5924s, 1995.
173. Kelly, K., Crowley, J., Bunn, P.A., Jr., Hazuka, M.B., Beasley, K., Upchurch, C., Weiss, G.R., Hicks, W.J., Gandara, D.R., Rivkin, S., Livingston R.: The role of alfa interferon (r-IFN 2a) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: A Southwest Oncology Group Study (SWOG). *J. Clin. Oncol.* 13:2924-2930, 1995.

174. Heasley, L.E., Zamarripa, J., Storey, B., Helfrich, B., Mitchell, F.M., Bunn, P.A., Jr., Johnson, G.L.: Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient Ga16. *J. Biol. Chem.* 27:349-354, 1996.
175. Cohen, A.J., Bunn, P.A., Franklin, W., Magill-Solc, C., Hartmann, C., Helfrich, B., Gilman, L., Folkvord, J., Helm, K., Miller, Y.E.: Neutral endopeptidase: Variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. *Cancer Res.* 56:831-839, 1996.
176. Bunn, P.A., Jr., Foss, F.: T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). *J. Cell Biochem Suppl* 27:1-12, 1996.
177. Phelps, R.M., Johnson, B.E., Ihde, D.C., Gazdar, A.F., Carbone, D.P., McClintock P.R. Linnoila I., Matthews, M.J., Bunn, P.A., Jr., Carney, D., Minna, J.D., Mulshine J.L.: NCI-Navy Medical Oncology Branch Cell Line Data Base. *J. Cell Biochem Suppl* 24:32-91, 1996.
178. Chan, D., Gera, L., Helfrich, B., Helm, K., Stewart, J., Whalley, E., Bunn, P.A., Jr.: Novel bradykinin antagonist dimers for the treatment of human lung cancers. *Immunopharmacology* 33:201-204, 1996.
179. Leonard, C.E., Chan, D.C., Chou, T-C, Kumar, R., Bunn, P.A., Jr.: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. *Cancer Res.* 56:5198-5204, 1996.
180. Franklin, W.A., Folkvord, J.M., Varella-Garcia, M., Kennedy, T., Proudfoot, S., Cook, R., Dempsey, E.C., Helm, K., Bunn, P.A., Jr., Miller, Y.: Expansion of bronchial epithelial cell populations in in vitro culture of explants from dysplastic and histologically normal sites. *Amer. J. Resp Cell. Molec. Biol.* 15:297-304, 1996.
181. Kelly, K., Pan, Z., Murphy, J., Huffman, J., Bunn, P.A., Jr.: A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. *Clin. Cancer Res.* 3:1117-1123, 1997.
182. Pisters, K., Kris, M., Bunn, P.A., Jr., Johnson, D., Ruckdeschel, J., Crowley, J., Ginsberg, R.: Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. *Semin. Oncol.* 24:41-44, 1997.
183. Bunn, P.A., Jr., Kelly, K.: New Chemotherapeutic Agents Prolong Survival and Improve Quality of Life in Non-Small Cell Lung Cancer: A Review of the Literature and Future Directions. *Clin. Cancer Res.* 5:1087-1100, 1998.
184. Ahnen, D.A., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L.C., Bunn, P.A., Jr., Stemmerman, G., Wells, J.D., Macdonald, J.S., and Meyskens, F.L., Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A southwest oncology group study. *Cancer Res.* 58:1149-1158, 1998.
185. Beekman, A., Helfrich, B., Bunn, P.A., Jr. and Heasley, L.E. Expression of Catalytically inactive phospholipase C β disrupts phospholipase C β and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. *Cancer Res.* 58:910-913, 1998.
186. Kelly, K., Hazuka, M., Pan, Z., Murphy, J., Caskey, J., Leonard, C., and Bunn, P.A., Jr. A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. *Int. J Radiation Oncology Biol. Phys.* 40:559-567, 1998.
187. Bunn, P.A., Jr., Helfrich, B., Brenner, D., Chan, D.C., Dykes, D.J., Cohen, A., Miller, Y.E.: Effects of recombinant neutral endopeptidase (NEP; EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. *Clin. Cancer Res.* 4:2849-2858, 1998.
188. Bunn, P.A., Jr., Soriano, A.R.: Chemotherapeutic Options in Lung Cancer, *Cancer*, 83:1740-1750, 1998.
189. Chan, D.C., Geraci, M., Bunn, P.A., Jr.: Anti-growth factor therapy for lung cancer. *Drug Resistance Updates* 1:377-388, 1998.
190. Bunn, PA, Jr.: Cancer and Acquired Immunodeficiency Syndrome Wasting Syndromes: Current and Future Therapies. *Semin Oncol* 25: 1-3, 1998.
191. Bunn, P.A., Jr.: Triplet Chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. *Semin. Oncol* 26:25-30, 1999.
192. Kelly, K., Pan, Z., Wood, M., Murphy, J., Bunn, P.A., Jr.: A phase I study of paclitaxel, etoposide, and cisplatin (PET) in extensive stage small cell lung cancer. *Clin. Cancer Res.*, 5:3419-3424, 1999.
193. Soriano, A.F., Helfrich, B., Chan, D. C., Heasley, L.E., Bunn, P.A., Jr.: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. *Cancer Res.* 59(24): 6178-84, 1999.

FASCO

194. Stewart, J.M., Gera, L, York, E.J., Chan, D.C., Heasley, L.E, Bunn, P. Bradykinin antagonists: present progress and future prospects. *Immunopharmacology* 43: 155-161, 1999.
195. Pisters, KMW, Ginsberg, R.J., Giroux, D.J., Putnam, J.B., Jr., Kris, M.D., Johnson, D.H., Roberts, J.R., Mault, J., Crowley, J.J., Bunn, P.A., Jr. on behalf of the Bimodality Lung Oncology Team (BLot), Induction chemotherapy prior to surgery for early stage lung cancer: A novel approach. *J Thorac Cardiovasc Surg*, 119: 429-39, 2000.
196. Kelly, K, Mikhaeel-Kamel, N, Pan Z, Murphy J, Prindiville, S, Bunn, P.A., Jr.: A phase I/II trial of paclitaxel, carboplatin and gemcitabine in untreated patients with advanced non-small cell cancer. *Clin Cancer Res* 6(9): 3474-3479, 2000.
197. Bunn, PA, Jr. New combinations in the treatment of lung cancer. A time for optimism. *Chest* 117: 138S-143S, 2000.
198. Bunn, PA, Jr., Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer. Biology and molecular biology come of age. *Chest* 117: 163S-168S, 2000.
199. Bunn, PA, Jr., Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer. A time for reassessment? *Chest* 117: 119S-122S, 2000.
200. Wood ME, Kelly K, Mullineaux LG, Bunn PA Jr. The inherited nature of lung cancer: a pilot study. *Lung Cancer* 30: 135-144, 2000.
201. Agus, DB, Bunn, PA Jr., Franklin, W, Garcia, M, Ozols RF. HER-2/NEU as a therapeutic target in non-small cell lung cancer, prostate cancer and ovarian cancer. *Semin Oncol* 27: 53-63, 2000.
202. Calvo, R, West, J, Franklin, W, Erickson, P, Bemis, L, Li, E, Helfrich, B, Bunn, P, Roche, J, Brambilla, E, Rossel R, Gemmill RM, Drabkin, HA. HOX gene expression in human lung cancer. *Proc Natl Acad Sci USA*, 97(23): 12776-81, 2000.
203. Kelly K, Crowley J, Bunn PA, Jr. Presant CA, Grevstad PK, Wozniak AJ, Weiss, GR, Moore DF, Israel VK, Livingston RB, Gandara DR. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. *J Clin Oncol*. 19(13): 3210-18, 2001.
204. Kelly K, Lovato L, Bunn PA, Jr., Livingston RB, Zangmeister J, Taylor SA, Roychowdhury, D, Crowley JJ, Gandara DR. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. *Clinical Cancer Research* 7: 2325-29. 2001.
205. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA, Jr. Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology. *Clinical Cancer Research* 7: 5-22, 2001.
206. Bunn PA, Jr., Helfrich B, Soriano AF, Franklin WF, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. *Clinical Cancer Research* 7: 3239-50, 2001.
207. Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Jr., Kennedy TC. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. *J Natl Cancer Inst*. 93: 1385-92, 2001.
208. Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA, Jr., Vavrek RJ. Metabolism-resistant bradykinin antagonists: Development and Applications. *Biol Chem* 382: 37-41, 2001.
209. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. *Leuk Lymphoma* 41: 77-87, 2001.
210. Stewart JM, Gera L, Chan DC, Bunn PA, Jr., York EJ, Simkeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. *Cancer J Physiol Pharmacol*. 80: 275-80, 2002.
211. Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA, Jr. Preclinical studies of gemcitabine (GemzarR) and Trastuzumab (HerceptinR) in breast- and lung cancer cell lines. *Clinical Breast Cancer* 3 (suppl. 1): S12-S16, 2002.
212. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA, Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. *Brit J Cancer* 86: 1449-56, 2002.

213. Chan DC, Earle KA, Zhao TLM, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukeu R, Thompson J, Alila H, Nelson P, Bunn PA, Jr. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. *Clin Cancer Res* 8: 904-12, 2002.
214. Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TLM, Wan YF, Chan K, Covey JM, Bunn PA, Jr. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. *Proc Nat Acad Sci USA* 99: 4608-13, 2002.
215. Chan DC, Gera L, York E, Stewart J, Helfrich B, Zhao TLM, Feng WY, Chan KK, Covey JM, Bunn PA, Jr. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other anti-tumor agents. *Clin Cancer Res* 8: 1280-87, 2002.
216. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapdat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis genes as biomarkers in lung carcinoma. *Cancer Res.* 62: 3971-79, 2002.
217. Bunn PA, Jr, Keith RL. The future of COX-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer. *Clin Lung Cancer* 3: 271-277, 2002.
218. Stewart JM, Gera L, Chan DC, Bunn PA, Jr., York EJ, Simeviciene V, Helfrich B. Bradykinin-related compounds as new drugs for cancer and inflammation. *Can J Physiol Pharmacol* 80: 275-280, 2002.
219. Bunn PA, Jr. Treatment of advanced non-small-cell lung cancer with two drug combinations. *J Clin Oncol* 20: 3565-67, 2002.
220. Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Jr., Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. *Int Immunopharmacol Kinase* 2: 1781-86, 2002.
221. Prindiville SA, Byers T, Hirsch FR, Franklin WA, Miller YE, Vu KO, Wolf HJ, Baron AE, Shroyer KR, Franklin WA, Zeng C, Kennedy TC, Bunn PA, Jr. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. *Cancer Epidemiology, Biomarkers and Prevention* 10: 987-93, 2003.
222. Hirsch FR, Varella-Garcia M, Di Marie MV, Veve R, Baron AE, Zeng C, Franklin WA, Bunn PA, Jr. Epidermal growth factor receptor in non-small cell lung carcinomas: Correlation between gene and protein expression and impact prognosis. *J Clin Oncol.*20: 3798-3807, 2003.
223. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TLM, Piazza G, Klein-Szanto AJP, Pamukcu R, Alila H, Bunn PA Jr., Thompson WJ. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic tumor model augments docetaxel treatment and contributes to increased survival. *Mol Cancer Ther* 2; 479-88, 2003.
224. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor-receptor in non-small-cell lung cancer. *Clin Cancer Res.* 9: 5813-24, 2003.
225. Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA, Jr., Miller YE. High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum. *Chest* 125: 109s, 2004.
226. Raben D, Helfrich B, Bunn PA, Jr. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. *Int. J. Radiat Oncol Biol Phys* 59: 27-38, 2004.
227. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA, Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 22: 1589-97, 2004.
228. Monnerat C, LeChevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn, PA Jr., Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced stage non-small cell lung cancer. *Clin Cancer Res* 10: 5439-46, 2004.
229. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Jr., Chan DC, Pallansch P and Eckhardt GS. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumor. *Clin Cancer Res* 10: 7229-37, 2004.

230. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignagna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. *Mol Cancer Ther* 8: 977-983, 2004.
231. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Jr., Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of Orthologous Gene Expression between human pulmonary adenocarcinoma and a carcinogen-induced Murine model. *Am J Pathol*. 167(6): 1763-75. 2005.
232. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK, Bunn PA, Jr. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. *Clin Cancer Res*. 11: 795-805, 2005.
233. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Jr., Varella-Garcia M. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. *J National Cancer Institute*. 97(9):643-55, 2005.
234. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Jr., Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. *J Clin Oncol* 23:5007-5018, 2005.
235. Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA, Jr., Miller YE. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. *Lung Cancer* 49:187-191, 2005.
236. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn Jr PA, Franklin WA, Crowley J, Gandara DR. Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients with Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. *J Clin Oncol* 23 (28):6838-45, 2005.
237. Thienelt CD, Bunn, P, Hanna N, Rosenberg A, Needle MA, Long ME, Gustafson DL, Kelly K. Multicenter Phase I/II study of Cetuximab with Paclitaxel and Carboplatin in untreated patients with Stage IV non-small cell lung cancer. *J Clin Oncol*. 2005; 23(34): 8786-8793.
238. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, Taraseviciene-Stewart L. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. *Peptides* 2005; 26(8):1288-1291.
239. Sunpaweravong P, Magree L, Rabinovitch R, Bunn P, Kelly K. A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. *Invest New Drugs*. 2006; 24(3): 213-221.
240. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. *Br.J Cancer* 2005; 1334-40.
241. Witta SE, Gemmill RM, Hirsch, FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines. *Cancer Res*; 66(2):944-950, 2006.
242. Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol*; 24(13):2038-43, 2006.
243. Miller YE, Vu KO, Kennedy TC, Hirsch FR, Petty TL, Bunn PA, Keith RL, Franklin WA, Wolf HJ, Prindiville S, Byers T. Lack of Association Between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality. *J Thoracic Oncol*, 1(4):302-307, 2006.
244. Cappuzzo F, Toschi L, Tallini G, Ceresoli G, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn, Jr. PA, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor I (IGFR-I) is significantly associated with longer survival in non-small cell lung cancer (NSCLC) patients treated with Gefitinib. *Annals Oncology*; 17: 1120-1127, 2006.

245. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. *Cancer Research*; 66(6):3338-44, 2006.
246. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Baron AE, Crino L, Franklin WA, Bunn Jr., PA, Varella-Garcia M, Danenberg LD and Hirsch F. Epidermal Growth Factor Receptor Messenger RNA Expression, gene dosage and gefitinib sensitivity in non-small cell lung cancer. *Clin Cancer Res* 12: 3078-3084, 2006.
247. Weiss G, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn L, Nguyen B, Paul S, McAndrews P, Bunn Jr., P, Kelly K. Elderly patients (≥ 70 years old) benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed versus docetaxel in patients with advanced non-small cell lung cancer previously treated with chemotherapy. *J Clin Onc*; 24(27): 4405-4411, 2006.
248. Bunn Jr., PA, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR. Biologic markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. *Clin Cancer Res*. 12 (12):3652-3656, 2006.
249. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Baron A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA, Jr. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. *Mol Cancer Res*. 4 (8):521-8, 2006.
250. Schefter TE, Kavanagh BD, Raben D, Kane M, Chen C, Stuhr K, Kelly K, Mitchell JD, Bunn PA, Jr., Gaspar LE. A Phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. *Int J Radiation Oncology Biol Phys*. 66(4):S120-S127, 2006.
251. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. *J Clin Oncol*; 24(31), 5034-42, 2006.
252. Helfrich, B. A., Raben, D., Varella-Garcia, M., Gustafson, D., Chan, D. C., Coldren, C., Baron, A., Zeng, C., Franklin, W. A., Hirsch, F. R., Gazdar, A., Minna, J., Bunn, P. A., Jr. Antitumor activity of the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in NSCLC cell lines and xenografts correlates with gene copy number and EGFR mutations but not EGFR protein levels. *Clin Can Research* 12:(23), 7117-7125. 2006.
253. Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Jr., Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small cell lung cancer patients treated with chemotherapy. *Annals Oncology*. 18:447-452, 2007.
254. Dziadziuszko, R., Siemiakowska, A., Limon, J., Rzyman, W., Jassem, J., Bunn, P. A., Jr., Varella-Garcia, M, Hirsch, F. R. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: A case report. *JTO* 2:(1), 91-92. 2007.
255. Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsy-pin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A., Jr., Carbone DP. Mass spectrometry to predict clinical outcome for NSCLC patients treated with EGFR TKIs: A multi-cohort cross institutional study. *J Natl Cancer Inst*, 99:(11), 838-46, 2007.
256. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 18(4), 752-60, 2007.
257. Weiss, G. J., Rosell, R., Fosella, F., Perry, M., Stahel, R., Barata, F., Nguyen, B., Paul, S., McAndrews, P., Hanna, N., Kelly, K., Bunn, P. A., Jr. The impact of induction chemotherapy on the outcome of second-line therapy with Pemetrexed or Docetaxel in patients with advanced non-small-cell lung cancer. *Ann Oncol*, 18:453-460, 2007.
258. Miller, Y. E., Blatchford, P., Hyun, D. S., Keith, R. L., Kennedy, T. C., Wolf, H., Byers, T., Bunn, P. A. Jr., Lewis, M. T., Franklin, W. A., Hirsch, F. R., Kittelson, J. Bronchial epithelial Ki-67 index is related to histology, smoking and gender but not lung cancer or chronic obstructive pulmonary disease. *Cancer Epidemiol Biomarkers Prev*, 16(11):2425-2431, 2007.

259. Frederick B., Helfrich B., Coldren C., Zheng D., Chan D, Bunn P.A., Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small-cell lung cancer. *Mol Cancer Ther* 6:(6), 2007.
260. Varella-Garcia M., Miller Y.E., Hirsch F.R., Mitchell J.D., Keith R.L. Baron A.E. Bunn P.A., Jr., Franklin W.A. Spectral karyotyping detects chromosome damage in bronchial cells of smokers and cancer patients. *Am J Respir Crit Care Med*, 176:(5), 505-12, 2007.
261. Weiss G., Vokes E., Bunn P.A., Jr., Magree, L., Rusk, J., Albert, D., Kelly, K. Docetaxel and Exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial. *J Thor Oncol* 2(10), 933-38, 2007.
262. Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA, Jr. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. *Clin Lung Cancer* 8: 335038, 2007.
263. Marek L.; Ware K.E.; Fritzsche A.; Hercule P.; Helton W.R.; Smith J.E.; McDermott L.A.; Coldren C.D.; Nemenoff R.A.; Merrick D.T.; Helfrich B.A.; Bunn P.A. Jr; Heasley L.E. Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-small cell lung cancer cells. *Mol Pharmacol*, 2008 Oct 10. Epub ahead of print.
264. Byers, T., Wolf, H. J., Franklin, W. A., Braudrick, S., Merrick, D. T., Shroyer, K. R., Hirsch, F. R., Zeng, C., Baron, A. E., Bunn, P. A., Miller, Y. E., Kennedy, T. C. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. *Cancer Epidemiol Biomarkers Prev* 17:(1), 158-162. 2008.
265. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums D, Speake G, Holloway B, Bunn PA, Jr., Franklin WA. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cut-off points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. *Cancer* 112:(5), 1114-1121, 2008.
266. Solomon, B., Helfrich, B, Zeng, C., Chansky, K., Nakajima, E., Gazdar, A. F., Gandara, D., Franklin, W. A., Hirsch, F. R., Duncan, M. W., Bunn, P. A., Jr., Hunsucker, S. W. Identification of putative biomarkers of gefitinib sensitivity in non-small cell lung cancer using difference gel electrophoresis (DIGE). *Clin Can Research*, submitted, 2008
267. Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., Varella-Garcia, M., Bunn, P. A., Jr., Haney, J., Helfrich, B. A., Kato, H., Hirsch, F. R., Franklin, W. A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. *Annals of Oncology*, 19: 1053-59, 2008.
268. Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P.A., Jr., Varella-Garcia, M., Gandara, D. R. Increased EGFR gene copy number detected by FISH predicts outcome in non-small cell lung cancer patients treated with cetuximab and chemotherapy. *J Clin Oncol*, 26: 3351-57, 2008
269. Hickinson, D.M., Marshall, G., Beran, G., Varella-Garcia, M., Mills, E.A., South, M., Cassidy, A.M., Acheson, K., McWalter, G., McCormack, R., Bunn, Jr. P.A., French, T., Graham, A., Holloway, B.R., Hirsch, F.R., Speake, G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. *Mol Cancer Therapeutics*, in press, 2008.
270. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neil V, Bunn PA, Jr. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. *Clin Cancer res* 14: 6317-23, 2008.
271. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P, Bunn PA, Jr. The IASLC Lung Cancer Staging Project: proposals for the including of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 3: 1213-23, 2008.
272. Witta, S.E., Dziadziuszko, R., Lapadat, R., Hedman, K., Gemmill, R.M., Bunn, Jr. P.A., Hirsch, F.R. ErbB-3 expression is associated with E-cadherin and their co-expression restores response to gefitinib in non-small cell lung cancer (NSCLC). *Annals of Oncology* 20: 689-695, 2009.
273. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Jr., Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. *J Thoracic Oncol* 4: 318-25, 2009.

274. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDeremott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Jr., Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. *Mol Pharmacol* 75: 196-207, 2009.
275. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P, Bunn, PA, Jr. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 4: 1049-59, 2009.
276. Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P, Bunn, PA, Jr. The IASLC Lung Cancer Staging Project: data elements for the prospective project. *J Thorac Oncol* 4:679-683, 2009.
277. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, Bunn PA, Jr. International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol* 4: 792-801, 2009.
278. Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. *Cancer Prev Res* 2: 440-449. 2009.
279. Gera L, Chan DC, Simkeviciene V, Bunn PA, Jr., Stewart JM. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. *Adv Exo Med Biol* 611: 465-466, 2009.
280. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, Bunn, PA, Jr. The IASLC lung cancer staging project: a proposal for a new international lymph node amp in the forthcoming seventh edition of the TNM classification for lung cancer. *J Thorac Oncol* 4: 568-77, 2009.
281. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. *Immunotherapy* 1: 19-25, 2009.
282. Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. *Clin Transl Sci* 2: 183-192, 2009.
283. Pisters KM, Vallieres E, Crowley JJ, Franklin W, Bunn P, Ginsberg RJ, Putnam JB, Chansky K, Gandara DR. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer: Southwest Oncology ///group Trial S9900, an intergroup, randomized, phase III trial. *J Clin Oncol* 28: 1843-1849, 2010.
284. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. *Cancer Lett*, October 25, 2010.
285. Dziadziuszko R, Merrick DR, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Jr., Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF 1R) gene copy number is associated with survival in operable non-small- cell lung cancerL a comparison between IGF 1R fluorescent in situ hybridization, protein expression, and mRNA expression. *J Clin Oncol* 28: 2174-2180, 2010.
286. Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H, Skuladottir H, Gudbjartsson T, Isaksson HJ, Isla D, Murillo L, Garcia-Prats MD, Panadero A, Aben KK, Vermeulen SH, van der Heijden HF, Feser WJ, Miller YE, Bunn PA, Kong A, Wolf HJ, Franklin WA, Mayordomo JI, Kiemenev LA, Jonsson S, Thorsteinsdottir U, Stefansson L. Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. *Cancer Res* 71: 1356-1361, 2011.
287. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garret-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. *Cancer Lett* 300: 66-78, 2011.
288. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr., Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. *Cancer Prev Res* 365: 793-902, 2011.

289. Hirsch FR, Kabbinar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr., Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. *J Clin Oncol* 29: 3567-3573, 2011.
290. Barash O, Peled N, Tisch U, Bunn PA Jr, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. *Nanomedicine*, 8: 580-589, 2012.
291. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spisa AI, Ruxer RL, Varella-Garcia M, Bunn Jr. PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small cell lung cancer who progressed on prior chemotherapy. *JCO* 30: 2248-2255, 2012.
292. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Baron AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. *Cancer*, 118: 4502-4510, 2012.
293. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Jr., Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. *Cancer Res* 72: 4154-4164, 2012.
294. Peled N, Hakim M, Bunn PA, Jr., Miller YE, Kennedy TC, Mattel J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. *J Thorac Oncol* 7: 1528-1533, 2012
295. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Jr., Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. *J Thoracic Oncol* 7: 1807 – 1814, 2012
296. Mascaux C, Feser WJ, Baron AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention. *Cancer Prev Res* 6: 100-118, 2013
297. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. *Cancer*. 2013 Jul 1;119(13):2383-90. doi: 10.1002/cncr.28089. Epub 2013 Apr 12. PMID:23585220
298. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of lung cancers harboring NRAS mutations. *Clin Cancer Res*. 2013 May 1;19(9):2584-91. doi: 10.1158/1078-0432.CCR-12-3173. Epub 2013 Mar 20. PMID: 23515407
299. Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. *Nanomedicine*. 2013 Aug;9(6):758-66. doi: 10.1016/j.nano.2013.01.008. Epub 2013 Feb 18. PMID: 23428987
300. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan A-C, Camidge RC, Varella-Garcia M, Doebele RC. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. *PLOS One* 8(12):e82236,2013
301. Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR. Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non-Small-Cell Lung Cancer. *J Thorac Oncol*. 2013 Dec;8(12):e112-3. PMID:24389447
302. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *Lancet*. 2014 May 3;383(9928):1561-71. doi: 10.1016/S0140-6736(13)62159-5. Epub 2014 Feb 25. Review. PMID: 24576776
303. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. *Clin Cancer Res*. 2014 Apr 25. PMID: 24771645
304. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.

- Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741. PMID: 24846037
305. Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. *Cancer*. 2014 Oct 1. doi: 10.1002/cncr.29042. PMID: 25273224
306. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2014 Oct 27. pii: JCO.2014.56.7412. PMID: 25349291
307. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. *Oncologist*. 2015 Mar;20(3):316-22. PMID: 25721120
308. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol*. 2015 May;10(5):768-77. PMID: 25738220
309. Bunn PA Jr, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. *Clin Lung Cancer*. 2015 Jul;16(4):245-51. PMID: 25887065
310. Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. *Oncologist*. 2015 Oct;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114. Epub 2015 Sep 1. PMID: 26330460
311. Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. *Oncologist*. 2015 Oct;20(10):1175-81. PMID: 26330460
312. Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. *Cancer Prev Res (Phila)*. 2016 Jan;9(1):96-104. PMID: 26542061
313. Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. *Cancer*. 2016 Mar 1;122(5):674-5. doi: 10.1002/cncr.29797. Epub 2015 Dec 23. PMID: 26700372
314. Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. *Cancer*. 2016 Mar 1;122(5):766-72. PMID: 26695526
315. Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? *J Thorac Oncol*. 2016 Apr;11(4):453-74. PMID: 26829312
316. Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. *Mol Cancer Ther*. 2016 Oct;15(10):2314-2322. Epub 2016 Aug 5. PMID: 27496133

317. He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. *Oncotarget*. 2016 Nov 21. doi: 10.18632/oncotarget.13486. [Epub ahead of print] PMID: 27893413
318. Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. *Lung Cancer*. 2016 Jun;96:27-32. doi: 10.1016/j.lungcan.2016.03.007. Epub 2016 Mar 26. PMID: 27133746
319. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. *J Thorac Oncol*. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. PMID: 27229180.
320. Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. *J Thorac Oncol*. 2017 Jan;12(1):27-35. doi: 10.1016/j.jtho.2016.09.003. Epub 2016 Sep 15. PMID: 27642065
321. Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. *J Clin Oncol*. 2017 Jan 10;35(2):243-252. Epub 2016 Nov 7. PMID: 28056194.
322. Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. *Lung Cancer*. 2017 Feb;104:45-51. doi: 10.1016/j.lungcan.2016.12.007. Epub 2016 Dec 12. PMID: 28212999
323. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. *J Thorac Oncol*. 2016 Sep;11(9):1411-22. doi: 10.1016/j.jtho.2016.05.024. Epub 2016 Jun 11. PMID: 27296106
324. Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. *Clin Cancer Res*. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23. PMID: 27642065
325. Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. *Anticancer Drugs*. 2017 Nov;28(10):1086-1096. doi: 10.1097/CAD.0000000000000545. PMID: 28857767
326. Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. *Cancer*. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25. PMID: 28743157
327. Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Brief Report: Baseline and on treatment characteristics of serum tumor markers in stage IV oncogene-addicted adenocarcinoma of the lung. *J Thorac Oncol*. 2017 Aug 23. pii: S1556-0864(17)30680-9. doi: 10.1016/j.jtho.2017.08.005. [Epub ahead of print]. PMID: 28843358
328. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer. *J Thorac Oncol*. 2017 Nov 23. pii: S1556-0864(17)33053-8. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. PMID: 29175116
329. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. *Nat Rev Cancer*. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. PMID: 29077690
330. Helfrich BA, Gao D, Bunn PA Jr. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. *Lung Cancer*. 2018 Apr;118:148-154. doi: 10.1016/j.lungcan.2018.02.001. Epub 2018 Feb 4. PMID: 29571994.

331. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. *Ann Oncol*. 2018 Jun 14. doi: 10.1093/annonc/mdy196. [Epub ahead of print]. PMID: 29905778
332. McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varela-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. *Clin Cancer Res*. 2018 Apr 10. doi: 10.1158/1078-0432.CCR-17-2452. [Epub ahead of print]. PMID: 29636358. PMCID: PMC6050099.
333. Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. *Clin Lung Cancer*. 2018 Mar 21. pii: S1525-7304(18)30056-1. doi: 10.1016/j.clc.2018.03.014. [Epub ahead of print]. PMID: 29773328
334. He YY, Liu ST, Mattei J, Bunn Jr PA, Zhou CC, Chan D. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. *Drug Des Devel Ther*. 2018 Apr 24;12:981-986. doi: 10.2147/DDDT.S163304. PMID:29731605.
335. Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). *Cancer*. 2018 Mar 26. doi: 10.1002/cncr.31313. [Epub ahead of print]. PMID: 29579334.
336. Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). *Clin Cancer Res*. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7. PMID: 29217530.
337. Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. *J Thorac Oncol*. 2018 Nov;13(11):1717-1726. doi: 10.1016/j.jtho.2018.07.001. Epub 2018 Jul 5. PMCID: PMC6204290
338. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. *Cancer Res*. 2018 Sep 1;78(17):4971-4983. doi: 10.1158/0008-5472.CAN-17-3822. Epub 2018 Jul 11. PMCID: PMC6147150.
339. Bunn PA Jr, Dimou A. Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. *J Clin Oncol*. 2018 Sep 1;36(25):2571-2574. doi: 10.1200/JCO.2018.79.2457. Epub 2018 Jul 20. PMID: 30028655
340. Navani N, Fisher DJ, Tierney JF, Stephens RJ, Burdett S; NSCLC Meta-analysis Collaborative Group. The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data. *Chest*. 2019 Mar;155(3):502-509. doi: 10.1016/j.chest.2018.10.020. Epub 2018 Oct 26. PMID: 30391190.
341. Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, Robin T, Liu A, Karam S, Gaspar L, Kavanagh B, Rusthoven C, Aisner D, Doebele R, Camidge DR. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2019 Apr;14(4):691-700. doi: 10.1016/j.jtho.2018.12.014. Epub 2018 Dec 30. PMID: 30599201
342. El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, Owonikoko TK, Kris MG, Johnson BE, Kwiatkowski DJ, Sholl LM, Aisner DL, Bunn PA, Khuri FR, Ramalingam SS. Characteristics and Outcomes of Patients With

- Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol*. 2019 Feb 5. pii: S1556-0864(19)30097-8. doi: 10.1016/j.jtho.2019.01.020. [Epub ahead of print]. PMID: 30735816.
343. Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. *Ann Oncol*. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542. PMID: 30596880.
344. Guo R, Berry LD, Aisner DL, Sheren J, Boyle T, Bunn PA Jr, Johnson BE, Kwiatkowski DJ, Drilon A, Sholl LM, Kris MG. MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. *J Thorac Oncol*. 2019 Jun 20. pii: S1556-0864(19)30474-5. doi: 10.1016/j.jtho.2019.06.009. [Epub ahead of print]. PMID: 31228623
345. Keith RL, Blatchford PJ, Merrick DT, Bunn PA, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci M, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High Risk Current and Former Smokers. *Cancer Prev Res (Phila)*. 2019 Jul 15. pii: canprevres.0006.2019. doi: 10.1158/1940-6207.CAPR-19-0006. [Epub ahead of print]. PMID: 31308004.

Editorials

1. Bunn, P.A., Jr.: Diagnostic factors in intermediate and high- grade lymphomas: Pathologic, immunologic, and clinical. *J. Clin. Oncol*. 6:1073-1075, 1988.
2. Bunn, P.A., Jr.: HTLV-1-associated diseases. *West. J. Med.*, 150:578-579, 1989
3. Bunn, P.A., Jr.: Operation for Stage IIIa Small Cell Lung Cancer. *Ann. Thor. Surgery*, 49:691, 1990. Bunn, P.A., Jr.: Tobacco: The epidemic for oncologists. *Oncol Times* 15:2,25, 1993.
4. Bunn, P.A., Jr., Kelly, K.: The role of routine chest radiotherapy in small cell lung cancer (SCLC) an issue of timing (and stage). *Chest* 104:661-662, 1993.
5. Bunn, P.A., Jr.: Cutaneous T-cell lymphomas. *Br Med J*, 308:551-552, 1994.
6. Bunn, P.A., Jr.: Rational therapy for cutaneous T-cell lymphomas in the 1990's. *Arch Dermatology* 131:603-605, 1995.
7. Bunn, P.A., Jr., Kelly, K.: Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer. *JNCI* 87:161-162, 1995.
8. Kelly, K., Bunn, P.A., Jr.: Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? *Lung Cancer*, 20:85-91, 1998.
9. Bunn, P.A., Jr.: Perspective: Immune therapy for lung cancer: are we getting closer? *Am J Respir Cell Mol Biol*, 21:10-12, 1999.
10. Bunn PA, Jr. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. *Annals Oncology*, 12: 1-2, 2001.
11. Hirsch FR, Franklin WA, Bunn PA, Jr. What is the role of HER-2/neu and trastuzumab (HERCEPTINR) in lung cancer? *Lung Cancer* 36: 263-64, 2002.
12. Bunn PA, Jr. Update in the management of lung cancer. *Scientia*, pp. 3-5. Leading Medical Opinion, 2002.
13. Bunn PA, Jr. Treatment of advanced non-small-cell lung cancer with two-drug combinations. *J Clin Oncol* 20: 3565-67, 2002.
14. Hirsch FR, Franklin WA, Bunn PA. What is the role of HER-2/neu and trastuzumab (Herceptin®) in lung cancer? *Lung Cancer* 36: 263-64, 2002.
15. Bunn PA, Jr., Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst* 95: 341-343, 2003.
16. Bunn PA, Jr. Early detection of lung cancer using serum RNA or DNA markers: Ready for prime time or for validation? *J Clin Oncol* 21: 3891-3893, 2003.
17. Hirsch FR, Bunn PA, Jr. Epidermal Growth Factor Receptor Inhibitors in Lung Cancer: Smaller or Larger Molecules, Selected or Unselected Populations? *J Clin Oncol*. 23(36): 9089-96, 2005.

FASCO

18. Bunn, PA., Jr. Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non-Small Cell Lung Cancer? *Clinical Cancer Research* 12:(20), 5919-5920. 2006.
19. Dziadziuszko R, Hirsch FR, Varela-Garcia M, Bunn PA, Jr. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization – why, when and how? *Clin Cancer Res* 12: 4409-15, 2006.
20. Solomon B, Bunn, PA, Jr. Adjuvant Chemotherapy for non-small cell lung cancer. *Cancer Invest* 25: 217-25, 2007.
21. Bunn, Paul A., Jr. Diseases Desperate Grown. *JNCI Journal of the National Cancer Institute*, 100: 520-521, 2008.
22. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. *Lancet Oncol* 10: 432-433, 2009.
23. Hirsch FR, Wynes MW, Gandara DR, Bunn PA, Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. *Clin Cancer Res* 16: 49-9-4911, 2010.
24. Bunn PA Jr., Hirsch FR, Doebele RC, Camidge DR, Varela-Garcia M, Franklin W. Biomarkers are here to stay for clinical research and standard care. *J Thorac Oncol* 5: 1113 – 1115, 2010.
25. Hirsch FR, Mok TS, Borges V, Bunn PA Jr. Molecularly targeted therapy: when to stop and when to continue? *Lancet Oncol* 11: 709-711, 2010.
26. Bunn PA Jr. Optimal therapy for elderly patients with early stage non-small cell lung cancer. *Am J Respir Crit Care Med* 181: 201-202, 2010.
27. Hirsch FR, Mok TS, Borges V, Bunn PA Jr. Molecularly targeted therapy: when to stop and when to continue? *Lancet Oncol* 11: 709-711, 2010.
28. Bunn PA Jr. Optimal therapy for elderly patients with early stage non-small cell lung cancer. *Am J Respir Crit Care med* 181: 201-202, 2010.
29. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissues is the issue: personalized medicine for non-small cell lung cancer. *Clin Cancer Res* 16: 4909-4911, 2010.
30. Bunn PA Jr, Hirsch FR, Doebele RC, Camidge DR, Varela-Garcia M, Franklin W. Biomarkers are here to stay for clinical research and standard care. *J Thorac Oncol* 5: 1113-1115, 2010.
31. Bunn PA Jr, Doebele RC. Genetic testing for lung cancer: reflex versus clinical selection. *J Clin Oncol* 29: 1943-1945, 2011.
32. Hirsch FR, Bunn PA, Jr. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. *Lancet Oncol* 13: 442-443, 2012
33. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? *J Clin Oncol*. 2012 Nov 10;30(32):3909-12. doi: 10.1200/JCO.2012.43.1866. Epub 2012 Oct 8. No abstract available. PMID:23045597
34. Bunn PA, Doebele Rc, Franklin WA. The Evolution of Tumor Classification: A role for Genomics. *Cancer Cell* 24:893-4, 2013
35. Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. *Lancet Respir Med*. 2014 Jan;2(1):19-21. doi: 10.1016/S2213-2600(13)70264-9. Epub 2013 Dec 23. PMID: 24461890
36. *Lancet Respir Med*. 2014 Jan;2(1):19-21. doi: 10.1016/S2213-2600(13)70264-9. Epub 2013 Dec 23. 24461890
37. Bunn PA Jr, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? *Clin Cancer Res*. 2014 Apr 1;20(7):1727-9. doi: 10.1158/1078-0432.CCR-13-3387. Epub 2014 Feb 28. PMID: 24583801
38. Hirsch FR, Bunn PA Jr, Herbst RS. "Companion diagnostics": has their time come and gone? *Clin Cancer Res*. 2014 Sep 1;20(17):4422-4. doi: 10.1158/1078-0432.CCR-14-0932. Epub 2014 Jul 24. PMID: 25059519
39. Scarborough HA, Bunn PA Jr, DeGregori J. Personalized one-two punches for lung cancer. *Cell Res*. 2015 Mar;25(3):269-70. PMID: 25547118
40. Hirsch FR, Bunn PA Jr. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? *Nat Rev Clin Oncol*. 2015 Dec;12(12):689-90. PMID: 26552954.
41. Bunn PA Jr, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. *Cancer*. 2016 Mar 1;122(5):674-5. PMID: 26700372.
42. Bunn PA JR. Robert Comis, MD, The Passing of a "Lung Man". *J Thorac Oncol*. 2017 Aug;12(8):1323-1324. doi: 10.1016/j.jtho.2017.06.014. PMID: 28748814

43. Bunn PA Jr, Aisner DA. Broad-Based Molecular Testing For Lung Cancer: Precisely the Time for Precision. *JAMA*. 2018 Aug 7;320(5):445-446. doi: 10.1001/jama.2018.10096. PMID: 30087992.
44. Bunn P. Adi Gazdar, MD: Physician, Pathologist, Scholar, Collaborator, Friend. *J Thorac Oncol*. 2019 Apr;14(4):742-743. doi: 10.1016/j.jtho.2019.02.021. PMID: 30922574.

Guest Editor

1. Bunn PA, Jr. New Developments in Lung Cancer Therapy with Irinotecan. *Clin Lung Cancer* 4: Suppl. 1, 2002.
2. Bunn PA, Jr. First IASLC/ASCO International Conference on Molecular Targeted Therapies in Lung Cancer. *Lung Cancer*, 41: Suppl. 1, 2003.
3. Bunn PA, Jr. Targeting Epidermal Growth Factor Receptor-Tyrosine Kinase in the Most Common Solid Tumors. *Semin Oncol* 30: suppl. 1, 2003.
4. Bunn PA, Jr. Year in Review – Treatment of Mesothelioma and NSCLC. *Medical Intelligence Solutions*, 2003.
5. Bunn PA, Jr. Section Editor – *Annals of Surgical Oncology*, 2004 – present
6. Bunn PA, Jr. Selected Presentations from the 10th World Congress on Lung Cancer, Vancouver, Canada. *Oncology* 18: 2004.
7. Bunn PA, Jr., Herbst RS, Johnson, DH. Novel Therapeutics for Lung Cancer. *J Thor Oncol* 1(7): 736, 2006.

Letters to the Editor

1. Bunn, P.A., Jr., Whang-Peng, J., Gazdar, A.F., Minna, J.D., Carney D.: Karyotypic derivation of H9 cell line. *J Natl Cancer Inst* 85:1168, 1993.
2. Kelly, K., Bunn, P.A., Jr.: Is it time to reevaluate our approach to the treatment of Brain metastases in patients with non-small cell lung cancer? *Lung Cancer* 20: 95-91, 1998.
3. Bunn, P.A., Jr., Kelly, K., Reply no 2. to Letter by Dr Macbeth. *Lung Cancer* 23: 75, 1999.
4. Norton L, Bunn P: Global tobacco control. *Lancet* 358 (9285): 924, 2001.
5. Bunn P: Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Reply to Letter to Editor from Tjan-Heijnen VCG, Postmus PE and Ardizzoni A. *Ann Oncol* 13: 2002.
6. Hirsch FR, Varella-Garcia M, Franklin WA, Bunn Jr. PA; Reply to Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. *J Clin Oncol* 24(7): 1220-1, 2006.

Reviews

1. Bunn, P.A., Jr., Cohen, M.H., Ihde, D.C., Fossieck, B.F., Jr., Matthews, M.J., Minna, J.D.: Advances in small cell bronchogenic carcinoma. *Cancer Treat. Rep.* 16:333-342, 1977.
2. Bunn, P.A., Jr., Nugent, J.L., Matthews, M.J.: Central nervous system metastases in small cell bronchogenic carcinoma. *Semin. Oncol.* 5:317-322, 1978.
3. Bunn, P.A., Jr., Lamberg, S.I.: Report of the committee on staging and classification of cutaneous T-cell lymphomas. *Cancer Treat. Rep.* 63:725- 728, 1979.
4. Radice, P.A., Bunn, P.A., Jr., Ihde, D.C.: Therapeutic trials with VP16 and VM26; Active agents in small cell lung cancer, non- Hodgkin's lymphomas and other malignancies. *Cancer Treat. Rep.* 63:1231-1239, 1979.
5. Lamberg, S.I., Bunn, P.A., Jr.: Introduction to the National Cancer Institute Workshop on cutaneous T-cell lymphomas. *Cancer Treat. Rep.* 63:561-564, 1979.
6. Lamberg, S.I., Bunn, P.A., Jr.: Cutaneous T-cell lymphomas. Summary of the mycosis fungoides cooperative group National Cancer Institute Workshop. *Arch. Dermatol.* 115:1103-1105, 1979.
7. Broder, S., Bunn, P.A., Jr.: Cutaneous T-Cell Lymphomas. Immunological aspects and therapy. *Semin. Oncol.* 7:310-331, 1980.
8. Bunn, P.A., Jr.: Manifestations of cutaneous T-cell lymphoma. *J. Dermatol. Surg. Oncol.* 6:5:369-377, 1980.
9. Bunn, P.A., Jr., Carner, D.N.: Treatment of cutaneous T-cell lymphoma. *J. Dermatol. Surg. Oncol.* 6:5:383-387, 1980.
10. Carney, D.N., Bunn, P.A., Jr.: Benign and malignant monoclonal gammopathies. *Primary Care* 7:369-394, 1980.
11. Myrie, C., Bunn, P.A., Jr., Edelson, R.L.: A clinic-histopathologic atlas. *J. Dermatol. Surg. Oncol.* 6:391-400, 1980.

FASCO

12. Minna, J.D., Carney, D.N., Oie, H., Bunn, P.A., Jr., Gazdar, A.F.: Growth of human small cell lung cancer in defined medium. Cold Spring Harbor: Conferences on Cell Proliferation 9:627-639, 1982.
13. Minna, J.D., Bunn, P.A., Jr., Carney, D.N., Cohen, M.H., Cuttitta, F., Fossieck, B.E., Gazdar, A.F., Ihde, D.C., Johnston-Early, A., Matthews, M.J., Makuch, R., Oie, H., Rosen, S., Lichter, A., Glatstein, E.: Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bulletin du Cancer 69:83-93, 1982.
14. Lamberg, S.I., Bunn, P.A., Jr.: Evaluation and staging of patients with cutaneous T-cell lymphomas: Mycosis Fungoides and Sezary Syndrome. Prog. in Dermatol., 16:2-8, 1982.
15. Bleeahan, N.M., Bunn, P.A., Jr., Cos, J.D., Dombrowsky, P., Fox, R.M., Host, H., Joss, R., White, J.E., Wittes, R.E.: Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat. Rep. 67:11-19, 1983.
16. Winkler, C.F., Bunn, P.A., Jr.: Cutaneous T-cell lymphomas. A Review. CRC Critical Reviews in Oncology/Hematology 1:49-92, 1983.
17. Bunn, P.A., Jr.: Lung cancer: The current approach to diagnosis, staging and treatment. Continuing Professional Education Press, pp. 1-46, 1983.
18. Morstyn, G., Ihde, D.C., Lichter, A.S., Bunn, P.A., Jr., Carney, D.N., Glatstein, E., Minna, J.D.: Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int. J. Rad. Oncol. Biol. Phys. 10:515-39, 1984.
19. Bunn, P.A., Jr., Foon, K.A.: Therapeutic options in advanced cutaneous T- cell lymphomas - A role for recombinant leukocyte A interferon. Semin. Onc. 12:18-24, 1985.
20. Bunn, P.A., Jr.: The role of Vepesid (VP-16-213) in small cell lung cancer. Continuing Med. Ed. Press, Chicago, IL, pp. 1-28, 1985.
21. Foon, K.A., Schroff, R.W., Bunn, P.A., Jr.: Monoclonal antibody therapy for patients with leukemia and lymphoma. In: Monoclonal Antibody Therapy of Human Cancer, K.A. Foon & A.C. Morgan, Jr. (eds). Martinus Nijhoff Publ. Co., pp. 85-101, 1985.
22. Glatstein, E., Ihde, D.C., Bunn, P.A., Jr., Lichter, A., Cohen, M., Makuch, R., Carney, D., Minna, J.D.: Radiotherapy in the management of small cell carcinoma of the lung with limited stage: A randomized prospective study. Cancer Treat Symp 2:97- 100, 1985.
23. Bunn, P.A., Jr., Greco, F.A., Einhorn, L.: Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small cell lung cancer. Semin. Oncol. 13:45-53, 1986.
24. Bunn, P.A., Jr.: Recent advances in the biology and treatment of small cell lung cancer. In: Advances in Oncology, 2:9-15, 1986.
25. Kuefler, P.R., Bunn, P.A., Jr.: Adult T-cell leukemia/lymphoma. Clin in Haemat. 15:695-726, 1986.
26. Foon, K.A., Roth, M.S., Bunn, P.A., Jr.: Alpha-interferon treatment of low-grade B-cell non-hodgkin's lymphomas, cutaneous T-cell lymphoma and chronic lymphocytic leukemia. Semin. Oncol. 13:35-39, 1986.
27. Foon, K.A., Bunn, P.A., Jr.: Alpha interferon treatment of cutaneous T-cell lymphoma and chronic lymphocytic leukemia. In: Hematologic Malignancies: Present Status and Future Prospects. Bertino, J. (ed) Semin. Oncol. 13:35-39, 1986.
28. Foon, K.A., Roth, M.S., Bunn, P.A., Jr.: Interferon therapy of non-Hodgkin's lymphoma. Cancer 59:601-604, 1987.
29. Bunn, P.A., Jr., Ihde, D.C., Foon, K.A.: Recombinant interferon alpha-2a, an active agent in advanced cutaneous T-cell lymphomas. Int. J. Cancer Suppl. 1:9-13, 1987.
30. Bunn, P.A., Jr.: Update: Alpha interferon for CTCL. The Interferon Letter #11.
31. Bunn, P.A., Jr.: Lung cancer: Current understanding of biology, diagnosis, staging and treatment. Bristol-Myers Company, Evansville, IN. 1988.
32. Beck, L.K., Kane, M.A., Bunn, P.A., Jr.: Innovative and future approaches to small cell lung cancer treatment. Semin. Oncol. 15:300-314, 1988.
33. Bunn, P.A., Jr.: The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin. Oncol. 16:10- 21, 1989.
34. Bunn, P.A., Jr.: Future directions in the therapy of non-small cell lung cancer. In: Treatment and prevention of small cell lung cancer and non-small cell lung cancer. R.J. Gralla and L.H. Einhorn (eds). Royal Society of Medicine Services International Congress and Symp. Series No. 150, Royal Soc. Med Serv Ltd., pp. 137-148, 1989.
35. Bunn, P.A., Jr.: Review of therapeutic trials of carboplatin in lung cancer. Semin. Oncol. 16(2) (Suppl 5):27-33, 1989

36. Bunn, P.A., Jr.: Biologic aspects of small cell lung cancer. In: Small Cell Lung Cancer: Current treatment and future directions. Vanderbilt University Continuing Medical Education Activity publication, pp. 22-30, 1989
37. Bunn, P.A., Jr., Cullen, M., Fukuoka, M., Green, M., Hansen, H., Harper, P., Johnson, D., Klastersky, J., Le Chevalier, T., Sagman, U., Splinter, T.: Chemotherapy in Small Cell Lung Cancer. A consensus report of the International Association for the study of lung cancer workshop. Lung Cancer 5:127-134, 1989.
38. Bunn, P.A., Jr., Norris, D.A.: The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Derm 95:209-212, 1990.
39. Bunn, P.A., Jr.: Current strategies in lung cancer: Biology and therapy. Lung Cancer Research Quarterly 1:9-12, 1991.
40. Bunn, P.A., Jr.: Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin. Oncol. 19:1-11, 1992.
41. Kemme, D, Bunn, P.A., Jr.: State of the art therapy of mycosis fungoides and sézary syndrome. Oncology 6:31-42., 1992.
42. Bunn, P.A., Jr., Kelly, K.: The role of GM-CSF in lung cancer: a review of the literature. Lung Cancer 9:45-58, 1993.
43. Cook, R.M, Miller, Y.E., Bunn, P.A., Jr.: Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Current Problems in Cancer 17:69-144, 1993.
44. Bunn, P.A., Jr.: Future Directions in the management of non-small cell lung cancer. Lung Cancer 9:S91-S107, 1993.
45. Aisner, J., Albain, K., Belani, C.P., Bunn, P.A., Jr., Choy, K., et al: Taxol (paclitaxel): Clinical experience in an outpatient setting. Bristol-Myers Squibb Company, Princeton, NJ, 1994.
46. Bunn, P., Arriagada, R., Choi, N., Feld, R., Gregor, A., Jett, J., Johnson, B., Komaki, R., Kristjansen, P., Murray, N., Ohnoshi, T., Perry, M., Quoix, E., Saijo, N., Shaw, E.: Combined modality therapy in small cell lung cancer. Lung Cancer 10:25-28, 1994.
47. Bunn, P.A., Jr.: The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions. Semin. Oncol. 21:49-59, 1994.
48. Feld, R., Borges, M., Giner, V., Ginsberg, R., Harper, P., Klastersky, J., Lacquet, L., Paesmans, M., Payne, D., Rosell, R., Sause, W., Sculier, J.P., Shaw, E., Sorensen, J.B., Splinter, T., Stahel, R., Bunn, P.A., Jr.: Prognostic factors in non-small cell lung cancer. Lung Cancer 2:19-23, 1994.
49. Bunn, P.A., Jr.: Future directions in clinical research for lung cancer. Chest 106:399S-407S, 1994.
50. Bunn, P.A., Jr., Kelly, K.: A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: A University of Colorado Cancer Center Study. Semin. Oncol. 22:2-6, 1995.
51. Bunn, P.A., Jr., Kelly, K.: New treatment agents for advanced small cell and non-small cell lung cancer. Semin. Oncol. 22:53-63, 1995.
52. Bunn, P.A., Jr. Combination Paclitaxel and Platinum in the treatment of lung cancer: US experience. Semin. Oncol. 23:9-15 1996.
53. Bunn, P.A., Jr., Kelly, K.: Phase I study of cisplatin, etoposide and paclitaxel in patients with extensive stage small cell lung cancer: A University of Colorado Cancer Center Study. Semin. Oncol. 23:6:11-15, 1996.
54. Bunn, P.A., Jr.: Future directions in therapeutic approaches for small cell lung cancer. Semin. Oncol. 23:136-138, 1996.
55. Bunn, P.A., Jr.: The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin. Oncol. 23:18-25, 1996.
56. Bunn, P.A., Jr.: Current therapy for small cell lung cancer. Semin. Oncol. 23:1-4, 1996.
57. Bunn, P.A., Jr.: New drug combinations in the treatment of advanced non-small cell (NSCLC) and small cell (SCLC) lung cancer. ASCO Education Book pp. 195-207, 1996.
58. Bunn, P.A., Jr.: Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin. Oncol. 24:153-162, 1997.
59. Bunn, P.A., Jr., Carbone, D., Grim, J., Harris, C., Havemann, K., Mabry, M., Roth, J., Saijo, N., Poulsen, Skovgaard, H., Stahel, R., Takahaski, T., Twentyman, P. Meeting report 5th I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland. Lung Cancer 16:239-257, 1997.
60. Bunn, P.A., Jr., Kelly, K.: A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin. Oncol. 24:144-148, 1997.
61. Dinarello, C.A., Bunn, P.A., Jr.: Fever. Semin. Oncol. 24:288-298, 1997.

FASCO

62. Bunn, P.A., Jr., Carney, D.N.: Overview of chemotherapy for small cell lung cancer. *Semin. Oncol.* 24(2, Suppl 7): S7-69-S7-74, 1997.
63. Bunn, P.A., Jr., Kelly, K.: Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer. *Semin. Oncol.* 24(3, Suppl 8): S8-46-S8-52, 1997.
64. Schefer, H., and Bunn, P.A., Jr.: To treat or not to treat metastatic non-small-cell lung cancer: still an ethical dilemma? *Oncology Nurses Today* 3:No.2, 1998.
65. Bunn, P.A., Jr., Le Chevalier, T.: Lung cancer research: new combinations and the emerging role of gemcitabine. *Semin. Oncol.* 24: 1, 1998.
66. Bunn, P.A., Jr., Vokes, E. E., Langer, C. J., Schiller, J.H.: An update on North American randomized studies in non-small cell lung cancer. *Semin. Oncol.* 25: 2-10, 1998.
67. Bunn, P.A., Jr., Triplet chemotherapy combinations with new agents: is there a rational? *Semin. Oncol.* 25: 55-61, 1998.
68. Ginsberg, R., Bunn, P.A., Jr., Keller, S. New approaches for the treatment of resectable non-small-cell lung cancer. *From Research to Practice* 1: 13-19, 1999.
69. Bunn, P.A., Jr.: Cancer and acquired immunodeficiency syndrome wasting syndromes: current and future therapies. *Semin. Oncol* 25 (2 Suppl 6): 1-3, 1998.
70. Bunn, P.A., Jr.: The emerging role of paclitaxel plus carboplatin in non-small-cell lung cancer. *Oncol. Suppl* 4: 35-41, 1999.
71. Bunn PA, Jr.: To treat or Not to treat non-small cell lung cancer patients? *Current Perspectives. Oncology*, suppl 4: 9-15, 1999.
72. Bunn, P.A., Jr., Kelly Karen. Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non-small-cell lung cancer. *Clinical Lung Cancer* 2(suppl. 1): S23-S28, 2000.
73. Agus DB, Bunn PA, Jr., Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. *Semin Oncol* 27: 53-63, 2000.
74. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor (EGFR) family expression in lung cancer and premalignancy. *Semin Oncol*, in press, 2001.
75. Bunn PA, Jr. Translation of the biology of lung cancer to targeted therapies. *ASCO Educational*: 395-405, 2001.
76. Bunn PA, Jr. Irinotecan and platinum in the treatment of non-small-cell lung cancer. *Clinical Lung Cancer* 2(suppl. 2): S14-S19, 2001.
77. Bunn PA, Jr. Triplet combination chemotherapy and targeted therapy regimens. *Oncology* 15: 26-32, 2001.
78. Bunn PA. State-of-the art treatment of locally advanced and metastatic non-small cell lung cancer. *Anti-Cancer Drugs* 12 (suppl. 3): S3-S8, 2001.
79. Bunn PA, Jr. Triplet combination chemotherapy regimens for the treatment of advanced non-small cell lung cancer. *Oncology* 15: 1-7, 2001.
80. Bunn PA, Jr., Kato H. Current Perspectives in the Treatment of Non-Small Cell Lung Cancer. *Semin Oncol*, 28: 1-2, 2001.
81. Kennedy TC, Lam S, Hirsch FR. Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer. *The Oncologist* 6: 257-62, 2001.
82. Postmus PE, Bunn PA, Jr. Pemetrexed as a single agent in the therapy of advanced lung cancer. *Semin Oncol* 2 suppl. 5: 17-22, 2002.
83. Hirsch FR, Franklin WA, Bunn PA, Jr. Expression of target molecules in lung cancer: Challenge for new treatment paradigm. *Semin Oncol* 29: 2-8, 2002.
84. Bunn PA, Jr. The impact of anemia on survival among cancer patients. *Oncology Spectrums* 3: 36-43, 2002.
85. Bunn PA, Jr., Chan DC, Earle K, Zhao TLM, Helfrich B, Whitehead C, Piazza G, Pamukeu R, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. *Semin Oncol* 29: 87-94, 2002.
86. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA, Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. *Semin Oncol* 29: 3-14, 2002.
87. Bunn PA, Jr. Novel Targeted Agents for the Treatment of Lung Cancer. *ASCO Spring Educational Book*, 683-92, 2002.

FASCO

88. Calvert H, Bunn PA, Jr. Future directions in the development of pemetrexed. *Semin Oncol*, 2 suppl. 5: 54-61, 2002.
89. Hirsch FR, Bunn PA, Jr., Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. International Conference on Prevention and Early Detection of Lung Cancer. *Lung Cancer*, in press, 2002.
90. Bunn PA, Jr. The role of Irinotecan combined with cisplatin or carboplatin in the treatment of advanced non-small cell lung cancer. *Clin Lung Cancer* 4: S5-S9, 2002.
91. Bunn PA, Jr. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). *Semin Oncol* 29: 17-22, 2002.
92. Niyikiza C, Hanauske A-R, Rusthoven J, Allen R, Paoletti P, Bunn PA. Pemetrexed safety and dosing strategy. *Semin Oncol* 29: 24-29. 2002.
93. Bunn PA, Jr. Update in the management of lung cancer. *Scientia Leading Medical Opinion* 2: 2-4, 2002.
94. Bunn PA, Jr. Molecular biology and early diagnosis in lung cancer. *Lung Cancer* 38: S5-S8, 2002.
95. Bunn PA, Jr. Chemotherapy for advanced non-small-cell lung cancer: Who, What, When, Why? *J Clin Oncol* 20: 23s-33s, 2002.
96. Bunn PA, Jr. New targeted therapies for lung cancer: expectations and reality. *MedGenMed* 4: 12, 2002.
97. Bunn PA, Jr., Smith IE. Introduction. *Semin Oncol* 29: 1-2, 2002.
98. Bunn PA, Jr., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. *Semin Oncol* 29: 38-44, 2002.
99. Hirsch FR, Franklin WA, Bunn PA, Jr. Pathogenetic and clinical importance of epidermal growth factor receptor overexpression in non-small-cell lung cancer. *Physicians Education Resource: New Develop in Lung Cancer* 3-10, 2002.
100. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA, Jr. HER2/neu expression in malignant lung tumors. *Semin Oncol* 29: 51-58, 2002.
101. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA, Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. *Semin Oncol* 29: 37-46, 2002.
102. Bunn PA, Jr. Implementing ASCO's strategic plan 2003: diverse membership needs, prevention, and patient partnerships. *J Clin Oncol* 21: 231s-236s, 2003.
103. Bunn PA Jr., Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. *Lung Cancer* 41: S175-S186, 2003.
104. Raben D, Helfrich B, Ciardiello F, Bunn PA, Jr. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. *Lung Cancer* 41: S15-S22, 2003.
105. Witta SE, Bunn PA, Jr. The Eckardt Article Review. *Oncology* 17: 191-206, 2003.
106. Simon GR, Bunn PA, Jr. Taxanes in the treatment of advanced (Stage III and IV) non-small cell lung cancer (NSCLC): Recent developments. *Cancer Invest* 21: 87-104, 2003.
107. Bunn PA, Jr. New investigative regimens and cytotoxic agents for the management of thoracic cancers: Focus on Gemcitabine and pemetrexed. *Oncology* 17: 1-10, 2003.
108. Whitsett JA, Bachurski CJ, Barnes KC, Bunn PA, Jr. et al. Functional genomics of Lung Disease. *Am J Resp Cell Mol Biol* 31: S1-S81, 2004.
109. Bunn PA, Jr. The potential role of proteasome inhibitors in the treatment of lung cancer. *Clin Cancer Res* 10: 4263-65, 2004.
110. Lynch TH, Adjei A, Bunn PA, Jr. et al. Novel agents in the treatment of lung cancer: conference summary statement. *Clin Cancer Res* 10: 4199-4204, 2004.
111. Bunn PA, Jr. Brain metastases in small cell lung cancer. *Oncology* 18: 974-980, 2004.
112. Bunn PA Jr. New investigative regimens and cytotoxic agents in thoracic cancers: Gemcitabine and pemetrexed. *Oncology* 18: 5-13, 2004
113. Bunn PA Jr. Contemporary issues in lung cancer and the role of chemotherapy. *American Academy of CME*. April 2004.
114. Bunn PA, Jr. Early-Stage non-small-cell lung cancer: Current perspectives in combined-modality therapy. *Clin Lung Cancer* 6: 85-98, 2004.

115. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA, Jr. Chemoprevention of lung cancer – from biology to clinical reality. *Ann Oncol* 15: 185-96, 2004.
116. Solomon B, Bunn PA Jr. Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. *Cancer Treatment Reviews* 31(7), 571-576, 2005.
117. Solomon B, Mitchell JD, Bunn PA Jr. Adjuvant chemotherapy for resected non-small-cell lung cancer. *Oncology* 19(13): 1685-1705, 2005.
118. Bunn PA Jr. Platinums in lung cancer: sufficient or necessary? *J Clin Oncol* 23(13): 2882-3, 2005.
119. Solomon B, Bunn PA Jr. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. *Future Oncol* 1(6): 773-746, 2005.
120. Dziadziuszko R, Hirsch FR, Bunn PA. Selecting Lung Cancer patients for Treatment with Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors by Immunohistochemistry and FISH – Why, When, and How? *Clin Cancer Res* 12(14): 4409s-4415s, 2006.
121. Solomon B, Bunn PA, Jr. Adjuvant chemotherapy for non-small cell lung cancer. *Cancer Invest*, 25 (4): 217-225, 2007
122. Lynch TJ, Adjei AA, Bunn PA Jr., Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Janne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. *Clin Cancer Res* 12 (14): 4365s-4371s, 2006.
123. Weiss GJ, Bunn PA, Jr., Camidge DR. From radiotherapy to targeted therapy: 20 years in the management of non-small-cell lung cancer. *Oncol* 20 (12): 1515-1524, 2006.
124. Weiss,G.J.; Zeng,C.; Kelly,K.; Tran,Z.V.; Bunn,P.A.,Jr. Single-Institution Experience with Pemetrexed and Bevacizumab as Salvage Therapy in Advanced Non-Small-Cell Lung Cancer. *Clinical Lung Cancer* 8(5):335-338, 2007.
125. Solomon, B.,Bunn, P. A., Jr. Adjuvant chemotherapy for non-small cell lung cancer. *Cancer Invest* 25:(4), 217-225. 2007.
126. Bunn, P. A., Jr. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? *J Clin Oncol* 25:(18), 2504-2505. 2007.
127. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA, Jr. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. *J thorac Oncol* 3: S138-42, 2008.
128. Einhorn LH, Bonomi P, Bunn PA, Jr., Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. *J thorax Oncol* 3: 545-55, 2008.
129. Bunn PA, Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options: more things to consider. Conclusion. *Oncologists* 13: 37-46, 2008.
130. Bunn PA, Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer. *Oncologist* 13: 1-4, 2008.
131. Bunn, PA, Jr. Novel therapies for non-small-cell lung cancer: a 2008 update. *Clin Lung Cancer*, suppl. 1: S6, 2009.
132. Hirsch FR, Bunn PA, Jr. EGFR testing in lung cancer is ready for prime time. *Lancet Oncol* 10: 432-433, 2009.
133. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. *J Thorac Oncol* 4: 930-935, 2009.
134. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. *Immunotherapy* 1: 19-25, 2009.
135. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA, Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitors therapy in non-small cell lung cancer. *Lung Cancer* 69: 1-12. doi: 10.1016/j.lungcan.2009.12.009. Epub 2010 Jan 25. PMID: 20092908
136. Bunn PA, Jr. Optimal therapy for elderly patients with early stage non-small cell lung cancer. *Am J Respir Crit Care Med* 181: 201-202, 2010.
137. Bunn PA Jr. Worldwide overview of the current status of lung cancer diagnosis and treatment. *Arch Pathol Lab Med*. 2012 Dec; 136(12):1478-81. doi: 10.5858/arpa.2012-0295-SA. PMID: 23194039

138. Shepherd FA, Bunn PA, Paz-Ares L., Lung cancer in 2013. *Am Soc Clin Oncol Educ Book*. 2013:339-46. doi: E10.1200/EdBook_AM.2013.33.339. PMID: 23714542
139. Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. *Lancet Respir Med*. 2014 Jan; 2(1):19-21. doi: 10.1016/S2213-2600(13)70264-9. Epub 2013 Dec 23. PMID: 24461890
140. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. *J Clin Oncol*. 2014 Apr 1; 32(10):973-82. doi: 10.1200/JCO.2013.53.1228. Epub 2014 Feb 24. PMID: 24567433
141. Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. *Lancet Respir Med*. 2014 Jan;2(1):19-21. doi: 10.1016/S2213-2600(13)70264-9. Epub 2013 Dec 23. PMID: 24461890
142. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. *J Clin Oncol*. 2014 Apr 1;32(10):973-82. doi: 10.1200/JCO.2013.53.1228. Epub 2014 Feb 24. Review. Erratum in: *J Clin Oncol*. 2014 May 10;32(14):1520. PMID: 24567433
143. Bunn PA Jr, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? *Clin Cancer Res*. 2014 Apr 1;20(7):1727-9. doi: 10.1158/1078-0432.CCR-13-3387. Epub 2014 Feb 28. PMID: 24583801
144. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *J Thorac Oncol*. 2015 Jan;10(1 Suppl 1):S1-63. PMID: 25535693.
145. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. *J Thorac Oncol*. 2016 May;11(5):613-38. PMID: 27013409
146. Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? *J Thorac Oncol*. 2016 Apr;11(4):453-74. PMID: 26829312
147. Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. *Lancet*. 2016 Sep 3;388(10048):1012-24. doi: 10.1016/S0140-6736(16)31473-8. Epub 2016 Sep 1. PMID: 27598681
148. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. *J Thorac Oncol*. 2016 Dec;11(12):2066-2081. doi: 10.1016/j.jtho.2016.08.138. Epub 2016 Aug 26. PMID: 27575423
149. Pacheco JM, Dimou A, Bunn PA. Advances in lung cancer. *Oncotarget*. 2017 Sep 13;8(45):78247-78248. doi: 10.18632/oncotarget.20854. eCollection 2017 Oct 3. PMID: PMC5667952
150. Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Filip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruyscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. *J Thorac Oncol*. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. PMID: 30268698.
151. Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. *Clin Lung Cancer*. 2019 Jan 2. pii: S1525-7304(18)30356-5. doi: 10.1016/j.clc.2018.12.019. [Epub ahead of print]. PMID: 30686680.

FASCO

152. Bunn PA Jr, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. *Oncology (Williston Park)*. 2019 Mar 13;33(3):101-6, 109. PMID: 30866032.

IASLC Related Articles

1. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW, Goldstraw P, International Staging Committee and participating institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 3: 1213-1223, 2008.
2. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw O, International Association for the Study of Lung Cancer International Staging Committee and participating institutions. The IASLC Lung Cancer Staging Project proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 4: 1049-1059, 2009.
3. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P: Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. *J thorac Oncol* 4: 568-577, 2009.
4. Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P, International Association for the Study of Lung Cancer International Staging Committee. *J Thorac Oncol* 4: 679-683, 2009.
5. Chansky K, Sculier JP, Crowley JJ, Giroux V, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions. *J thorac Oncol* 4: 792-801, 2009.
6. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *Zhongguo Fei Ai Za zhi* 13: 9-18, 2010 - Chinese
7. Vallieres E, Van Houtte P, Travis WD, Rami-Porta R, Goldstraw P. International Association for the Study of Lung Cancer (IASLC) International Staging Committee. *J Thorac Oncol* 6: 1617-1623, 2011.
8. Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, Giroux DJ, Hasegawa S, Kernstine KH, Waller D, Rami-Porta R. International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma interest Group. *J Thorac Oncol* 6: 1304-1312, 2011.
9. National Lung screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 365: 395-409, 2011.10.
10. National Lung Screening Trial research Team: Aberle, DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: overview and study design. *Radiology* 258: 243-253, 2011.
11. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks Results of the two incidence screenings in the National Lung Screening Trial. *J; National Lung Screening Trial Research Team. N Engl J Med*. 2013 Sep 5;369(10):920-31. doi: 10.1056/NEJMoa1208962.PMID:24004119
12. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS; AACR Subcommittee on Tobacco and Cancer. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. *Clin Cancer Res*. 2013 Apr 15; 19(8):1941-8. doi: 10.1158/1078-0432.CCR-13-0666. Epub 2013 Apr 9. PMID:23570694
13. Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and Participating Institutions Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2013 Mar;8(3):31521. doi:10.1097/JTO.0b013e31827dc74d.PMID:23334092

Journal Edited

1. National Cancer Institute Workshop on Cutaneous T-cell Lymphoma, 1978.

FASCO

2. Lung Cancer, *Semin. Oncol.* 15:197, 1988
3. Innovations in multimodality therapy for lung cancer. *Chest* 103:1S, 1993.
4. Chemotherapy with paclitaxel and platinum compounds: Current status and future directions. Volume 1: Non-small cell lung cancer. *Semin. Oncol.* 22:1, 1995.
5. Chemotherapy with paclitaxel and platinum compounds: current status and future directions. Volume 2: Head and neck cancer, breast cancer, gynecologic malignancies, and other tumor types. *Semin. Oncol.* 22, 1995.
6. Bunn, P.A., Jr., Deutsch, J.C.: Recent developments and future directions in the research and management of anorexia and cachexia. *Semin. Oncol.* 25 (Suppl 9), 1998.
7. Bunn, P.A., Jr., Le Chevalier, T.L.: Current status of new agents in the treatment of lung cancer.
8. Bunn, P.A., Jr.: The emerging role of paclitaxel plus carboplatin in non-small-cell lung cancer. *Oncol. Suppl* 4: 35-41, 1999

Books

1. Bunn, P.A., Jr.: Carboplatin (JM-8) current perspectives and future directions. P. Bunn, Jr., R. Canetta, R. Ozols, M. Rozenceveig (eds.), W.B. Saunders, Philadelphia, PA, 1990.
2. Bunn, P.A., Jr.: Current topics in lung cancer. Monographs. European School of Oncology, Springer-Verlag, New York, pp. 1, and 33-46, 1991.
3. Bunn, P.A., Jr.: Clinical experiences with platinum and etoposide therapy in lung cancer. *Oncology (Suppl) International Journal of Cancer Research and Treatment*, July 1992.
4. Wood, M.E., Bunn, P.A., Jr.: Hematology/Oncology Secrets. Hanley & Belfus, Inc., Philadelphia, PA, 1994.
5. Kane, M., Bunn, P.A., Jr.: Biology of lung cancer. Marcel Dekker, Inc. Publishers, Vol. 122, 1998.
6. Hansen, H.H., Bunn, P.A., Jr. Lung Cancer Therapy Annual 2000. Martin Dunitz, 2000.
7. Hansen, H.H., Bunn, P.A., Jr. Lung Cancer Therapy Annual 2001. Martin Dunitz, 2001.
8. Hansen, H.H., Bunn, P.A., Jr., Kelly K. Lung Cancer Therapy Annual 3. Martin Dunitz, 2003
9. Hirsch, F.R., Bunn, P.A., Jr., Kato, H., Mulshine, J.L. (eds.). Textbook of Prevention and Detection of Early Lung Cancer. Taylor & Francis, 2006

Book Chapters

1. Ihde, D.C., Bernath, A.M., Cohen, M.H., Matthews, M.J., Gazdar, A.F., Eddy, J., Bunn, P.A., Jr., Minna, J.D.: Utility of fiberoptic bronchoscopy in assessing response to combination chemotherapy in small cell carcinoma of the Lung. *Lung Cancer*, Muggia, F., Rozenzweiz, M. (eds), Raven Press, N.Y., pp. 543-548, 1978.
2. Bunn, P.A., Jr., Cohen, M.H., Ihde, D.C., Shackney, S.E., Matthews, M.J., Fossieck, B.E., Jr., Minna, J.D.: A review of recent therapeutic trials in small cell bronchogenic carcinoma. In: *Lung Cancer*, Muggia, F., Rozenzweiz, M. (eds), Raven Press, N.Y., pp. 549-557, 1978.
3. Shackney, S.E., Cohen, M.H., Bunn, P.A., Jr., Ihde, D.C., Minna, J.D.: The application of principles of cell kinetics in the design of treatment regimens for small cell carcinoma of the lung. In: *Lung Cancer*, Muggia, F., Rozenzweiz, M. (eds), Raven Press, N.Y., pp. 63-72, 1978.
4. Minna, J.D., Brereton, A.D., Cohen, M.H., Ihde, D.C., Bunn, P.A., Jr., Shackney, S.E., Fossieck, B.E., Matthews, M.J.: Treatment of the lung: Prospects for cure of small cell carcinoma. In: *Lung Cancer*, Muggia, F., Rozenzweiz, M. (eds), Raven Press, N.Y., pp. 593-600, 1978.
5. Cohen, M.H., Fossieck, B.E., Jr., Ihde, D.C., Bunn, P.A., Jr., Matthews, M.J., Shackney, S.E., Minna, J.D.: Chemotherapy of small cell carcinoma of the lung: Results and concepts. In: *Lung Cancer*, Muggia, F., Rozenzweiz, M. (eds), Raven Press, N.Y., pp. 593-600, 1978.
6. Bunn, P.A., Jr., Fischman, A.B.: Treatment of Mycosis Fungoides. In: *Current Therapy 1979*, Conn, H.F. (ed), W.B. Saunders Co., Philadelphia, PA, pp. 306-309, 1979.
7. Anderson, T., Makuch, R., Bunn, P.A., Jr., Ritch, P., Radice, P., Huberman, M., Young, R.: Peritoneoscopy utilization in evaluation of hepatic metastases. In *EORTC. Monograph on the Diagnosis of Hepatic Metastases*. Bleiberg, H., Fruhlin, J. (eds), Alan R. Liss, Inc., New York.
8. Vrana, M., Bunn, P.A., Jr.: A review of therapeutic trials in multiple myeloma and perspectives for future trials. In: *Progress in Myeloma*, Potter, M. (ed), Elsevier Press, N.Y., pp. 239-262, 1980.
9. Alibaster, O., Bunn, P.A., Jr.: Myeloma growth kinetics: Potential applications of flow cytometry. In: *New Directions in Multiple Myeloma*, Potter, M. (ed), Elsevier Press, N.Y., pp. 185- 194, 1980.

10. Bunn, P.A., Jr., Ihde, D.C.: Small cell bronchogenic carcinoma: A review of therapeutic results. In: Lung Cancer 1. Cancer Treatment and Research, Livingston, R.B.(ed), Martinus Nijhoff Publ., Boston, MA, 1:169-208, 1981.
11. Carney, D.N., Bunn, P.A., Jr., Gazdar, A.F., Minna, J.D.: In vitro cloning of small cell carcinoma of the lung. In: Small Cell Lung Cancer, Greco, A., Bunn, P.A., Jr., Oldham, R. (eds), Grune & Stratton, N.Y., pp. 79-94, 1981.
12. Cohen, M.H., Chretein, P.B., Johnston-Early, A., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Jr., Makuch, R., Matthews, M.J., Shackney, S.E., Minna, J.D.: Thymosin fraction V prolongs survival of intensively treated small cell lung cancer patients. In: Immunotherapy of Human Cancer. Terry, W.D. (ed), Elsevier, North Holland, NY, pp. 141-145, 1981.
13. Shackney, S.E., Straus, M., Bunn, P.A., Jr.: The Growth Characteristics of Small Cell Carcinoma of the Lung. In: Small Cell Lung Cancer, Greco, A., Bunn, P.A., Jr., Oldham, R. (eds), Grune & Stratton, N.Y., pp. 225-234, 1981.
14. Bunn, P.A., Jr., Lichter, A., Glatstein, E.J., Minna, J.D.: Further prospects for the cure of small cell lung cancer. In: Small Cell Lung Cancer, Greco, A., Bunn, P.A., Jr., Oldham, R. (eds), Grune & Stratton, N.Y., pp. 413-446, 1981.
15. Bunn, P.A., Jr., Levine, R.F., Schlam, M.L., Hazzard, K.C.: Analysis of megakaryocyte DNA content: Comparison of feulgen microdensitometry and flow cytometry. In: Megakaryocyte Biology and Precursors, Evatt, B., Levine, R., Williams, N. (eds), Elsevier, North Holland, N.Y., pp. 217-232, 1981.
16. Bunn, P.A., Jr., Nitrosourea containing combinations in small cell lung cancer. In: Nitrosoureas--Current Status and New Developments, Schein, P., Baker, H., Carter, S. (eds), Academic Press, N.Y., pp. 233-244, 1981.
17. Ihde, D.C., Bunn, P.A., Jr.: Chemotherapy of small cell bronchogenic carcinoma. In: Recent Advances in Clinical Oncology, Whitehouse, J.M.A., Williams, C.J. (ed), Churchill Livingstone Co., Edinburgh, (Vol. 1), pp. 305-323, 1982.
18. Minna, J.D., Bunn, P.A., Jr.: Paraneoplastic Syndromes. In: Principles and Practice of Oncology. DeVita, V.T., Hellman, S., Rosenberg, S. (eds), J.B. Lippincott Co., Philadelphia, PA, Third Edition, Vol. 3. pp. 1797-1842, 1982.
19. Bunn, P.A., Jr., Fischmann, A.B., Glatstein, E.: Staging and treatment of the cutaneous T-cell lymphomas (Mycosis Fungoides and the Sezary Syndrome) at the National Cancer Institute (USA). In: Cutaneous Lymphoma, Christophers, E.A., Goos, M. (eds), Springer-Verlag, Berlin, pp. 270-282, 1982.
20. Lichter, A.S., Bunn, P.A., Jr.: The management of small cell lung cancer. In: Update of Pulmonary Diseases and Disorders, Fishman, A.P. (ed), McGraw Hill, N.Y., pp. 300-317, 1982.
21. Ihde, D.C., Matthews, M.J., Oie, H., Rosen, S., Whang-Peng, J., Gazdar, A.F.: Heterogeneity and homogeneity of human small cell lung cancer. In: Tumor Cell Heterogeneity: Origins and Implications, Owens, A., Coffey, D., Baylin, S. (eds), Academic Press, pp. 29-52, 1982.
22. Whang-Peng, J., Kao Shan, C.S., Lee, E.C., Bunn, P.A., Jr., Carney, D.N., Gazdar, A.F., Portlock, C., Minna, J.D.: Deletion 3p (14-23), Double minute chromosomes, and homogeneously staining regions in small cell lung cancer. In: Gene Amplification, Schimke, R.T. (ed), Cold Spring Harbor Laboratory, pp. 107-113, 1982.
23. Minna, J.D., Carney, D.N., Alvarez, R., Bunn, P.A., Jr., Cuttitta, F., Ihde, D.C., Matthews, M.J., Oie, H., Rosen, S., Whang-Peng, J., Gazdar, A.F.: Heterogeneity and homogeneity of human small cell lung cancer. In: Tumor Cell Heterogeneity. Owens, A.H., Coffey, D.S., Baylin, S.B., (eds) Academic Press, pp. 29-52, 1982.
24. Bunn, P.A., Jr., Poesz, B.J.: Mycosis fungoides and the sezary syndrome. In: Hematology, Williams, W.J., Beutler, E., Erslev, A.J., Lichtman, M.A. (eds), McGraw-Hill Co., N.Y., 3rd edition, pp. 1056-1066, 1983.
25. Knop, R., Bunn, P.A., Jr.: Management of small cell lung cancer. In: Radiation Oncology Annual. Phillips, T., Pistenma, D.A. (eds), Raven Press, pp. 65-104, 1983.
26. Whang-Peng, J., Carney, D.N., Lee, E.C., Kao-Shan, C.S., Bunn, P.A., Jr., Gazdar, A., Minna, J.D.: A non-random chromosomal abnormality, del (3)(14- 23) in small cell lung cancer. In: Cancer: Etiology and Prevention. Crispen, R.G. (ed), Elsevier Science Publishing Company, Inc., NY, pp. 47-60, 1983.
27. Foon, K.A., Sherwin, S.A., Bunn, P.A., Jr., Longo, D., Oldham, R.K.: Recombinant leukocyte A interferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and cutaneous T- cell lymphoma. In: Interferon Workshop, Academic Press, NY, 1983.
28. Foon, K.A., Schroff, R.W., Mayer, D., Sherwin, S.A., Oldham, R.K., Bunn, P.A., Jr., Hsu, S.-M.: Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: preliminary observations.

- In: *Monoclonal Antibodies and Cancer*, Boss, B.D., Zangman, R.E., Trowbridge, I.S., Delbecco, R. (eds), Academic Press, NY, pp. 39-52, 1983.
29. Cuttitta, F., Rosen, S., Carney, D.N., Gazdar, A.F., Bunn, P.A., Jr., Minna, J.D.: Human tumor associated antigens. In: *Monoclonal Antibodies: Progress and Reviews*. Kennet, R. (ed), W.P. Saunders, Philadelphia, PA, 1984.
 30. Ihde, D.C., Bunn, P.A., Jr., Lichter, A.S., Cohen, M.H., Makuch, R.W., Carney, D.N., Johnston-Early, A., Minna, J.D., Glatstein, E.: Randomized trial of chemotherapy with or without adjuvant chest irradiation in limited stage small cell lung cancer. In: *Adjuvant Therapy of Cancer IV*. Jones, S.E., Salmon, S. (eds), Grune & Stratton, NY, pp. 147-155, 1984.
 31. Bunn, P.A., Jr.: The role of chemotherapy in small cell lung cancer. In: *Etoposide (VP-16): Current Status and New Developments*. Isell, B.F., Muggia, F.M., Carter, S.K. (eds), Academic Press, NY, pp. 141-158, 1984.
 32. Winkler, C.F., Bunn, P.A., Jr.: Combination chemotherapy in cutaneous lymphomas. In: *Progress in Diseases of the Skin*. Fleischmajer, R. (ed). Grune & Stratton, Orlando, FL, Vol. 2, pp. 185-215, 1984.
 33. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., Bunn, P.A., Jr.: Quality control of monoclonal antibodies after radiolabeling. The fraction of immunoreactive antibody determined at Infinite antigen Excess. In: *Proceedings of the European Nuclear Medicine Congress*. Martinus Nijhoff, Helsinki, pp. 807-810, 1984.
 34. Foon, K.A., Schroff, R.W., Bunn, P.A., Jr.: Monoclonal antibody therapy for patients with leukemia and lymphoma. In: *Monoclonal Antibody Therapy of Human Cancer*. Foon, K.A., Morgan, A.E. (eds). Martinus-Nijhoff, Boston, MA, pp. 85-101, 1984.
 35. Bunn, P.A., Jr., Rosen, S.T.: CNS metastases in small cell lung cancer. In: *Lung Cancer*, Aisner, J. (ed), Churchill Livingstone, N.Y., pp. 287-306, 1985.
 36. Bunn, P.A., Jr., Minna, J.D.: Paraneoplastic syndromes. In: *Principles and Practice of Oncology*. Second Edition. DeVita, V., Hellman, S., Rosenberg (eds), J.B. Lippincott Co., Inc., NY, pp. 1797-1842, 1985.
 37. Winkler, C.F., Bunn, P.A., Jr.: Treatment of T-cell lymphomas: Mycosis fungoides and the Sezary Syndrome. In: *Current Therapy*, 1985, Conn, H.F. (ed). Philadelphia, W.B. Saunders, pp. 317-322, 1985.
 38. Bunn, P.A., Jr., Foon, K.A., Ihde, D.C., Longo, D., Schroff, R., Minna, J.D., Carrasquillo, J., Keenan, A., Larson, S., Glatstein, E.: Treatment of cutaneous T- cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T1-1 monoclonal Antibody. In: *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*. Cavalli, F., Bonadonna, G., Rozencweig, M. (eds). Martinus Nijhoff, Boston, MA, pp. 579-590, 1985.
 39. Foon, K.A., Bunn, P.A., Jr.: Treatment of advanced lymphoproliferative disorders with recombinant leukocyte A interferon. In: *Proc. Recombinant Interferon in Cancer Treatment: An Interactive Workshop*, Sikora, K. (ed), Stockholm, 1985.
 40. Ihde, D.C., Bunn, P.A., Jr., Lichter, A.S., Glatstein, E., Minna, J.D.: Chemotherapy in combined modality treatment of small cell lung cancer. In: *Proceedings 14th Inter. Congress of Chemotherapy*, Kyoto, Japan, 1985.
 41. Sedlacek, S., Bunn, P.A., Jr.: Debulking (cytoreductive) surgery. In: *Surgical Secrets*. Abernathy, C. (ed). Hanley & Belfast, Philadelphia, PA pp. 186-189, 1986.
 42. Lindmo, T., Bunn, P.A., Jr.: Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. In: *Immunochemical Techniques*. DiSabato, G., Langone, J.J., vanVunakis, H., (eds). Academic Press Inc., Orlando FL, pp. 678-691, 1986.
 43. Sausville, E.A. and Bunn, P.A. Jr.: Biologic and clinical spectrum of T-cell neoplasms. In: *Harrison's Principles of Internal Medicine, Update VII Oncology*, pp. 159-180, 1986.
 44. Braun, T.J., Bunn, P.A., Jr.: Current concepts of chemotherapy and radiotherapy for small cell lung cancer. In: *Lung Cancer: Current Status and Prospects for the Future*, Mountain, C.F. & Carr, D.F., (eds.). University of Texas Press, Austin, TX, pp. 259-289, 1986.
 45. Minna, J.D., Cuttitta, F., Mulshine, J., Bunn, P.A., Jr., Carney, D., Doyle, A., Fedorko, J., Gazdar, A.F., Linnoila, I., Nau, M., Rosen, S.: New approaches to using monoclonal antibodies in the diagnosis and treatment of lung cancer. In: *Lung Cancer: Current Status and Prospects for the Future*, Mountain, C.F. & Carr, D.F., (eds.). University of Texas Press, Austin, TX, pp. 345-350, 1986.
 46. Dienhart, D.G., Bunn, P.A., Jr.: Small cell carcinoma of the lung. In: *Current Pulmonology*, Vol. 8., Simmons, D. H., (ed.), Year Book Med Publishers, Chicago, IL, pp. 17-48, 1987.

47. Dienhart, D., Bunn, P.A., Jr.: Patterns of relapse in small cell lung cancer - Implications for future studies. In: Lung Cancer: A Comprehensive Treatise. Bitran, J.D., Golomb, H.M., Little, A.G., Weichselbaum, R.R. (eds.). Grune & Stratton Publishers, Orlando, FL, pp. 369-397, 1988.
48. Bunn, P.A., Jr.: Paraneoplastic syndromes. In: Cecil's Textbook of Medicine, 18th edition. Wyngaarden, J.B. and Smith, L., Jr. (eds). W.B. Saunders Company, Philadelphia, PA, pp. 1097-1099, 1988.
49. Bunn, P.A., Jr.: Tumor markers. In: Cecil's Textbook of Medicine, 18th edition. Wyngaarden, J.B. and Smith, L., Jr. (eds). W.B. Saunders Company, Philadelphia, PA, pp. 1099-1100, 1988.
50. Roth, M.S., Bunn, P.A., Jr., Foon, K.A.: Interferon therapy for lymphoproliferative disorders. In: Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemia: Bennett, J.M. and Foon, F.A. (eds). Martinus Nijhoff Publishing, Boston, MA., pp. 231-252, 1988.
51. Bunn, P.A., Jr., Fuks, Z.: Cutaneous and acute T-cell lymphomas. In: Principles and Practice of Oncology, Third Edition, DeVita, V., Hellman, S., and Rosenberg, S. (eds). J.B. Lippincott Company, Philadelphia, PA. Third Edition, Vol. 2, pp. 1799-1808, 1988.
52. Bunn, P.A. Jr., Ridgeway, E.C.: Paraneoplastic syndromes. In: Principles and Practice of Oncology, Third Edition, DeVita, V., Hellman, S., and Rosenberg, S. (eds). J.B. Lippincott Company, Philadelphia, PA. Third Edition, Vol. 2, pp. 1896-1940, 1988.
53. Foon, K.A. and Bunn, P.A. Jr.: Interferon alfa-2a in advanced cutaneous T-cell lymphoma. In: Interferons Today and Tomorrow, M. Talpaz (ed.), Mediscript, London, 1988.
54. Bunn, P.A., Jr.: Mesothelioma. In: Textbook of Internal Medicine. Kelley, W. N. (ed). J.B. Lippincott Company, Philadelphia, PA, Vol. 1, pp. 1268-1270, 1989.
55. Bunn, P.A. Jr.: Chemotherapy for non-small cell lung cancer (NSCLC). In: Lung Cancer Advanced Concepts and Present Status, G. Motta (ed.), G. Motta Publ., Genoa, Italy, pp.257-266, 1989.
56. Bunn, P.A. Jr., Dienhart, D.G., Schmelter, R.F., Lear, J.L., Miller, G., Bloedow, D.C., Longley, C., Furmanski, P., Ceriani, R.L.: In vivo studies of radiolabeled monoclonal antibodies of MC5 and KC4 in human breast cancer. Ceriani, R., (ed.), Plenum Corp., NY, pp. 237-248, 1989.
57. Lamb, R., Bunn, P.A., Jr.: T-cell lymphoreticular malignancies in adults. In: Non-Hodgkin's Lymphoma, I. Magrath (ed), pp. 330- 351, 1990.
58. Bunn, P.A., Jr.: Carboplatin: Current status and future direction. In: Carboplatin (JM-8) Current Perspectives and Future Directions. P. Bunn, Jr., R. Canetta, R. Ozols, M. Rozenzweig (eds), W.B. Saunders Company, Philadelphia, PA, pp 371-381, 1990.
59. Bunn, P.A., Jr.: The role of systemic chemotherapy in non-small cell lung cancer. In Current Topics in Lung Cancer. P.A. Bunn, Jr., (ed.), Springer-Verlag, New York, In Current Topics in Lung Cancer, European School of Oncology, pp. 33-46, 1991.
60. Bunn, P.A., Jr., Dienhart, D.G., Gonzalez, R., Kasliwal, R., Bloedow, D., Hartmann, C., Lear, J., Johnson, T., Furmanski, P., Miller, G.J., Glenn S., Longley, C., Ceriani, R.L. and Butchko, G.: Imagine, Pharmacokinetics, Dosimetry and Antitumor Effects of Radiolabeled Anti-breast Cancer Antibodies in Mouse and Man. In breast epithelial antigens: Molecular biology to Clinical Applications. R.L. Ceriani (ed.) Plenum Press, New York, NY, 1991.
61. Bunn, P.A., Jr.: Paraneoplastic syndromes. In: Cecil's Textbook of Medicine, 19th edition. Wyngaarden, J.B. Smith, L., Jr. and Bennett JC (eds). W.B. Saunders Company, Philadelphia, PA, pp. 1032-1034, 1992 .
62. Bunn, P.A., Jr.: Tumor markers. In: Cecil's Textbook of Medicine, 19th edition. Wyngaarden, J.B. Smith, L., Jr. and Bennett JC (eds). W.B. Saunders Company, Philadelphia, PA, pp. 1034-1037, 1992.
63. Bunn, P.A., Jr.: Approach to the Management of Mesotheliomas. In: Textbook of Internal Medicine, 2nd edition. WN Kelley (ed), J.B. Lippincott Co., Philadelphia, PA, pp. 1152-1154, 1992.
64. Bunn, P.A., Jr.: Clinical role of growth factors in small cell lung cancer. In: Lung Cancer: Status and Future Perspectives. F. R. Hirsch (ed), Bristol-Myers Squibb, Denmark, pp. 153-183, 1993.
65. Bunn, P.A., Jr.: Lung Cancer: Approach to the management of lung cancer. In: Essentials of Internal Medicine. J. P. Lippincott Co., Philadelphia, PA, pp 376-378, 1994.
66. Bunn, P.A., Jr.: The Biology of Lung Cancer: 1993. In: Lung Cancer: Frontiers in Science and Treatment. G. Motta (ed.), Motta Publ., Genoa, Italy, pp. 49-56, 1994.
67. Bunn, P.A., Jr.: The Role of Hematologic Growth Factors in Lung Cancer Therapy. In: Lung Cancer: Frontiers in Science and Treatment. G. Motta (ed.), Motta Publ., Genoa, Italy, pp. 571-579, 1994.

FASCO

68. Bunn, P.A., Jr.: Surgical Adjuvant Chemotherapy in Operable and Inoperable Stage III Non Small-Cell Lung Cancer. In: Lung Cancer: Frontiers in Science and Treatment. G. Motta (ed.), Motta Publ., Genoa, Italy, pp. 635-644, 1994.
69. Olsen, E.A., Bunn, P.A., Jr.: Interferon in the treatment of cutaneous T-cell lymphoma. In: Hematology/Oncology Clinics of North America. Koh, H.K., Foss, F.M. (eds.), W. B. Saunders Company, Philadelphia, PA, pp. 1089-1107, 1995.
70. Bunn, P.A., Jr., Kelly, K., Cook, R., Proudfoot, S., Kennedy, T.: Prevention and early detection of lung cancer. 2nd Nordic Symposium, Sorrento, Italy, pp 31-53, August, 1995.
71. Chan, D.C.F., Kirpotin, D.B., Bunn, P.A. Physical chemistry and in vivo tissue haeting properties of colloidal magnetic iron oxides with increased power absorption rates. In: Scientific and Clinical Application of Magnetic Carriers. Hafeli (ed.), Plenum Press, New York 1997.
72. Bunn, P.A., Jr. Molecular biologic changes toward cancer caused by cigarette smoking. In: Book of Proceedings Jakarta International Cancer Conference' 95. Berkel, H.J, Kresno, S.B, Tjarta, A (eds.). PT Gaya Baru, Jakarta, Indonesia.
73. Soriano, A.F., Schefer, H., and Bunn, P.A., Jr.: Current Cancer Therapeutics, Third Edition. Churchill Livingstone, New York, pp 177-199, 1998.
74. Bunn, P.A., Jr., Kane, M.A.: Overview of the Biology of Lung Cancer. Biology of Lung Cancer, Marcel Dekker, New York, Vol. 122, pp. 1-9, 1998.
75. Kane, M. A., Bunn, P.A., Jr.: Perspectives on Lung Cancer for the Twenty-First Century: Impact of Cellular and Molecular Biology. Biology of Lung Cancer, Marcel Dekker, New York, Vol. 122, pp 571-578, 1998.
76. Soriano, A.F., Bunn, P.A., Jr.: New drug combinations in NSCLC progress in Cancer Therapy. Progress in Anti-Cancer Chemotherapy, Springer-Verlag, France, pp. 131-174, 1999.
77. Hirsch, F.R., Lassen, U., Bunn, P.A., Jr.: Chemotherapy of small cell lung cancer. Lung Cancer Recent Developments in Diagnosis and Treatment, Bristol-Myers Squibb, Denmark, pp. 157-178, 1999.
78. Hirsch, F.R., Bremmes, R., Jensen, P.B., Lassen, U., Palshof, T., Bunn, P.A., Jr.: Treatment of patients with small lung cancer. Lung Cancer Recent Developments in Diagnosis and Treatment, Bristol-Myers Squibb, Denmark, pp. 179-182, 1999.
79. Chan, DC, Soriano A, Kane MA, Helfrich B, Bunn, P.A., Jr.: Biology of lung cancer. In: Textbook of Lung Cancer, Hansen, H. (eds.) Martin Dunitz, London, UK, pp 27-73, 1999.
80. Bunn, P.A., Jr., Holden, S, Jotte, R, Simon, G. Treatment of non-small lung cancer. In: Lung Cancer Therapy Annual 2000, Hansen, H.H., Bunn, P.A. Jr. (eds.) Martin Dunitz, London, UK, pp. 53-129, 2000.
81. Jotte, R, Bunn, P.A., Jr. Biologic therapy of lung cancer. In: Lung Cancer Therapy Annual 2000, Hansen, H.H., Bunn, P.A. Jr. (eds.) Martin Dunitz, London, UK, pp. 131-152, 2000.
82. De Araujo C.W., Bunn, P.A., Jr. Lung Cancer. In: Current Cancer Therapeutics (eds.) Kirkwood JM, Lotze MT, Yasko JM. 4th Edition, Current Medicine Inc., Philadelphia, pp. 177-195: 2001.
83. Bunn PA, Jr. Treatment of non-small cell lung cancer. Hansen HH, Bunn PA, Jr. (eds). Lung Cancer Therapy. Martin Dunitz, London, UK, pp. 63-128, 2001.
84. Bunn PA, Jr. Biologic therapy of lung cancer. Hansen HH, Bunn PA, Jr. (eds). Lung Cancer Therapy. Martin Dunitz, London, UK, pp. 129-144, 2001.
85. York EJ, Chan DC, Helfrich B, Bunn PA, Jr., Gera L, Stewart JM. Exploring the "Double-Ring" Motif in Bradykinin Antagonists. Lebl M, Houghten RA (eds.). The Wave of the Future. American Peptide Society, pp. 721-22, 2001.
86. Gera L, Chan DC, Helfrich B, Bunn PA, Jr., York EJ, Stewart JM. Development of New Analogs of the Highly Potent Anti-Cancer Compound BKM-570. Lebl M, Houghten RA (eds.). The Wave of the Future. American Peptide Society, pp. 642-43, 2001.
87. Gera L, Chan DC, York EJ, Simkeviciene V, Bironaite D, Vagonis A, Bunn PA, Jr., Taraseviciene-Stewart L, Stewart JM. In: Benedetti E, Pedone C (eds.) Peptides. Napoli, Italy. Pp. 498-499.
88. Gera L, Chan DC, York EJ, Simkeviciene V, Vagonis A, Bironaite D, Bunn PA, Jr., Taraseviciene-Stewart L, Stewart JM. BKM-570 and its new acyl-amino acid amide analogs for lung and prostate cancer. Chorev M & Sawyer TK (eds): Peptide Revolution: Genomics, Proteomics & Therapeutics. 2003.

FASCO

89. Keith RL, Miller YE, Bunn PA, Jr., Nana-Sinkam P, Nemenoff RA, Geraci MW. Prostacyclin and lung Cancer Prevention. In: Kelloff GJ, Hawk ET, Sigman CC (eds.): *Cancer Chemoprevention, vol I: Promising Cancer Chemoprevention Agents*, pp. 175-189, 2003.
90. Bunn, PA, Jr. Treatment of non-small cell lung cancer. In: Hansen HH, Bunn PA, Jr., Kelly K (eds.): *Lung Cancer Therapy Annual 3*. Martin Dunitz, London, UK, pp. 67-126, 2003.
91. Dziadziuszko, R., Bunn, P. A., Jr., & Dziadziuszko R, H. F. B. Jr. P. (2008). Advances in lung cancer treatment. In: *Quantitative Imaging Tools for Lung Cancer Drug Assessment* (JL Mulshine, TM Baer, eds), Wiley-Interscience, Hoboken, NJ. 17-38.
92. Franklin WA, Aisner DL, Post MD, Bunn, PA, Garcia M. Pathology, biomarkers and molecular diagnostics. In: *Niederhuber & Armitage & Donoshow & Kastan & Tepper* (eds). Elsevier, chapter 17, 2013.
93. Wilbur A. Franklin, Dara L. Aisner, Kurtis D. Davies, Kristy Crooks, Miriam D. Post, Bette DeMasters, Edward Ashwood, Paul A. Bunn, and Marileila Varela-Garcia. Pathology, Biomarkers, and Molecular Diagnostics. In: *Niederhuber*. Elsevier, Chapter 15. 2018. (Publication in review).

Abstracts

1. Hexter, S.M., Lozner, E.C., Bunn, P.A., Jr.: Genetic recombination at the spineless, spineless-aristopedia locus in *Drosophila melanogaster*. *Genetics* 56:565, 1967.
2. Bunn, P.A., Jr., Okamoto, M., Riker, W.F., Jr.: Subacute denervation of skeletal muscle. *Federation Proc.* 29:280, 1970.
3. Shackney, S.E., Bunn, P.A., Jr., Ford, S.S.: Colcemid induced thrombopoiesis. *Proc. Amer. Assoc. Cancer Res.* 16:39, 1976.
4. Bunn, P.A., Jr., Ford, S.S., Shackney, S.E.: Semi-automated cell and grain counting. *Cancer Treat. Rep.* 60:1986, 1976.
5. Cohen, M.H., Widerlite, L., Bunn, P.A., Jr., Nugent, J.: Carcinoembryonic antigen in gastric disease. *Gastroenterology*.
6. Cohen, M.H., Ihde, D.C., Fossieck, B.E., Bunn, P.A., Jr., Matthews, M.J., Johnston, A.V., Minna, J.D.: Intensive chemotherapy of small cell bronchogenic carcinoma (SCBC). *Proc. Amer. Soc. Clin. Oncol.* 18:286, 1977.
7. Matthews, M., Gazdar, A.F., Cohen, M.H., Ihde, D.C., Bunn, P.A., Jr., Minna, J.D.: Small cell carcinoma of the lung (SCBC) correlation of morphology with clinical response. *Proc. Amer. Assoc. Cancer Res.* 18:86, 1977.
8. Bunn, P.A., Jr., Nugent, J., Ihde, D.C., Cohen, M.H., Fossieck, B.E., Jr., Minna, J.D.: 5-fluorouracil (5-FU), methyl CCNU (MeCCNU), adriamycin and mitomycin-C in advanced gastric cancer. *Proc. AACR and ASCO* 19:358, 1978.
9. Bunn, P.A., Jr., Edelsen, R.L., Ford, S.C., Shackney, S.E.: Cellular proliferation in the Sezary syndrome: Growth kinetics and therapeutic implications. *Proc. AACR and ASCO* 19:226, 1978.
10. Cohen, M.H., Ihde, D.C., Fossieck, B.E., Jr., Bunn, P.A., Jr., Matthews, M.J., Shackney, S.E., Johnston, A.V., Minna, J.D.: Cyclic alternating combination of small cell bronchogenic carcinoma (SCBC). *Proc. AACR and ASCO* 19:359, 1978.
11. Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Fossieck, B.E., Eddy, J., Minna, J.D.: Combination chemotherapy in metastatic carcinoma of the prostate: Methods of detecting tumor response and progression. *Proc. AACR and ASCO* 19:339, 1978.
12. Minna, J.D., Matthews, M.J., Gazdar, A.F., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Jr., Cohen, M.H.: Identification and combination chemotherapy of mixed histology large cell-small cell (WP = 40/22). *Proc. AACR and ASCO* 19:397, 1978.
13. Simms, E.B., Ihde, D.C., Matthews, M.J., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D., DeVita, V.T.: Therapeutic implications of bone marrow involvement in small cell carcinoma of the lung. *Proc. AACR and ASCO* 19:393, 1978.
14. Matthews, M.J., Gazdar, A.F., Ihde, D.C., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D.: Histologic subtypes of small cell carcinoma of the lung (SCCL) and their clinical significance. *Proc. AACR and ASCO* 19:397, 1978.
15. Huberman, M.S., Fossieck, B.E., Jr., Bunn, P.A., Jr., Cohen, M.H., Ihde, D.C., Minna, J.D.: Herpes Zoster (HZ) in patients with small cell carcinoma of the lung (SCCL) receiving intensive chemotherapy. *Proc. AACR and ASCO* 19:354, 1978.

FASCO

16. Cohen, M.H., Chretien, P.B., Ihde, D.C., Fossieck, B.E., Jr., Bunn, P.A., Jr., Kenady, D.E., Lipson, S.D., Minna, J.D.: Thymosin fraction V prolongs the survival of small cell lung cancer (SCLC) patients treated with intensive combination chemotherapy. Proc. AACR and ASCO 19:117, 1978.
17. Minna, J.D., Pelsor, F., Ihde, D.C., Bunn, P.A., Jr., Gazdar, A.F., Cohen, M.H.: High dose methotrexate (HDMTX) therapy by 6 or 30 hour infusion with leucovorin rescue (LR) in non-small cell lung cancer. Proc. AACR and ASCO 19:135, 1978.
18. Ihde, D.C., Brodie, E.M., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D.: Radiotherapeutic responsiveness of small cell carcinoma of the lung (SCCL) after failure of combination chemotherapy. Proc. AACR and ASCO 19:122, 1978.
19. Nugent, J.L., Bunn, P.A., Jr., Ihde, D.C., Matthews, M.J., Cohen, M.H., DeVita, V.T., Minna, J.D.: Diagnosis and treatment of CNS complications of small cell bronchogenic carcinoma (SCBC). Proc. AACR and ASCO 19:116, 1978.
20. Matthews, M.J., Ihde, D.C., Cohen, M.H., Bunn, P.A., Jr., Binder, R., Minna, J.D.: Effects of chemotherapy on the histology of small cell carcinoma of the lung (SCCL): A postmortem study of 54 cases. Proc. AACR and ASCO 19:397, 1978.
21. Brigham, B., Bunn, P.A., Jr., Minna, J.D., Cohen, M.H., Ihde, D.C., Shackney, S.E.: Growth rates of small cell bronchogenic carcinoma (SCBC). Proc. AACR and ASCO 19:357, 1978.
22. Levine, R.F., Bunn, P.A., Jr., Schlam, M.L.: Rapid analysis of DNA content of large numbers of megakaryocytes by flow microfluorometry. Blood 52:166, 1978.
23. Bunn, P.A., Jr., Schechter, G., Ihde, D.C., Cohen, M.H., Binder, R., Minna, J.D.: Cyclic alternating combination chemotherapy for multiple myeloma. Proc. AACR and ASCO 20:410, 1979.
24. Whang-Peng, J., Bunn, P.A., Jr., Knutsen, T., Gazdar, A.F., Minna, J.D.: Cytogenetic studies in cutaneous T-cell lymphomas (CTCL). Proc. AACR and ASCO 20:261, 1979.
25. Huberman, M., Bunn, P.A., Jr., Matthews, M.J., Fischmann, B., Whang-Peng, J., Guccion, J., Dunnick, R., Ihde, D.C., Cohen, M.H., Minna, J.D.: Extra-cutaneous involvement in patients with cutaneous T-cell lymphomas (CTCL): Mycosis fungoides and Sezary syndrome. Proc. AACR and ASCO 20:410, 1979.
26. Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Combination chemotherapy of hepatocellular carcinoma with adriamycin (ADM) and streptozotocin (STZ). Proc. AACR and ASCO 20:410, 1979.
27. Cohen, M.H., Bunn, P.A., Jr., Fossieck, B.E., Jr., Ihde, D.C., Johnston- Early, A., Minna, J.D.: Laboratory parameters as a replacement for performance status in prognostic stratification. Proc. AACR and ASCO 20:409, 1979.
28. Gazdar, A.F., Chopra, H.C., Bunn, P.A., Jr.: Mitogen induced replication of cutaneous T-cell lymphomas (CTCL). Proc. AACR and ASCO 20:261, 1979.
29. Carney, D.N., Gazdar, A.F., Russell, E.K., Schechter, G.P., Bunn, P.A., Jr.: Mitogen responses and flow microfluorometry (FMF) of circulating cells in the Sezary syndrome (SS). Proc. AACR and ASCO 20:39, 1979.
30. Posner, L.E., Fossieck, B.E., Jr., Eddy, J.L., Bunn, P.A., Jr., Primack, A.: Bacteremia in the cutaneous T-cell lymphomas (CTCL). Proc. AACR and ASCO 20:409, 1979.
31. Ihde, D.C., Makuch, R.W., Cohen, M.H., Bunn, P.A., Jr., Matthews, M.J., Minna, J.D.: Prognostic implications of sites of metastases in patients with small cell carcinoma of the lung (SCCL) given intensive chemotherapy. Proc. AACR and ASCO 20:264, 1979.
32. Radice, P.A., Matthews, M.J., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Cohen, M.H., Minna, J.D.: Characterization of mixed histology large cell/small cell lung cancer and its response to combination chemotherapy. Proc. AACR and ASCO 20:409, 1979.
33. Carney, D.N., Bunn, P.A., Jr., Schlam, M., Gazdar, A.F.: Flow microfluorometric (FMF) analysis of normal and neoplastic lymphocytes in response to mitogen stimulation: A comparison of tritiated thymidine (3HTdR) incorporation. Blood 54:97a, 1979.
34. Bunn, P.A., Jr., Schlam, M., Schechter, G.P.: Flow cytometric analysis of DNA content in patients with plasma cell dyscrasias. Blood 54:180, 1979.
35. Schechter, G.P., Bunn, P.A., Jr., Munson, O., Fischmann, A.B., Matthews, M.J., Guccion, J., Soehnlem, F., Minna, J.D.: Detection of peripheral blood involvement in cutaneous T-cell lymphomas (CTCL): Usefulness of lymphocytic surface marker studies. Blood 54:183a, 1979.

FASCO

36. Bunn, P.A., Jr., Fischmann, A.B., Kumar, P., Schechter, G.P., Ihde, D.C., Fossieck, B., Cohen, M.H., Matthews, M., Minna, J.D.: Combined electron beam irradiation (EBRT) and systemic chemotherapy for cutaneous T-cell lymphomas. Proc. AACR and ASCO 21:464, 1980.
37. Levenson, R.M., Ihde, D.C., Matthews, M.J., Cohen, M.H., Bunn, P.A., Jr., Minna, J.D.: Small cell carcinoma (SCC) arising in extrapulmonary sites: Response to chemotherapy. Proc. AACR and ASCO 21:143, 1980.
38. Bunn, P.A., Jr., Schlam, M., Gazdar, A.F.: Comparison of cytology and DNA content analysis by flow cytometry (FCM) in specimens from lung cancer patients. Proc. AACR and ASCO 21:40, 1980.
39. Bradley, E., Matthews, M., Cohen, M.H., Fossieck, B., Bunn, P.A., Jr., Ihde, D.C., Minna, J.D.: Erythroleukemia, pancytopenia, and peripheral blood aneuploidy as complications of therapy in long term survivors in small cell carcinoma of the lung (SCCL). Proc. AACR and ASCO 21:320, 1980.
40. Johnston-Early, A., Cohen, M.H., Paxton, L.M., Fossieck, B.E., Jr., Ihde, D.C., Bunn, P.A., Jr., Matthews, M.J., Minna, J.D.: Smoking abstinence prolongs survival of small cell lung cancer patients. Proc. AACR and ASCO 21:380, 1980.
41. Minna, J.D., Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Fossieck, B., Matthews, M.: Extensive stage small cell carcinoma of the lung (SCCL): Effect of increasing intensity of induction chemotherapy. Proc. AACR and ASCO 21:448, 1980.
42. Cohen, M.H., Lichter, A.S., Bunn, P.A., Jr., Glatstein, E.J., Ihde, D.C., Fossieck, B.E., Matthews, M.J., Minna, J.D.: Chemotherapy-radiation therapy (CT-RT) versus chemotherapy (CT) in limited small cell lung cancer (SCLC). Proc. AACR and ASCO 21:448, 1980.
43. Ihde, D.C., Dunnick, N.R., Johnston-Early, A., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Abdominal computed tomography in small cell lung cancer: Assessment of extent of disease and response to therapy. Clin. Research 28:416A, 1980.
44. Minna, J.D., Lichter, A., Brereton, H., Bunn, P.A., Jr., Cohen, M.H., Fossieck, B., Ihde, D.C., Johnson, R., Matthews, M., Glatstein, E.: Small cell lung cancer: Long term, potentially cured survivors in National Cancer Institute trials. Clin. Research 28:419A, 1980.
45. Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Dunnick, N.R., Eddy, J.L., Minna, J.D.: Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. Cancer 45:1300-10, 1980.
46. Bunn, P.A., Jr., Rosen, S., Aisner, J., Matthews, M., Glatstein, E., Ihde, D.C., Wiernick, P.: Carcinomatous leptomeningitis (CL) in patients with small cell carcinoma of the lung: A frequent, treatable complication. Proc. AACR and ASCO 22:162, 1981.
47. Rosen, S., Bunn, P.A., Jr., Lichter, A., Matthews, M., Ihde, D.C., Cohen, M.H., Carney, D.N., Minna, J.D., Glatstein, E.: Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Benefit restricted to patients in complete response. Proc. AACR and ASCO 22:499, 1981.
48. Whang-Peng, J., Bunn, P.A., Jr., Kao Shan, E., Lee, E., Minna, J.D., Gazdar, A.F.: Non-random chromosomal abnormalities (3p) in continuous cultures of small cell lung cancer. Proc. AACR and ASCO 22:45, 1981.
49. Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Eddy, J.L., Dunnick, N.R., Bensimon, H., Jawadpour, N., Minna, J.D.: Combination chemotherapy as initial treatment for stage D-2 prostatic cancer: Response rate and results of subsequent hormonal therapy. Proc. AACR and ASCO 22:163, 1981.
50. Bunn, P.A., Jr., Carney, D.N., Gazdar, A.F., Minna, J.D.: DNA content analysis of small cell lung cancer cells cultures in serum supplemented medium, agarose, and serum-free medium supplemented with selenium, hydrocortisone, insulin, transferrin, and estriol. Cell Tissue Kinet.
51. Foon, K.A., Schroff, R.W., Bunn, P.A., Jr., Cline, M.J., Fahey, J.L.: Cell surface antigens defining functional T-cell subsets in Sezary cell leukemia. Proc. AACR and ASCO 22:306, 1981.
52. Ihde, D.C., Matthews, M.J., Seeff, L.B., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: "Long-term" survivors (LTS) in doxorubicin-treated patients with hepatocellular carcinoma (HC). Proc. AACR and ASCO 22:456, 1981.
53. Levenson, R.M., Sauerbrunn, B.J.L., Ihde, D.C., Bunn, P.A., Jr., Cohen, M.H., Fossieck, B.E., Minna, J.D.: Value of radionuclide bone scans in determination of extent of disease and response to treatment in small cell carcinoma of the lung. Proc. AACR and ASCO 22:501, 1981.
54. Alvarez, R., Gazdar, A.F., Carney, D.N., Dermody, W.C., Bunn, P.A., Jr., Minna, J.D.: Clonal heterogeneity of small cell carcinoma of the lung (SCCL). Proc. AACR and ASCO 22:339, 1981.

55. Johnston-Early, A., Cohen, M.H., Makuch, R., Ihde, D.C., Bunn, P.A., Jr., Fossieck, B.E., Matthews, M.J., Minna, J.D.: Delayed hypersensitivity skin testing as a prognostic indicator in small cell lung cancer (SCLC). Proc. AACR and ASCO 22:338, 1981.
56. Carney, D.N., Bunn, P.A., Jr., Gazdar, A.F., Matthews, M.J., Pagan, J.F., Minna, J.D.: Selective growth of small cell lung cancer in clinical specimens in serum-free, hormone supplemented medium. Proc. AACR and ASCO 22:385, 1981.
57. Munson, D., Bunn, P.A., Jr., Schechter, G.P.: FC receptor-defined T-lymphocyte subpopulations in patients with cutaneous t-cell lymphoma. J. Invest. Dermatol. 79:317-321, 1982.
58. Bunn, P.A., Mulshine, J., Matthews, M., Johnston-Early, A., Makuch, R., Ihde, D., Carney, D., Cohen, M., Minna, J.: Methods of detection and significance of liver metastases in small cell lung cancer. Abstr III World Conf Lung Cancer, Tokyo, p. 80, 1982.
59. Mulshine, J., Matthews, M., Radice, P., Johnston-Early, A., Makuch, R., Ihde, D.C., Carney, D.N., Cohen, M.H., Minna, J.D., Bunn, P.A., Jr.: Staging evaluation of the liver in small cell carcinoma of the lung (SCCL). Proc. ASCO 1:140, 1982.
60. Johnston-Early, A., Cohen, M.H., Fossieck, B.E., Ihde, D.C., Bunn, P.A., Jr., Matthews, M.J., Minna, J.D.: Treatment related diffuse interstitial pulmonary disease (DIPD). A retrospective review. Proc. ASCO 1:146, 1982.
61. Morstyn, G., Ihde, D.C., Eddy, J.L., Bunn, P.A., Jr., Cohen, M.H., Minna, J.D.: Combination chemotherapy with doxorubicin and streptozotocin (DXR/STZ) in hepatocellular carcinoma (HC). Proc. AACR 23:133, 1982.
62. Sherwin, S.A., Longo, D.A., Bunn, P.A., Jr., Fein, S., Oldham, R.K.: Phase II efficacy trial in recombinant leukocyte A interferon (IFLrA) in refractory lymphoproliferative disorders and metastatic breast cancer. Ann. International Congress for Interferon Research.
63. Morstyn, G., Schechter, G., Ihde, D., Carney, D., Eddy, J., Cohen, M., Minna, J.D., Bunn, P.A., Jr.: Therapy of multiple myeloma with alternating noncross-resistant chemotherapy combinations. Blood 60:162a, 1982.
64. Schechter, G.P., Bunn, P.A., Jr., Gritsman, A., Soehnen, F., Schulof, R., Abrams, R.: Functional studies of lymphocytes from patients with T-cell chronic lymphoproliferation of the cytotoxic/suppressor phenotype. Blood 60:75a, 1982.
65. Gritsman, A., Winkler, C., Gazdar, A., Robert-Guroff, M., Schechter, G., Bunn, P.A., Jr.: Characterization of T lymphocytes cultured from patients with cutaneous T-cell lymphomas (CTCL). Blood 60:144a, 1982.
66. Bunn, P.A., Jr., Cohen, M., Lichter, A., Makuch, R., Ihde, D., Carney, D., Johnston-Early, A., Schwartz, S., Minna, J.D., Glatstein, E.: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy in limited stage small cell lung cancer. Proc. ASCO 2:200, 1983.
67. Ihde, D.C., Lichter, A.S., Deisseroth, A.B., Bunn, P.A., Jr., Carney, D.N., Cohen, M.H., Makuch, R.W., Johnston-Early, A., Minna, J.D.: Late intensive combined modality therapy (LIRX) with autologous bone marrow (ABM) infusion in extensive stage small cell lung cancer (SCLC). Proc. ASCO 2:198, 1983.
68. Foon, K., Bunn, P.A., Jr., Schroff, R., Mayer, D., Sherwin, D., Longo, D., Ochs, J., Bottino, G., Fer, M., Herberman, R., Oldham, R.: Monoclonal antibody therapy of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL). Proc. ASCO 2:48, 1983.
69. Crane, J., Nelson, M., Macdonald, J., Johnston-Early, A., Ihde, D., Bunn, P.A. Jr.: A comparison of computer tomography (CT) and radionuclide (RN) Tc99m scanning of the brain in small cell lung cancer (SCLC). Proc. ASCO 2:200, 1983.
70. Winkler, C.F., Ihde, D., Dunnick, N.R., Eddy, J.L., Newman, R.D., Bunn, P.A., Jr.: Computer tomography of the abdomen and pelvis (CTAP) and lymphography (LG). Proc. ASCO 2:139, 1983.
71. Fargion, S., Carney, D.N., Cuttitta, F., Mulshine, J., Bunn, P.A., Jr., Little, C., Gold, G.L., Minna, J.D.: Antigenic heterogeneity in small cell lung cancer (SCLC) defined by 15 monoclonal antibodies (MA). Proc. ASCO 2:55, 1983.
72. Blayney, D.W., Blattner, W.A., Jaffe, E.S., Fisher, R.I., Bunn, P.A., Jr., Clark, J.W., Robert-Guroff, R., Gallo, R.C.: Short remission duration in lymphoma associated with the human T-cell leukemia/lymphoma virus (HTLV). Proc. ASCO 2:216, 1983.
73. Bunn, P.A., Jr., Schechter, G., Jaffe, E., Young, R., Blayney, D., Blattner, W., Robert-Guroff, M., Gallo, R.: Adult T-cell lymphoma in the United States: A high grade non-Hodgkin's lymphoma associated with human T-cell lymphoma virus. Clinical Research 31:404A, 1983.

74. Schroff, R.W., Foon, K.A., Bunn, P.A., Jr., Sherwin, S.A., Oldham, R.K.: Immunologic studies of chronic lymphocytic leukemia (CLL) and cutaneous T-cell lymphoma (CTCL) patients receiving monoclonal antibody therapy. *Clinical Research* 31:352A, 1983.
75. Cuttitta, F., Moody, T.W., Carney, D.N., Fedorko, J., Mulshine, J., Bunn, P.A., Jr., Minna, J.: A monoclonal antibody 4 against amphibian bombesin which binds to bombesin-like neuropeptides produced by human small cell lung cancer. *Clinical Research* 31:405A, 1983.
76. Fargion, S., Cuttitta, F., Mulshine, J., Carney, D.N., Bunn, P.A., Jr., Minna, J.: Monoclonal antibodies against a lung cancer cell line highly enriched in "stem cells". *Proc. AACR* 24:221, 1983.
77. Winkler, C.F., Carney, D.N., Bunn, P.A., Jr.: Growth and cloning of malignant T-cell lymphomas in serum-free media (SFM). *Proc. AACR* 24:5, 1983.
78. Crane, J., Lichter, A., Ihde, D., Carney, D., Gold, G.L., Glatstein, E., Minna, J., Bunn, P.A., Jr.: Therapeutic cranial radiotherapy (RT) for brain metastases in small cell lung cancer (SCLC). *Proc. AACR* 24:145, 1983.
79. Sidi, Y., Edwards, N.Y., Bunn, P.A., Jr., Mitchell, B.S.: Differential toxicity of deoxyribonucleosides for acute and chronic leukemia cells of T cell origin. *Proc. AACR* 24:300, 1983.
80. Bunn, P.A., Jr., Foon, K.A., Schroff, R.W., Hsu, S.M., Longo, D.L., Winkler, C.F., Oldham, R.K.: T101 monoclonal antibody (MOAB) therapy for T-cell lymphomas. *Blood* 62:210a, 1983.
81. Whang-Peng, J., Bunn, P.A., Jr., Knutsen, T., Kao-Shan, C.S., Broder, S., Jaffe, E., Gelmann, E., Blattner, W., Gallo, R.C.: Cytogenetic studies in human T-cell lymphoma virus (HTLV) positive leukemia/lymphoma in the U.S.A. *Blood* 62:198a, 1983.
82. Foon, K.A., Schroff, R.W., Bunn, P.A., Jr., Oldham, R.K.: Effects of monoclonal antibody serotherapy on patients with chronic lymphocytic leukemia (CLL). *Blood* 62:202a, 1983.
83. Sherwin, S., Foon, K.A., Bunn, P.A., Jr., Longo, D., Oldham, R.: Recombinant leukocyte A interferon in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and mycosis fungoides. *Blood* 62:215a, 1983.
84. Batist, G., Ihde, D.C., Cowan, K., Veach, S., Gilliam, M., Bunn, P.A., Jr.: Phase II trial of cisplatin and VP16 in previously treated small cell lung cancer. *Proc. AACR* 25:175, 1984.
85. Sausville, E., Matthews, M., Gazdar, A., Worsham, G.F., Makuch, R., Bunn, P.A., Jr.: Role of lymph node biopsy in evaluation of cutaneous T cell lymphoma. *Proc. AACR* 25:193, 1984.
86. Bunn, P.A., Jr., Foon, K.A., Ihde, D.C., Longo, D.L., Winkler, C.F., Zefferen, J., Oldham, R., Sherwin, S.: Recombinant leukocyte A interferon in the treatment of advanced refractory cutaneous T cell lymphomas. *Proc. ASCO* 3:52, 1984.
87. Doyle, A., Gazdar, A., Martin, J., Carney, D., Bunn, P.A., Jr., Minna, J.: The deficit in HLA expression in small cell lung cancer resides at the transcriptional level and is reversed by interferon. *Proc. ASCO* 3:52, 1984.
88. Johnson, B.E., Ihde, D.C., Lichter, A.S., Johnston-Early, A., Cohen, M.H., Walsh, T., Weinstein, Z., Becker, B., Whang-Peng, J., Glatstein, E., Carney, D.N., Minna, J.D., Bunn, P.A., Jr.: 5 to 10 year follow-up of small cell lung cancer patients disease free at 30 months: chronic toxicities and late relapses. *Proc. ASCO* 3:218, 1984.
89. Sausville, E., Matthews, M., Makuch, R., Ihde, D., Schechter, G., Fischmann, B., Gazdar, A., Glatstein, E., Eddy, J., Veach, S., Bunn, P.A., Jr.: Natural history and prognosis in cutaneous T cell lymphoma. *Proc. ASCO* 3:243, 1984.
90. Penderson, A., Marangos, P., Gazdar, A., Bach, F., Hansen, H., Bunn, P.A., Jr.: Neuron specific enolase in the cerebrospinal fluid as a marker of CNS metastases in small cell lung cancer. *Proc. ASCO* 3:7, 1984.
91. Dodd, R.C., Newman, Bunn, P.A., Jr., S.L., Winkler, C.F., Cohen, M.S., Gray, T.K.: Lymphokine-induced monocytic differentiation as a possible mechanism for hypercalcemia associated with adult T-cell lymphoma. *Cancer Res.* 45:2501-2506, 1985.
92. Brooks, B., Seifter, E., Walsh, T., Zabell, A., Johnston-Early, A., Makuch, R., Edison, M., Bunn, P.A., Jr., Lichter, A., Cohen, M., Glatstein, E., Ihde, D.: Pulmonary toxicity (PT) with combined modality therapy for limited stage small cell lung cancer (SCLC). *Proc. AACR* 26:172, 1985.
93. Bunn, P.A., Jr., Ihde, D., Lichter, A., Makuch, R., Cohen, M., Edison, M., Minna, J., Glatstein, E.: Randomized trial of combination chemotherapy (CT) with or without radiotherapy (RT) in limited stage small cell lung cancer. *Progr IV World Conf Lung Cancer*, p. 87, 1985.

94. Schroff, R.W., Carrasquillo, J.A., Foon, K.A., Keenan, A.M., Morgan, A.C., Jr., Bunn, P.A., Jr., Reynolds, J.C., Perentesis, P., Larson, S.M., Abrams, P.G.: Clinical trials of radioimmunoconjugates of monoclonal antibodies for biodistribution and tumor diagnosis. *FASEB*, April, 1985.
95. Ihde, D.C., Bunn, P.A., Jr., Lichter, A.S., Glatstein, E., Minna, J.D.: Chemotherapy in combined modality treatment of small cell lung cancer. In *Recent Advances in Chemotherapy: Anticancer Section*, Ishigami J (ed). Tokyo, University of Tokyo Press, pp. 128-30, 1985.
96. Ihde, D.C., Johnson, B.E., Matthews, M.J., Zabell, A., Johnston-Early, A., Makuch, R.W., Cohen, M.H., Bunn, P.A., Jr., Glatstein, E.: Non-small cell lung cancer (NSCLC): A major cause of late mortality in small cell lung cancer (SCLC). *Proc. ASCO* 4:185, 1985.
97. Winkler, C., Ihde, D., Fischmann, A., Matthews, M., Gazdar, A., Schechter, G., Eddy, J., Makuch, R., Kumar, P., Bunn, P.A., Jr.: Combined modality treatment (CMT) of mycosis fungoides (MF) and sezary syndrome (SS). *Proc. AACR* 26:184, 1985.
98. Mulshine, J., Keenan, A., Carrasquillo, J., Larson, S., Walsh, T., Linnoila, I., Bunn, P.A., Jr., Weinstein, J.: Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes: A new approach to lung cancer imaging. *Proc. AACR* 26:295, 1985.
99. Weinstein, J., Parker, R., Holton, O., Barbet, J., Black, C., Keenan, A., Sieber, S., Mulshine, J., Carrasquillo, J., Larson, S., Bunn, P.A., Jr., Talley, M.J., Covell, D.: Detection of tumor in lymph nodes by delivery of monoclonal antibodies via the lymphatics: an analysis of immunolymphoscintigraphy. *Proc. AACR* 26:295, 1985.
100. Boven, E., Lindmo, T., Mitchell, J., Bunn, P.A., Jr.: Radioimmunotherapy of malignant human T cell lines with ¹²⁵I-T101 monoclonal antibody. *Proc. AACR* 26:289, 1985.
101. Ihde, D., Brooks, B., Seifter, E., Walsh, T., Zabell, A., Johnston-Early, A., Makuch, R., Edison, M., Bunn, P.A., Jr., Lichter, A., Cohen, M., Glatstein, E.: Pulmonary toxicity (PT) with combined modality therapy for limited stage small cell lung cancer (SCLC) (abstr 112). *Progr IV World Conf Lung Cancer*, Toronto, p. 142, 1985.
102. Ihde, D., Johnson, B., Matthews, M., Zabell, A., Johnston-Early, A., Makuch, R., Cohen, M., Bunn, P.A., Jr., Glatstein, E.: Non-small cell lung cancer (NSCLC): A major cause of late mortality in small cell lung cancer (SCLC) (abstr. 113). *Progr IV World Conf Lung Cancer*, Toronto, p. 138, 1985.
103. Dmitrovsky, E., Matthews, M., Bunn, P.A., Jr., Winkler, C., Schechter, G., Eddy, J., Ihde, D.: Cytologic transformation (CT) in cutaneous T-cell lymphoma (CTCL). *Proc. ASCO* 4:205, 1985.
104. Bunn, P.A., Jr., Carrasquillo, J., Mulshine, J., Keenan, A., Foon, K., Schroff, R., Reynolds, J., Larson, S.: Successful imaging of cutaneous T cell lymphoma (CTCL) patients with intravenous ¹¹¹In-T101. *Proc. ASCO* 4:205, 1985.
105. Mulshine, J., Keenan, A., Carrasquillo, J., Weinstein, J., Reynold, J., Larson, S., Foon, K., Bunn, P.A., Jr.: Successful immunolymphoscintigraphy after lymphatic delivery of ¹¹¹In-T101. *Proc. ASCO* 4:221, 1985.
106. Carrasquillo, J.A., Bunn, P.A., Jr., Keenan, A.M., Reynolds, J.C., Schroff, R.W., Foon, K.A., Ming-Hsu, S., Gazdar, A.F., Mulshine, J.M., Oldham, R.K., et al.: Radioimmunodetection of cutaneous T-cell lymphoma with ¹¹¹In-labeled T101 monoclonal antibody. *N Engl J Med*. 315:673-80, 1986.
107. Doyle, L.A., Cuttitta, F., Mulshine, J.L., Bunn, P.A., Jr., Minna, J.D.: Markedly different immunologic responses to immunized small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells. *Proc. ASCO* 5:233, 1986.
108. Robinson, W.A., Mughal, M.R., Thomas, J., Thomas, M., Johnson, M., Spiegel, R., and Bunn, P.A., Jr.: Treatment of advanced malignant melanoma with subcutaneous recombinant interferon. *Proc. ASCO* 5:132, 1986.
109. Kaye, F., Ihde, D., Fischmann, A., Glatstein, E., Minna, J., Schechter, G., Matthews, M., Veach, S., Eddy, J., Wesley, M., and Bunn, P.A., Jr.: A randomized trial comparing conservative and aggressive therapy in mycosis fungoides (MF). *Proc. ASCO*, 5:195, 1986.
110. Seifter, E., Bunn, P.A., Jr., Cohen, M., Makuch, R., Dunnick, N., Javadpour, J., Bensimon, H., Eddy, J., Minna, J., and Ihde, D.: Combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. *Proc. AACR* 27:183, 1986.
111. Mulshine, J., Carrasquillo, J., Keenan, A., Herdt, J., Weinstein, J., Sausville, E., Bunn, P.A., Jr., Perentesis, P. and Larson, S.: Direct intralymphatic administration (DILA) of ¹¹¹Indium T101 monoclonal antibody (MOAB) in patients with cutaneous T-cell lymphoma. *Proc. AACR* 27:332, 1986.

FASCO

112. Frontiera, M., Thomas, J. Schmelter, R., Unger, M., Bunn, P.A., Jr. and Robinson, W.A.: Comparison of ¹¹¹indium-labeled monoclonal antibodies 96.5 and ZME018 in patients with metastatic malignant melanoma. Proc. AACR 27:164, 1986.
113. Bunn, P.A. Jr., Ihde, D.C., Foon, K.C.: Recombinant interferon alpha-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer Suppl 1:9-13, 1987.
114. Carrasquillo, J.A., Mulshine, J.L., Bunn P.A., Jr., Reynolds, J.C., Foon, K.A., Schroff, R.W., Perentesis, P., Steis, R.G., Keenan, A.M., Horowitz, M, et al.: Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 28:281-287, 1987.
115. Ihde, D.C., Steis, R., Sausville, E.A., Veach, S.R., Eddy, J., Bunn, P.A., Jr.: Phase II Trial of intermittent high dose recombinant interferon alfa-2a (IFN- ALFA) in mycosis fungoides and sezary syndrome (MF/SS). Proc. AACR 28:209, 1987.
116. Schechter, G., Kosinski, R., Addo, K., Chan, C., Pierce, Lessin, L., Weiss, R., Binder, R., Cohen, P., Schulof, R., Perlin, E., Bang, K-M, Bunn, P.A., Jr.: Alternating vs. single combination chemotherapy in multiple myeloma. Proc. ASCO 6:154, 1987.
117. Frontiera, M., Schmelter, R., Chu, H., Bunn P.A., Jr., Thomas, J., Satterlee, W., Robinson, W.: Immunolymphoscintigraphy with radiolabeled monoclonal antibodies in patients with malignant melanoma. Proc. ASCO 6:213, 1987.
118. Kruse, C.A., Waldrop, S., Jewett, P., Bunn, P.A., Jr.: Autoadoptive immunotherapy for brain tumors using autologous interleukin-2 stimulated lymphocytes. J. Cell Biochem. 11D:294, 1987.
119. Mulshine, J., Keenan, A., Carrasquillo, J., Walsh, T., Linnoila, I., Holton, O., Harwell J., Larson S., Bunn, P.A., Jr., Weinstein, J.: Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: a new approach to lung cancer imaging. Cancer Res. 47:5009-5013, 1987.
120. Hofheinz, D., Dienhart, D., Miller, G., Healy, S., Furmanski, P., Sedlacek, S., Longley, C., Bunn, P.A. Jr., Kortright, K.: Monoclonal antibody, KC4G3, recognizes a novel widely expressed antigen on human epithelial cancers. Proc. AACR 28:391, 1987.
121. Dienhart, D., Grauer, L., Miller, Y., Kane, M., Bunn, P.A. Jr.: A monoclonal antibody, BBC353, binds gastrin releasing peptide (GRP) and inhibits growth of small cell lung cancer In Vitro and In Vivo. Clin. Res. 35:523A, 1987.
122. Dienhart, D., Schmelter, R., Lear, J., Sedlacek, S., Braun, T., Miller, G., Glenn, S., Kortright, K., Bunn, P.A. Jr.: Imaging and treatment of non-small cell lung cancer (NSCLC) with monoclonal antibody (MoAb) KC4. Proc. ASCO 6:184, 1987.
123. Kaye, F., Ihde, A., Fischmann, E., Glatstein, G., Schechter, G., Matthews, M., Veach, S., Eddy, J., Steinberg, S., Bunn, P.A. Jr.: Three prognostic groups in patients with mycosis fungoides. Proc. ASCO 6:201, 1987.
124. Aguayo, S.M., Kane, M., Schwarz, M.I., King, T., Grauer, L., Dienhart, D., Bunn, P.A. Jr., Miller, Y.E.: Bombesin-like immunoreactivity in broncho-alveolar lavage from smokers and interstitial lung disease. Clin. Res. 35:530A, 1987.
125. Dienhart, D., Schmelter, R., Lear, J., Miller, G., Longley, C., Furmanski, P., Braun, T., Hofheinz, D., Glenn, S., Kortright, K., Bunn, P.A. Jr.: Imaging and therapy of metastatic non-small cell lung cancer (NSCLC) with monoclonal antibody (MoAb) KC4G3. Proc. of the Third International Conference on MoAb Immunoconjugates for Cancer, p. 142, 1988.
126. Kaplan, E.H., Rosen, S.T., Norris, D., Roenigk, H., Jr., Saks, S., Bunn, P.A. Jr.: Phase II trial of recombinant human interferon-gamma in cutaneous T-cell lymphoma (CTCL). Proc. ASCO 7:226, 1988.
127. Dienhart, D., Bloedow, D., Schmelter, R., Hofheinz, D., Kortright, K., Bunn, P.A. Jr.: Pharmacokinetics of monoclonal antibody KC4G3 (MoAb) and 111-indium label in lung and breast cancer patients. Proc. AACR 29:419, 1988.
128. Dienhart, D., Schmelter, R., Sedlacek, S., Lear, J., Miller, G., Longley, C., Furmanski, P., Tagawa, M., Hofheinz, D., Glenn, S., Kortright, K., and Bunn, P.A. Jr.: Imaging breast cancer with Indium-111 labeled monoclonal antibody (MoAb) KC4G3. Proc. ASCO 7:41, 1988.
129. Graham, M., Bunn, P.A., Jr., Jewett, P.B., Horwitz, K.B.: Simultaneous flow-cytometry measurement of progesterone receptors (PR) and DNA indices in breast cancer. Proc. AFCC 1988.

130. Dienhart, D., Schmelter, R., Lear, J., Miller, G., Sedlacek, S., Glenn, S., Bloedow, D., Kortright, K., Bunn, P.A., Jr.: Biologic, therapeutic, and imaging results with monoclonal antibody KC4G3 in patients with breast and lung cancers. *J. Cell. Biochem. Suppl.* 12E:143, 1988.
131. Johnston, M., Minchen, R., and Bunn, P.A., Jr.: Isolated lung perfusion with high dose chemotherapy: Early clinical experience. *Lung Cancer* 4A80, 1988.
132. Dienhart, D., Schmelter, R., Lear, J., Bloedow, D., Miller, G., Glenn, S., Kortright, K., Bunn, P.A., Jr.: Imaging and treatment of non-small cell lung cancer (NSCLC) with monoclonal antibody, KC4G3. *Lung Cancer* 4:A175, 1988.
133. Dienhart, D., Hofheinz, D., Miller, G., Healy, S., Kortright, K., Furmanski, P., Longley, C., Bunn, P.A. Jr.: Human milk fat globule antigens (HMFG) should be included in the lung cancer cluster designation (CD) of tumor antigens. *Lung Cancer* 4:A19, 1988.
134. Schechter, G.P., Sausville, E., Soehnlen, F., Eddy, J., Fischmann, A.B., Bunn, P.A., Jr.: Evolution of peripheral blood involvement in cutaneous T cell lymphoma (CTCL). *Blood* 72(5) (Suppl 1):256a, 1988.
135. Peterson, V., Rundus, C., Doud, A., Wu, J., Bunn, P.A., Jr., Ambruso, D., Bakemeier, R.F.: Interleukin-1 alpha (IL-1) corrects postburn suppression of myelopoiesis. *Blood* 72(5) Suppl 1:p. 131a, 1988.
136. Graham, M.L., Bunn, P.A., Jr., Jewett, P., Gonzalez-Aller, C., Horwitz, K.B.: Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines. *Cancer Res.* 49:3934-3942, 1988.
137. Bloedow, D., Dienhart, D., Schmelter, R., Furmanski, P., Longley, C., Hofheinz, D., Kortright, K., Bunn, P.A., Jr.: Kinetics of ¹¹¹indium-labeled monoclonal antibody KC4G3 in mice. *Pharmaceutical Research* 5:S188, 1988.
138. Mulvin, D., Dienhart, D., Howard, R., Kasliwal, R. Bunn, P.A., Jr., Johnston, M.: Isolated total lung perfusion with radiolabeled monoclonal antibodies ¹¹¹In-KC4G3 and ¹³¹I-MC5. *Proc. AACR* 30:601, 1989.
139. Salem, P., Zukiwski, A., Robinson, W., Bunn, P.A., Jr., Lamb, R., Benjamin, R. S., Spittler, L., Wedel, N., Ackerman, S.: Treatment of advanced metastatic melanoma using single dose murine monoclonal antibody-ricin A chain Immunotoxin with Dose escalation-A Phase I Study. *Proc. AACR* 30:288, 1989.
140. Chan, D., Dienhart, D., Stewart, J., Tagawa, M., Jewett, P., Braunschweiger, E., Bunn, P.A., Jr.: Response of small cell lung cancer (SCLC) cell lines to gastrin releasing peptide (GRP) analogues. *Proc. AACR* 30:81, 1989.
141. Dienhart, D., Chan, D., Graver, L., Braunschweiger, E., Tagawa, M., Jewett, P., Bunn, P.A., Jr.: Effects of an anti-gastrin releasing peptide (GRP) antibody, BBC353 on growth signals and proliferation of small cell lung cancer (SCLC) cell lines. *Proc. AACR* 30:104, 1989.
142. Bunn, P.A., Jr., Dienhart, D., Chan, D., Tagawa, M., Jewett, P., Braunschweiger, E.: Heterogeneity of intracellular calcium [Ca²⁺]_i response to gastrin releasing peptide (GRP) in small cell lung cancer (SCLC). *Proc. AACR* 30:36, 1989.
143. Bunn, P.A., Jr. Bakemeier, R.F.: Research experiences in the training of oncologists. *J. Cancer Education* 4:13, 1989.
144. Bunn, P.A., Jr., Livingston, R., Crowley, J., McCracken, D., Goodman, G.: Southwest Oncology Group (SWOG) Trials in small cell lung cancer. 3rd Workshop on SCLC, 1989.
145. Longley, C., Furmanski, P., Dienhart, D., Lear, J., Ritenour, R., Bloedow, D., Kortright, K., Ceriani, R., Bunn, P.A., Jr.: Biodistribution of ¹¹¹In-KC4G3 and ¹³¹I-MC5 human milkfat globule monoclonal antibodies in mice. *Proc. AACR* 30:398, 1989.
146. Kaye, F., Eddy, J., Ihde, D.C., Steinberg, S., Fischmann, A.B., Glatstein, E., Schechter, G., Bunn, P.A., Jr., Sausville, E.: Conservative vs aggressive therapy in mycosis fungoides. *Proc. ASCO* 8:257, 1989.
147. Howard, R.B., Marcell, T., Mulvin, D.W., Bunn, P.A., Jr., Johnston, M.R.: Additional immunosuppression of nude rates increases the intrabronchial take-rate of human lung cancer cell lines. *Proc. AACR* 30:109, 1989.
148. Dienhart, D.G., Chan, D., Puck, T., Tagawa, M., Jewett, P.B., Braunschweiger, E., and Bunn, P.A. Jr.: Multiple neuropeptides increase intracellular calcium concentrations via separate but related second messenger pathways in small cell lung cancer. *Clin. Res.* 38:131A, 1990.
149. Chan, D., Stewart, J., Vavrek, R., Tolley, R., Dienhart, D., Jewett, P., Tagawa, M., Braunschweiger, E., Bunn, P.A., Jr.: Effects of bradykinin and bradykinin antagonists on intracellular calcium concentrations in human lung cancer cells. *Proc. AACR* 31:54, 1990.
150. Howard, R.B., Marcell, T., Tagawa, M., Bunn, P.A., Jr., and Johnston, M.R.: Disaggregation of orthotopic human lung carcinomas from nude rats for clonogenic assay. *Proc. AACR* 31:435, 1990.

151. Howard, R.M., Mulvin, D.W., Marcell, T., Bunn, P.A., Jr., McLemore, T.L., Johnston, M.R.: An orthotopic nude rat model system to evaluate anticancer therapies for human lung cancer. *FASEB* 4:A479, 1990.
152. Taylor, C.W., Chase, E.M., Hersh, E.M., Rinehart, J.J., Whitehead, R.P., Gonzalez, R., Bunn, P.A., Jr., Neidhart, J., Southwest Oncology Group.: A phase I study of the sequential combination of recombinant gamma-interferon (IFN γ) and recombinant interleukin-2 (IL2) in patients with disseminated malignant disease. *Proc. ASCO* 9:192, 1990.
153. Maroun, J.A., Robert, F., Natale, R.B., Hait, W., Bunn, P.A., Jr., Meyer, M., Kowal, C.: Pilot study of trimetrexate (CI-898) administered in combination with cisplatin (CDDP) and etoposide (E) to patients with nonsmall cell lung cancer (NSCLC). *Proc. ASCO* 9:243, 1990.
154. Johnson, T.K., Gonzalez, R., Kasliwal, R., Lear, J., Ceriani, R., Bunn, P.A., Jr.: Measurement of Mc5 antibody distribution in blood and bone marrow: Implications for radioimmunotherapy. *Radiology* 177:135, 1990.
155. Cowen, M., Howard, R.B., Marcell, T., Bunn, P.A., Jr., McLemore, T.L., Johnston, M.R.: Validation of an orthotopic human lung cancer model in the nude rat by dose response to perfused adriamycin. *Proc. AACR* 31:434, 1990.
156. Bunn, P.A., Jr., Dienhart, D.G., Gonzalez, R., Kasliwal, R., Bloedow, D., Johnson, T., Lear, J., Hartmann, C., Glenn, S., Butchko, G., Maddock, S., Ceriani, R.: Imaging and treatment of patients with metastatic breast cancer with radiolabelled monoclonal antibodies. Meeting abstract of the 4th International Workshop on Monoclonal Antibodies and Breast Cancer, November 5-6, 1990.
157. McAteer, M., Pastusiak, H., Hamstra, A., Maddock, E., Dienhart, D., Kasliwal, R., Glenn, S., Heal, A., Bunn, P.A., Jr., Maddock, S.: Performance of an immunoabsorption column used to improve radioimmunodection. *Antibody Immunoconjugates, and Radiopharmaceuticals* 4:23, 1991.
158. Johnson, T.K., Maddock, S., Kasliwal, R., Bloedow, D., Hartmann, C., Feyerabend, A., Dienhart, D., Glenn, S., Gonzalez, R., Lear, J., Bunn, P.A., Jr.: Radioimmunoabsorption of KC-4G3 antibody in peripheral blood: Implications for radioimmunotherapy. *Antibody Immunoconjugates, and Radiopharmaceuticals* 4:24, 1991.
159. Maddock, S., Bunn, P.A., Jr., Dienhart, D., Feyerabend, A., Glenn, S., Johnson, T., Kasliwal, R., Lear, J., Maddock, E., McAteer, M.: Strategy and use of immunoabsorption to improve RAIT. *Antibody Immunoconjugates, and Radiopharmaceuticals* 4:34, 1991.
160. Malkinson, A.M., Siegel, D., Ross, D., Thaete, L.G., Chan, D.C., Bunn, P.A., Jr., Oie, H.K., Gazdar, A.F.: DT-diaphorase activity in neoplastic lung cells. *J. Cell Biochem.* 15F:23, 1991.
161. Bunn, P.A., Jr., Chan, D., Dienhart, D., Tagawa, M., Jewett, P.: Responsiveness of lung cancer cell lines to a series of neuropeptides. *J. Cell. Biochem. Supp* 15F:19, 1991.
162. Malkinson, M., Siegel, D., Ross, D., Thaete, L.G., Chan, D.C., Bunn, P.A., Jr., Oie, H.K., Gazdar, A.F.: DT-Diaphorase activity in neoplastic mouse and human lung cells. *J. Cell. Biochem. Supp* 15F:23, 1991.
163. Chan, D., Stewart, J., Vavrek, R., Kasliwal, R., Bunn, P.A., Jr.: Therapeutic potential of bradykinin analogs in human lung cancer. *Proc. AACR* A285, 1991.
164. Dienhart, D.B., Kasliwal, R., Lear, J.L., Johnson, T., Bloedow, D., Hartmann, C., Glenn, S., McAteer, M., Feyerabend, A., Gupta, R., Maddock, E., Maddock, S., Bunn, P.A., Jr.: Extracorporeal immunoabsorption of radiolabeled monoclonal antibody: Pharmacokinetic, imaging and dosimetric results. *Proc. ASCO*:246, 1991.
165. Hazuka, M.B., Bunn, P.A., Crowley, J., Livingston, R.B.: Concurrent daily low-dose cisplatin (LDCP) plus chest irradiation (RT) followed by standard dose cisplatin (SDCP) in locally advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. *Lung Cancer*, 7:154, 1991.
166. Bunn, P.A., Crowley, J., Hazuka, M., Tolley, R., Livingston, R.: A randomized study of VP-16/cisplatin/chest RT + GM-CSF in limited stage small cell lung cancer (SCLC): Preliminary results of a Southwest Oncology Group (SWOG) study. *Lung Cancer*, 7:139, 1991.
167. Hartmann, C., Bloedow, D., Dienhart, D., Kasliwal, R., Johnson, T., Gonzalez, R., Bunn, P.A., Jr.: A pharmacokinetic model describing the removal of radiolabeled antibody by extracorporeal immunoabsorption. *J Pharmacokinet Biopharm* 19:385-403, 1991.
168. Shpall, E.J., Jones, R.B., Johnston, C., Hami, L., Morgan, M.J., Stemmer, S., Bunn, P.A., Jr., Shaw, L., Walter, J., McCulloch, W., Schein, P.: Amifostine (WR-2721) shortens the engraftment period of 4-HC purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. *Blood* 78:192a, 1991.
169. Bunn, P.A., Jr., Crowley, J., Hazuka, M., Tolley, R., Livingston, R.: The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG). *Proc. ASCO* 11:292, 1992.

170. Kirpotin, D., Chan, D.C., Bunn, P.A. Jr.: In vitro studies of ferromagnetic colloidal particles in radiofrequency induced hyperthermia. *Proc. ASCO* 33:503, 1992.
171. Chan, D.C., Dienhart, D., Carl, G., Tagawa, M., Jewett, P., Bunn, P.A. Jr.: Selective inhibition of cell proliferation by R-Niguldipine B8509-35 in human lung cancer cell lines. *Proc. AACR* 33:512, 1992.
172. Bunn, P.A., Jr., Chan, D.C., Stewart, J.S., Jewett, P., Tagawa, M.: Substance P derivatives. Effects on calcium flux, serum stability and proliferation in lung and breast cancer cell lines. *Proc. ASCO* 33:557, 1992.
173. Hazuka, M., Crowley, J., Bunn, P.A., Jr., Livingston, R.: Concurrent daily low-dose cisplatin (LDLCP) combined with chest irradiation (RT) in locally advanced non-small cell lung cancer: preliminary results of a Southwest Oncology Group (SWOG) study. *Proc. ASCO* 11:295, 1992.
174. Chan, D., Chung, N., Jewett, P., Kirpotin, D., Helfrich, B., Bunn, P.A., Jr.: Reversal of multidrug resistance by a dextran-niguldipine (B8509-035), niguldipine and verapamil in small cell lung carcinoma cell lines. *Proc. Am. Assoc. Can. Res.* 34:323, 1993.
175. Kirpotin, D., Chan, D., Bunn, P.A., Jr.: Colloidal magnetic iron oxides with improved power absorption rates for ferromagnetic hyperthermia of cancer. *Proc. ASCO* 12:148, 1993.
176. Panella, T.J., Constanzi, J., Rathgeb, F., Schuller, H., Bunn, P.A., Jr.: A phase I trial of oral dextran-niguldipine (B8509-035) (dNNGD) in patients with refractory solid tumors. *Proc. ASCO* 12:151, 1993.
177. Kelly, K., Bunn, P.A., Jr., Hazuka, M., Beasley, K., Crowley, J., Livingston, R.: The role of alpha interferon (rINFa2a) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: a Southwest Oncology Study (SWOG). *Proc. ASCO* 12:330, 1993.
178. Kirpotin, D.B., Chan, D.C.F., Bunn, P.A., Jr.: Enhancement of radiofrequency energy absorption of a tumor by somaxides, a new class of polymer-associated colloidal iron oxides. *Proc. AACR* 35:638, 1994.
179. Chan, D.C.F., Kirpotin, D.B., Bunn, P.A., Jr.: Synthesis and physico-chemical properties of somaxides, a new class of polymer-associated colloidal superparamagnetic iron oxides for energy absorption enhancement in hyperthermia of tumors. *Proc. AACR*, 35:638, 1994.
180. Sobolevsky, S., Chan, D., Kirpotin, D., Helfrich, B., Helm, K., Bunn, P.: Comparative effects of dextran-niguldipine, verapamil, and cyclosporine A on drug accumulation and cytotoxicity in multidrug resistant human small cell lung cancer and epidermoid carcinoma cells. *Clin. Res.* 42:56A, 1994.
181. Chan, D., Sobolevsky, S., Kirpotin, D., Helfrich, B., Helm, K., Bunn, P.: Effects of dextran-niguldipine, verapamil, and cyclosporin A on multidrug resistance in aerodigestive cancers. *Proc. AACR* 35:355, 1994.
182. Chan, D.C.F., Kirpotin, D.B., Bunn, P.A., Jr.: Synthesis and physico-chemical properties of somaxides, a new class of polymer-associated colloidal superparamagnetic iron oxides for energy absorption enhancement in hyperthermia of tumors. *Proc. AACR* 35:638, 1994.
183. Bunn, P.A., Jr.: Growth factors and their receptors in the pathogenesis and prevention of lung cancer. *Proc. AACR* 35:691, 1994.
184. Chan, D., Stewart, J., Gera, L., Helfrich, B., Helm, K., Tagawa, M., Jewett, P., Bunn, P., Jr.: Bradykinin analogs: structural and functional studies in lung cancer cell lines. *Lung Cancer* 11:4, 1994.
185. Cohen, A.J., Bunn, P.A., Franklin, W.A., Folkvord, J., Miller, Y.E.: Expression of neutral endopeptidase is reduced in lung cancer. *Lung Cancer* 11:24, 1994.
186. Chan, D., Sobolevsky, S., Kirpotin, D., Helfrich, B., Helm, K., Bunn, P.: Effects of the multidrug resistance modulators dextran-niguldipine, verapamil, and cyclosporin A on drug accumulation and cytotoxicity in MDR-1 and MRP expressing lung cancer cell lines. *Lung Cancer* 11:29, 1994.
187. Kelly, K., Bunn, P.A., Jr.: Phase I trials of taxol-containing chemotherapy regimens for the treatment of advanced non-small cell (NSCLC) and small cell lung cancer (SCLC). *Lung Cancer* 11:122, 1994.
188. Kelly, K., Bunn, P.A., Jr., Hazuka, M., Turrisi, A.: A phase I-II study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation followed by carboplatin in patients with regionally inoperable non-small cell lung cancer (NSCLC). *Lung Cancer* 11:179, 1994.
189. Kelly, K., Bunn, P.A., Jr., Hazuka, M., Turrisi, A., Leonard, C., Caskey, J.: A phase I-II trial of daily carboplatin and simultaneous accelerated hyperfractionated chest irradiation (CRT) followed by carboplatin in patients with regionally inoperable non-small cell lung cancer (NSCLC). *Proc. ASCO* 14:377, 1995.
190. Chan, D., Bunn, P.A., Jr., Helfrich, B., Helm, K., Cohen, A., Miller, Y., Brenner, D.: Effects of recombinant neutral endopeptidase (rNEP) on human lung cancer cell lines. *Proc. AACR* 36:426, 1995.

191. Kelly, K., Wood, M.E., Bunn, P.A., Jr.: A phase I study of cisplatin, etoposide, and paclitaxel (PET) in extensive stage small cell lung cancer (SCLC). *Proc. ASCO* 15:400, 1996.
192. Schrier, D., Stemmer, S., Johnson, T., Kasliwal, R., Lear, J., Matthes, S., Taffs, S., Dufton, C., Glenn, S., Butchko, G., Rovira, D., Bunn, P., Shpall, R., Bearman, S., et al.: Radioimmunotherapy (RIT) of advanced breast cancer with high doses of ⁹⁰Y-MXDTPA-BrE-3 and autologous hematopoietic stem cell support (AHSCS). *Proc. AACR* 37:213, 1996.
193. Chan, D., Gera, L., Helfrich, B., Helm, K., Ashton, M., Whalley, E., Stewart, J., Bunn, P.A., Jr.: Novel cytolytic bradykinin antagonist dimers inhibit human lung cancer growth. *Proc. AACR* 37:417, 1996.
194. Chan, D., Walley, E., Helfrich, B., Gera, L., Helm, K., Ashton, M., Kirpotin, D., Stewart, J.M., Bunn, P.A., Jr.: Effect of linker length and type on the cytotoxic activity of bradykinin antagonist dimers in human lung cancer cells *in vitro*. *Proc. AACR* 37:417, 1996.
195. Kelly, K., Wood, M.E., Bunn, P.A., Jr.: A phase I study of cisplatin, etoposide and paclitaxel (PET) in small cell lung cancer (SCLC). *Lung Cancer* 18:28, 1997.
196. Pisters, K.M., Kris, M.G., Bunn, P.A., Jr., Crowley, J.J., Ginsberg, R.J.: Phase II trial of induction paclitaxel/carboplatin (PC) in early stage (T2NO, T1-2N1, and selected T3NO-1 non-small cell lung cancer (NSCLC). *Lung Cancer*, 18:84, 1997.
197. Helfrich, B., Chan, D., Helm, K., Ashton, M., Bunn, P.A., Jr.: Expression of MDR-1, MRP and LRP in human lung cancer cell lines from previously treated and untreated patients, chemosensitivity of the cell lines and effects of modulators on sensitivity. *Lung Cancer*, 18:147, 1997.
198. Bunn, P.A., Jr., Chan, B., Helfrich, B., Helm, K., Cohen, A., Miller, Y., Brenner, D.: Recombinant neutral endopeptidase inhibits the in vitro and in vivo growth of human lung cancers with neuroendocrine features. *Lung Cancer*, 18:147, 1997.
199. Cohen, A.J., Yanagisawa, M., Zamora, M., Gilman, L., Bunn, P.A. Jr., Franklin, W., Miller, Y. Evidence for an endothelin-1 autocrine loop in lung cancer. *Lung Cancer*, 18:148, 1997.
200. Chan, C., Helfrich, B., Gera, L., Helm, K., Whalley, E., Stewart, J., Chou, T-C., Bunn, P.A., Jr.: Combination of peptide antagonist monomers and dimers enhances killing of human cancer cells. *Lung Cancer*, 18:149, 1997.
201. Chan, D., Gera, L., Helfrich, B., Helm, K., Whalley, E., Stewart, J., Bunn, P.A., Jr.: Novel cytotoxic bradykinin antagonist dimers inhibit human lung cancer growth in vitro and in vivo. *Lung Cancer*, 18:150, 1997.
202. Wood, M.E., Kelly, K., Mullineaux, L.G., Tucker, B., Bunn, P.A., Jr.: Analysis of the inherited nature of lung cancer: A pilot study. *Lung Cancer*, 18:187, 1997.
203. Wood, M.E., Kelly, K., Mullineaux, L.G., Tucker, B., Bunn, P.A., Jr.: Analysis of the inherited nature of lung cancer: a pilot study. *Proc. ASCO* 16:535a, 1997.
204. Chan, D., Gera, L., Helfrich, B., Helm, K., Whalley, E., Bunn, P.A., Jr., Stewart, J.: A new class of peptide antagonist dimers inhibits the growth of human lung cancer cells in vitro and in vivo. *Proc. AACR*, 38:232, 1997.
205. Chan, D., Helfrich, B., Helm, K., Chou, T., Bunn, P.A., Jr.: Synergistic effects of doxorubicin and modulators of multidrug resistance in small cell lung cancer (SCLC) cells naturally expressing MDR-1, MRP and LRP phenotypes. *Proc. AACR*, 38:591, 1997.
206. Jarpe, M., Chan, D., Gera, L., Stewart, J., Bunn, P.A., Jr., Johnson, G.: Kinase regulated signal transduction pathways committing small cell lung cancer cells to apoptosis. *Proc. AACR*, 39:620, 1997.
207. Kelly, K., Prindiville, S., Bunn, P.A., Jr.: A phase I trial of paclitaxel(P), carboplatin(C), and Gemcitabine(G) in advanced non-small cell lung cancer (NSCLC). *Proc. ASCO* 17:490a, 1998.
208. Soriano, A., Chan, D., Helfrich, B., Zhang, Z.Y., Heasley, L., Nemenoff, R., Bunn, P.A., Jr.: Non-steroidal anti-inflammatory drugs (NSAIDS) inhibit the in vitro and in vivo growth of human lung cancer. *Proc. AACR*, 39:196, 1998.
209. Chan, D., Helfrich, B., Gera, L., Zhang, Z.Y., Stewart, J., Bunn, P.A., Jr.: Novel bradykinin antagonist dimers kill prostate cancer cells in vitro. *Proc. AACR*, 39:587, 1998.
210. Pisters, K.M.W., Ginsberg, R.J., Bunn, P.A., Jr.: Induction chemotherapy prior to surgery for early stage lung cancer – A novel approach. *Am. Assoc. Thorac. Surg*, in press, 1998.
211. Chan, D.C., Gera, L., Helfrich, B., York, E., Zhang, Z.Y., Stewart, J., Bunn, P.A., Jr.: In vitro and in vivo growth inhibitory effects of bradykinin peptidomimetics on human lung cancer cells. *Proc. AACR* 40: 186, 1999.

FASCO

212. Kelly, K., Crowley, J., Bunn, P.A., Jr, Livingston, R.B., Gandara, D.R.: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A southwest oncology group (SWOG) trial. Proc. ASCO, 18:461, 1999.
213. Bunn, P.A., Jr., Kelly, K., Crowley, J., Livingston, R.B., Gandara, D.R., SWOG.: Preliminary toxicity results from southwest oncology group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung cancer (SCLC). Proc. ASCO, 18:468, 1999.
214. Bunn, P.A., Jr.: Update on lung cancer SPORE in the USA. Lung Cancer, 25: 226-227, 1999.
215. Pisters, K.M.W, Ginsberg, R.J., Putnam, J.B., Jr., Johnson, D.H., Roberts J.R., Kris, M.G., Crowley, J, Bunn, P.A., Jr. Paclitaxel and Carboplatin Prior to Surgery in Early Stage Non-Small Cell Lung Cancer (NSCLC). Proc. Semin Oncol 26 (suppl. 18): p. 19, 1999.
216. Kelly, K, Wood, M.E., Bunn, P.A., Jr. A Phase I Study of Cisplatin, Etoposide and Paclitaxel (PET) in Small Cell Lung Cancer (SCLC). Proc. Semin Oncol 26 (suppl. 18): p. 20, 1999.
217. Bunn, P.A., Jr., Kelly, K, Mikhaeel, N. Triplet Chemotherapy with Paclitaxel, Gemcitabine and Carboplatin in Advanced Non-Small Cell Lung Cancer. Proc. Semin Oncol 26 (suppl. 18): p. 21, 1999.
218. Kelly, K, Crowley, J, Bunn, P.A., Jr., Livingston, R.B., Gandara, D.R., The Southwest Oncology Group, San Antonio, TX. Toxicity Analysis of SWOG 9509: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (PC) Versus Vinorelbine Plus Cisplatin (VC) in Untreated Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). A Southwest Oncology Group Trial. Proc. Semin Oncol 26 (suppl. 18): p. 24, 1999.
219. Hirsch, F, Veve, R, Varella-Garcia, M, Bunn, P.A., Jr., Franklin, W.A. Evaluation of HER2/neu Expression in Lung Tumors by Immunohistochemistry and Fluorescence in Situ Hybridization (FISH). Proc. ASCO, no. 1900, vol. 19, 2000.
220. Kelly, K, Bunn, P.A., Jr., Lovato, L, Crowley, J, Livingston, R.B., Gandara, D.R. Final Results from Southwest Oncology Group Trial (SWOG) 9705: A phase II Trial of Cisplatin, Etoposide and Paclitaxel (PET) with G-CSF in Untreated Patients (Pts) with Extensive Stage Small Cell Lung Cancer (SCLC). Proc. ASCO, no. 1923, vol. 19, 2000.
221. Kelly, K, Mikhaeel N, Dempsey, E, Magree, L, Bunn, P.A., Jr. A phase I study of exisulind in previously treated patients with lung cancer. Lung Cancer 29 (suppl. 1): 76, 2000.
222. Chan DC, Earle, K, Zhao, T.L.M., Helfrich, B, Pallansch, P, Nelson, P, Alila, H, Bunn, P.A., Jr. Synergistic Effects of Exisulind with Taxotere against Orthotopic Human Lung Cancers in Athymic Nude Rats. Lung Cancer 29 (suppl. 1): 186, 2000.
223. Ettinger, D.S., Bunn, P.A., LeChevalier, T, Kelly, K, Monnerat, C. Gemcitabine + ALIMTA™ in advanced non-small cell lung cancer (NSCLC): Why this regimen? Lung Cancer 29 (suppl. 1): 58, 2000.
224. Hirsch, F.R., Veve, L, Varella-Garcia, L, Bunn, P.A., Franklin, W.A. Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH). Lung Cancer 29 (suppl. 1): 211, 2000.
225. Kelly, K, Dempsey, E, Kennedy, T, Miller, Y, Franklin, W, Prindiville, S, Holte, J, Bunn, P.A. Preliminary results from a phase II trial evaluating 13 cis-retinoic acid with or without alpha tocopherol or observation in patients at high risk for lung cancer. Lung Cancer 29 (suppl. 1): 230, 2000.
226. Kelly, K, Bunn, P.A., Lovato, L, Crowley, J, Livingston, R.B., Gandara, D.R. A phase II study of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: A Southwest Oncology Group trial. Lung Cancer 29 (suppl. 1): 8, 2000.
227. Chan, D.C., Gera, L, York, E, Swize, L, Helfrich, B, Yang, J, Stewart, J, Bunn, P.A., Jr. Non-peptide bradykinin antagonists for lung cancer treatment. Lung Cancer 29 (suppl. 1): 192, 2000.
228. Kennedy, T.C., Hirsch, F.R., Miller, Y.E., Prindiville, S, Murphy, J.R., Dempsey, E, Proudfoot, S, Bunn, P.A., Franklin, W.A. A randomized study of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients. Lung Cancer 29 (suppl. 1): 244, 2000.
229. Chan, D.C., Gera, L, York, E, Simpson, S, Yang, J, Helfrich, B, Stewart, J, Johnson, G, Bunn, P.A., Jr. Peptidomimetic antagonists kill human cancer cells with neuroendocrine features. Proc. AACR, no. 3367, p. 528, 2000.
230. Bunn, P.A., Soriano A, Helfrich, B.A., Raben, D, Holden, S, Chan, D, Garcia, M. HER2/NEU expression and effects of herceptin alone and in combination with cytotoxic agents in lung cancer. Proc. AACR, no. 4571, p. 719, 2000.

231. Bunn, P.A., Jr. New Treatment Paradigms. *Lung Cancer* 29 (suppl. 2): 149-150, 2000.
232. Bunn, P.A., Jr. Treatment of NSCLC with 3-drug combinations. *Lung Cancer* 29 (suppl. 2): 11-12, 2000.
233. Bunn, P.A., Jr. Novel agents for the treatment of lung cancer. *Lung Cancer* 29 (suppl. 2): 68-70, 2000.
234. Bunn, P., Paoletti, P, Niyikiza, C, Rusthoven, J, Nelson, K, Hanauske, A, Stabler, S, Calvert, AH, Allen, R. B₁₂ and folate strikingly reduce toxicity of an antimetabolite, ALIMTA. *Proc. ASCO*, 20: 76a, no. 300, 2001.
235. Jotte R, Kelly K, Magree L, Gaspar L, Bunn P. A phase II trial of docetaxel, etoposide, and carboplatin chemotherapy before and after chest radiotherapy administered concomitantly with cisplatin and etoposide in limited stage small cell lung cancer (SCLC). *Proc. ASCO*, 20: no. 2878, 2001.
236. Pisters K, Ginsberg R, Giroux D, Kris M, Putnam JB, Roberts JR, Johnson DH, Crowley J, Bunn P. Phase II bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin (PC) in early stage non-small cell lung cancer (NSCLC): Effect of number of induction cycles, sites of relapse and survival. *Proc. ASCO* 20: 323a, no. 1288, 2001.
237. Raben D, Helfrich B, Chan D, Phistry M, Kee A, Zhao T, Zundel W, Bunn P, Jr. C225 Anti-EGFR Antibody Potentiates Radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. *Proc. ASCO* 20: 257a, no. 1026, 2001.
238. Raben D, Helfrich B, Chan D, Shogun T, Zundel W, Scafani R, Bunn P, Jr. The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro. *AACR-NCI-EORTC*: 153, no. 756, 2001.
239. Hirsch FR, Bunn PA, Miller YE, Kelly K, Kennedy TC, Bremnes RM, Prindiville S, Sclafani RA, Franklin WA. Intermediate biomarker profile for lung cancer chemoprevention trials. *Proc. ASCO* 20: 322a, no. 1286, 2001.
240. Chan DC, Gera L, York E, Zhao TLM, Helfrich B, Stewart J, Bunn PA. Therapeutic potential of peptido-mimetic antagonists for the treatment of human lung cancers. *Proc. AACR*, no. 380, 2001.
241. Chan DC, Earle K, Zhao TLM, Helfrich B, Pallansch P, Nelson P, Alila H, Pamukcu R, Whitehead C, Piazza G, Bunn PA. Exisulind and docetaxel combination prolongs survival in orthotopic human non-small cell lung cancer rat model. *Proc. AACR*, no. 456, 2001.
242. Whitehead CM, Earle KA, Xu S, Chan D, Zhao T, Alila H, Pamukcu R, Klein-Szanto A, Bunn PA, Thompson WJ, Piazza G. Efficacy of exisulind and docetaxel combination in an orthotopic human NSCLC rat model involves apoptosis induction and angiogenesis inhibition. *Proc. AACR*, no. 1950, 2001.
243. Helfrich B, Raben D, Chan D, Garcia L, Zundel W, Hirsch F, Franklin W, Bunn P. C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo. *Proc. ASTRO*, 2001.
244. Pierson AS, Gustafson D, Long M, Chan DC, Kelly K, Bunn P, Mikule C, Holden SN, Persky M, Eckhardt S. A phase I and pharmacologic (PK) study of exisulind (E) combined with taxotere (T) in patients with advanced cancer. *Proc. ASCO* 20: 120a, no. 475, 2001.
245. Bunn PA, Jr. New chemotherapy and targeted therapy approaches to the treatment of advanced NSCLC. *Lung Cancer* 34: S10-11, 2001.
246. Ettinger D, Le Chevalier T, Bunn P, Readeltt D, Rusthoven J, Monnerat C, Brahmer J, Kelly K. Phase II Trial of Pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: Importance of survival over response. *Proc. American Society Clinical Oncology* 21: 311a, no. 1243, 2002.
247. Hirsch FR, Prindiville SA, Byers T, Miller YE, Franklin WA, Keith R, Wolf HJ, Bunn PA, Kennedy TC. Sputum cytology as a marker of risk for lung cancer – preliminary results from the University of Colorado High Risk Cohort Study. *Proc. American Society Clinical Oncology* 21: 301a, no. 1201, 2002.
248. Basche M, Sandler AN, Eckhardt SG, Bunn PA, Holden SN, Pierson AS, Jenner W, Paty V, Persky M, Aitchison RD, Gordon GS, Parker VP, Usman N, Rothenberg ML. Angiozyme, an anti-VEGFR1 ribosome, carboplatin, and paclitaxel: results of a phase I study. *Proc. American Society Clinical Oncology* 21: 112a, no. 445, 2002.
249. Hirsch FR, Byers T, Prindiville SA, Miller YE, Franklin WA, Bunn PA, Kennedy TC. The Colorado High-risk Cohort Study. 18th UICC International Cancer Congress, Oslo, Norway, 2002.
250. Bunn PA, Jr. Advances in the chemoprevention of lung cancer. 18th UICC International Cancer Congress, Oslo, Norway, 2002.
251. Bunn PA, Jr. Management of screened detected lung cancer. 18th UICC International Cancer Congress, Oslo, Norway, 2002.

252. Bunn PA, Jr. Which population should be targeted for screening and chemoprevention programs? 18th UICC International Cancer Congress, Oslo, Norway, 2002.
253. Whitehead CM, Earle KA, Songmei X, Hartman T, Chan DC, Zhao TLM, Pamucu R, Bunn PA, Jr., Alila H, Thompson WJ. CP461 inhibits cGMP PDE activity, induces apoptosis and arrests cell cycle progression in A549 cells in culture and in an orthotopic lung tumor model. AACR, 43, 924, no. 4577, 2002.
254. Chan D, Gera L, Helfrich B, Helm K, York E, Garcia M, Wacker M, Stewart J, Bunn PA, Jr. Apoptosis and antiangiogenesis induced by bradykinin antagonist dimers and mimetic molecules in lung cancer cells. AACR 43: 411, no. 2048, 2002.
255. Gera L, Chan DC, York EJ, Simkeviciene V, Bironaite D, Vagonis A, Bunn PA, Jr., Taraseviciene-Stewart L, Stewart JM. A journey from bradykinin peptide antagonists to peptide and peptidomimetic antineoplastics. Proc. 27th European Peptide Symposium, 2002.
256. Raben D, Chan DC, Franklin W, Helfrich B, Garcia M, Hirsch FR, Bunn PA, Jr. EGFR expression and effects of ZD1839 (Iressa) alone and in combination with cytotoxic agents in NSCLC cancer in vitro and in vivo. ASCO Molecular Therapeutic Symp. San Diego, November 2002.
257. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis genes as biomarkers in lung carcinoma. ESMO (European Society of Medical Oncology) Congress, Nice, France, 2002.
258. Sandler A, Langer C, Bunn PA, Jr., Einhorn L. Phase III study comparing Irinotecan (IRI) and Cisplatin (CDDP) to Cisplatin and Etoposide (VP) for Previously Untreated Extensive Small Cell Lung Cancer: Interim Safety Analysis. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S82, 2003.
259. Keith R, Miller YE, Kennedy TC, Hirsch FR, Kittelson J, Bunn PA, Kelly K, Franklin W. Angiogenic squamous dysplasia (ASD): A biomarker highly associated with squamous cell lung cancer. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S161, 2003.
260. Kelly K, Kittelson J, Hirsch FR, Franklin W, Keith RL, Kennedy TC, Miller YE, Bunn PA. A histological model to predict airway response to promising chemoprevention agents in phase II lung cancer prevention trials. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S162, 2003.
261. Franklin WA, Helfrich B, Sugita M, Lapadat R, Hirsch FR, Bunn PA. Oligonucleotide microarray gene expression profiles of lung cancer cell lines sensitive and resistant to ZD-1839. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S25, 2003.
262. Shepherd FA, Pereira JR, von Pawel J, Gatzemeier U, Tsao TCY, Hanna N, Rosell R, Paoletti P, Paul S, Bunn PA, Einhorn L. A phase III study of pemetrexed vs decetaxel in patients with advanced non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S4, 2003.
263. Chan DC, Le MS, Zhao TLM, Gerard NP, Gerard C, Avram C, Helfrich B, Gera L, Stewart J, Bunn PA, Jr., Miller YE. Growth inhibition of lung tumors in NEP knockout and wild type mice by bradykinin antagonist dimer CU201 and mimetic CU317. Proc. 10th World Lung Cancer Congress, Vancouver, Canada. Lung Cancer 41: S61, 2003.
264. Hirsch FR, Belinski SA, Kennedy TC, Miller YE, Franklin WA, Wolf HJ, Bunn PA, Jr., Byers T. Aberrant DNA methylation and sputum atypia predict lung cancer – Preliminary report from the University of Colorado SPORE high risk cohort study. Proc. American Society Clinical Oncology (ASCO) 22: 92, 2003.
265. Chan DC, Le M, Zhao TLM, Gerard NP, Gerald C, Avram C, Helfrich B, Gera L, Stewart J, Bunn PA, Jr., Miller Y. Inhibition of lung tumors in NEP knockout and wild type mice by bradykinin antagonist dimer CU201 and mimetic CU317. Proc. American Association for Cancer Research (AACR) 44: #5675, 2003.
266. Stewart JM, Gera L, York EJ, Chan DC, Bunn PA, Jr., Simkeviciene V, Vagonis A, Bironaite D, Stewart LT. Bradykinin antagonists as potential drugs for lung and prostate cancer. German Peptide Symp., Berlin, Germany. March 2003.
267. Sunpaweravong P, Holden S, Ratts V, Eckhardt SG, Gustafson D, Bunn PA, Kelly K. A University of Colorado phase I trial of irinotecan (CPT-11) and carboplatin in advanced lung cancer. Proc. American Society Clinical Oncology (ASCO) 22: 657, 2003.
268. Kelly K, Hanna N, Rosenberg A, Bunn PA, Needle MN. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. American Society Clinical Oncology (ASCO) 22: 644, 2003.

269. Pister K, Ginsberg R, Giroux D, Kris M, Putnam JB, Roberts JR, Johnson D, Crowley J, Bunn PA. Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer (NSCLC): Long term followup of a phase II trial. Proc. American Society Clinical Oncology (ASCO) 22: 633, 2003.
270. Sandler A, Langer C, Bunn PA, Einhorn LH. Interim safety analysis of irinotecan and cisplatin combination chemotherapy for previously untreated extensive small cell lung cancer. Proc. American Society Clinical Oncology (ASCO) 22: 631, 2003.
271. Hanna NH, Shepherd FA, Rosell R, Pereira JR, De Marinis F, Fossella L, Kayitalire L, Paul S, Einhorn LH, Bunn PA. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc. American Society Clinical Oncology (ASCO) 22: 622, 2003.
272. Winterhalder RC, Kotantoulas G, Miller YE, Kittelson J, Keith RL, Ingeberg S, Bunn PA, Franklin WA, Hirsch FR. The role of Ki67, p53, EGFR, HER2 and CD31 as possible predictive biomarkers for development of lung cancer in high-risk population. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S161, 2003.
273. Hirsch FR, Belinski SA, Kennedy TC, Miller YE, Franklin WA, Wolf HJ, Bunn PA, Byers T. Aberrant DNA methylation and sputum atypia predict lung cancer – Preliminary report from the University of Colorado SPORE High Risk Cohort Study. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S86, 2003.
274. Kennedy TC, Franklin WA, Keith RL, Hirsch FR, Merrick TA, Shroyer K, Petty TL, Byers T, Bunn PA, Miller YE. High prevalence of endobronchial malignancy in high-risk patients who have moderate dysplasia in sputum. Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S41, 2003.
275. Hanna N, Paul S, DeMarinis F, Fossella F, Salzberg M, Mueller T, Shepherd F, Nguyen B, Kayitalire L, Bunn PA, Einhorn L. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Proc. 10th World Lung Cancer Congress IASLC, Vancouver, Canada. Lung Cancer 41: S5, 2003.
276. Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA, Jr., Taraseviciene-Stewart L, Stewart JM. Combination cancer therapy with a single agent: Bradykinin peptide antagonists and their mimetics. 3rd International and 28th European Peptide Symposium, Prague, Czech Republic, 2004. Submitted.
277. Hirsch FR, Franklin WA, Witta SE, Helfrich B, Lapadat R, Coldren CD, Sugita M, Bunn PA, Jr. Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Proc. American Society Clinical Oncology 23: 620, 2004.
278. Cappuzzo F, Toschi L, Shigematsu H, Rossi E, Ceresoli G, Crino L, Bunn PA, Gazdar AF, Hirsch FR, Varella-Garcia M. HER2 and HER3 genomic gain increases sensitivity to gefitinib in epidermal growth factor receptor positive advanced non-small cell lung cancer. Proc. ASCO. J Clin Oncol 23: #3021, 2005.
279. Hanna NH, Einhorn L, Sandler A, Langer C, Hariharan S, Ansari R, Ellis P, Byrne M, Wang B, Bunn P. Randomized phase III trial comparing Irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (E) small cell lung cancer (SCLC). Proc. ASCO. J Clin Oncol 23: #7004, 2005.
280. Pisters K, Vallieres E, Bunn P, Crowley J, Ginsberg R, Ellis P, Meyers B, Marks R, Treat J, Gandara D. S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. Proc. ASCO. J Clin Oncol 23: #7012, 2005.
281. Hirsch FR, Gandara DR, McCoy J, Crowley J, West HJ, Gemmerlock PH, Bunn PA, Franklin WA, Varella-Garcia M. Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (SO126). Proc. ASCO. J Clin Oncol 23: #7030, 2005.
282. Witta SE, Helfrich B, Chan D, Hirsch F, Franklin W, Drabkin HA, Gemmill RM, Bunn PA. Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors. Proc. ASCO. J Clin Oncol 23: #7083, 2005.
283. Skokan M, Xavier AC, Schulte AP, Palma AC, Helfrich B, Minna JD, Gazdar AF, Bunn PA, Varella-Garcia M. EGFR-related genomic abundance associates with EGFR mutation in non-small cell lung cancer and is accurately detected by interphase FISH. Proc. AACR, 2006.
284. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Holloway B, Watkins C. Molecular Analysis of EGFR Gene Copy Number, EGFR

- Expression and Akt Activation Status in Advanced Non-small cell lung cancer (aNSCLC) Treated with Gefitinib or Placebo (ISEL trial). Proc. AACR. Clinical Cancer Research 24(2): #A268, 2005.
285. Taguchi F, Solomon B, Gregorc V, Kasahara K, Nishio M, Grigorieva J, Hunsucker SW, Duncan M, Hirsch FR, Bunn Jr., PA, Caprioli RM, Roder H, Carbone DP. Serum proteomic profiles for predicting response to gefitinib, a cross-laboratory technical validation study. Proc. AACR. 47: #2852, 2006.
286. Solomon B, Gregorc V, Taguchi F, Kasahara K, Nishio M, Roder H, Hirsch FR, Duncan MW, Bunn, Jr. PA, Carbone DP. Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. Proc. ASCO. J Clin Oncol 24: #7004, 2006.
287. Hirsch FR, Franklin WA, McCoy J, Cappuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, West H, Gandara DR, Bunn Jr., PA. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proc. ASCO. J Clin Oncol 24: #7072, 2006.
288. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kasaka T, Nakajima E, Franklin W, Bunn Jr., PA, Hirsch FR. EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. Proc. ASCO. J Clin Oncol 24: # 7164, 2006.
289. Dziadziuszko R, Holm B, Skov BG, Osterlind K, Franklin WA, Varella-Garcia M, Bunn, Jr. PA, Hirsch FR. Prognostic significance of EGFR FISH and IHC in non small-cell lung cancer patients treated with chemotherapy alone. Proc. ASCO. J Clin Oncol 24: #7193, 2006.
290. Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, Ma D, Bunn Jr. PA: Enzastaurin, a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. Proc. ASCO. J Clin Oncol 24: #13138, 2006.
291. Chan DC, Chen VJ, Zhang Z, Helfrich B, Hirsch FR, Ma D, Bunn Jr. PA: Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. Proc. ASCO. J Clin Oncol 24(18S):#17114, 2006.
292. Varella-Garcia M, Acheson K, Marshall GB, McCormack RM, Rya A, Hirsch FR, Bunn Jr. PA, Hickinson DM, Speake G. Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors. Proc. ASCO, J Clin Oncol 25, #6063, 2007.
293. Solomon BJ, Roder H, Robert R, Taguchi F, Brahmer J, Joan SH, Duncan MW, Hirsch FR, Bunn Jr. PA, Carbone DP. Validation of preteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3503). Proc. ASCO. J Clin Oncol 25: #7508, 2007.
294. Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, Jassem J, Franklin WA, Bunn Jr. PA, Hirsch FR. High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). Proc. ASCO. J Clin Oncol 25: # 7550, 2007.
295. Hirsch FR, Varella-Garcia M, Bunn Jr. PA, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, Waring P, O'Neill V. Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC. Proc. ASCO. J Clin Oncol 25: # 7570, 2007.
296. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Thatcher N, Mann H, Watkins C, Speake G, Holloway B, Bunn Jr. PA, Franklin WA. Epidermal growth factor receptor (EGFR) immunohistochemistry. Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC). Proc. ASCO. J Clin Oncol 25: # 7576, 2007.
297. Nakajima E, Sugita M, Dziadziuszko R, Tsuboi M, Kato H, Bunn Jr. PA, Franklin WA, Hirsch FR. Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR) detected by a new sensitive PCR-based method. Proc. ASCO. J Clin Oncol 25: #10614, 2007.
298. Pisters K, Vallieres E. Bunn Jr. PA, Crowley J, Chansky K, Ginsberg R, Gandara DR. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (pc) chemotherapy in early stage non-small cell lung cancer (NSCLC). Follow-up on a phase III trial. Proc. ASCO J Clin Oncol 25: #7520, 2007.
299. Weiss GJ, Franklin WA, Zeng C, Tran ZV, Coldren CD, Magree L, Sugita M, Bunn Jr. PA, Kelly K. Gene predictors for extrathoracic metastases (EM) in advanced bronchioloalveolar carcinoma (BAC) of the lung obtained from formalin-fixed paraffin embedded tissue (FFPE). Proc. ASCO. J Clin Oncol 25: #7622, 2007.

300. Weiss GJ, Franklin WA, Bemis LT, Sugita M, Haney J, Bunn Jr. PA, Varella-Garcia M. HER2 and HER3 regulation in non-small cell lung cancer (NSCLC) associated with microRNAs (miRs) localized to 4q and 19q. Proc. AACR-Oncogenomics, Phoenix, AZ, 2007.
301. Bunn Jr. PA, Helfrich BA, Zeng C, Baron A, Heasley A. FGF2 and FGFRs comprise an auxiliary autocrine pathway in non-small cell lung cancer cell lines. # 81, 15th SPORE Investigators' Workshop, Baltimore, MD, 2007.
302. Drabkin, H. A., Helfrich, B., Chan, D., Phang, T., Franklin, W. A., Bunn, P., Gemmill, R. M. Strategy to identify genes responsible for EGFR-inhibitor resistance and novel biomarkers in lung cancer. 15th SPORE Investigators' Workshop, July 7-10, 2007, Baltimore, MD. Proceedings. 2007.
303. Gera, L., Simkeviciene, V., Stewart, J. M., Chan, D. C., Bunn, P. A. N-(Fluorenyl-9-methoxycarbonyl)amino acid amide derivatives as a new class of anti-cancer agents. 20th American Peptide Society Symposium, June 26-30, 2007, Montreal, Quebec, Canada. Proceedings. 2007.
304. Heasley, L. E., Marek, L., Fritzsche, A., Helton, W. R., Nemenoff, R. A., McDermott, L. A., Helfrich, B., Bunn, P. A. Dominant FGF autocrine signaling in gefitinib-resistant non-small cell lung cancer cells. Experimental Biology 2008 meeting, April 5-9, 2008, San Diego, CA. Proceedings , Abstr #4192. 2008.
305. Helfrich, B., Bunn, P., McDermott, L. A., Heasley, L. FGF2 and FGFRs comprise an auxiliary autocrine pathway in NSCLC cell lines. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S325. 2007.
306. Hirsch, F. R., Kittelson, J., Keith, R., Wolf, H., Lewis, M. T., Kennedy, T. C., Bunn, P. A., Byers, T. A., Miller, Y., Franklin, W. A. Predictive factors for preneoplasia in the bronchus. AACR's Advances and Challenges in Aerodigestive Epithelial Cancer Research: Genetics, Diagnosis, and Therapy Conference, February 6-9, 2007, Charleston, SC. Proceedings, Abstr #5629. 2007.
307. Kabbinar, F., Ross, H., Martins, R., Kelly, K., Camidge, D. R., Vokes, E., Wacker, B., Conlan, M., Hirsch, F., Bunn, P. Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-enriched, previously untreated NSCLC population. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S394. 2007.
308. Keith, R. L., Miller, Y. E., Jackson, M. K., Kittelson, J., Meisinger, V. G., Kelly, K., Hirsch, F., Franklin, W. A., Merrick, D., Bunn, P. A. Update on the use of oral iloprost for the chemoprevention of lung cancer. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S330-S331. 2007.
309. Miller, Y. E., Hyun, D. S., Keith, R. L., Kennedy, T. C., Byers, T., Bunn, P. A., Franklin, W. A., Hirsch, F. Bronchial epithelial proliferation measured by Ki-67 is related to current smoking and sex but not to lung cancer or chronic obstructive pulmonary disease. 15th SPORE Investigators' Workshop, July 7-10, 2007, Baltimore, MD. Proceedings. 2007.
310. Nakajima, E., Sugita, M., Helfrich, B., Chan, D. C., Kato, H., Bunn, P. A. Jr., Franklin, W. A., Hirsch, F. R. Putative biomarker genes for pemetrexed treatment in small and non-small cell lung cancer cell lines, detected by microarray analysis. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S508-S509. 2007.
311. Skokan, M. C., Gajapathy, S., Xiao, Y., Franklin, W. A., Hirsch, F. R., Bunn, P. A. Jr., Varella-Garcia, M. Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): Molecular patterns and sensitivity to tyrosine kinase inhibitors. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thoracic Oncol 2:(8 (Suppl 4)), S323. 2007.
312. Spreafico, A., Gregorc, V., Dziadziuszko, R., Vigano, M., Giovannini, M., Duncan, M., Bunn, P. A., Villa, E., Hirsch, F. R. Serum E-cadherin does not associate with response to gefitinib in patients with non-small cell lung cancer (NSCLC). 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S716. 2007.
313. Sugita, M., Nakajima, E., Kato, H., Bunn, P. A. Jr., Franklin, W. A., Hirsch, F. R. PCR method for detection of EGFR exon 19 deletion in NSCLC. American Association for Cancer Research Annual Meeting, April 14-18, 2007, Los Angeles, CA. Proc Am Assoc Cancer Res 48:(Suppl), Abstr #394. 2007.
314. Sugita, M., Nakajima, E., Kato, H., Bunn, P. A. Jr., Hirsch, F. R., Franklin, W. A. Sensitive PCR method detects EGFR exon19 deletions in NSCLC. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. J Thorac Oncol 2:(8 (Suppl 4)), S741. 2007.

315. Taguchi, F., Solomon, B., Gregorc, V., Heinrich, R., Gray, R., Kasahara, K., Nishi, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsy-pin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A. Jr et al. Prediction of benefit from EGFR TKIs b proteomic analysis of pretreatment serum. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. *J Thorac Oncol* 2:(8 (Suppl 4)), S167-S168. 2007.
316. Weiss, G. J., Bemis, L. T., Sugita, M., Varella-Garcia, M., Haney, J., Bunn, P. A. Jr., Franklin, W. A. MicroRNAs predicted to regulate highly expressed genes in non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) are localized to 19q. American Association for Cancer Research Annual Meeting, April 14-18, 2007, Los Angeles, CA. *Proc Am Assoc Cancer Res* 48:(Suppl), Abstr #4517. 2007.
317. Weiss, G. J., Zeng, C., Kelly, K., Tran, Z. V., Bunn, P. A., Jr. Single-Institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. *Clinical Lung Cancer* 8:(5), 335-338. 2007.
318. Weiss, G. J., Hu, Z., Peake, D., Kelly, K., Bunn, P. A. Jr., Zhou, M., Sugita, M., Keith, R., Wong, D. T. Saliva mRNA expression profiling for early stage non-small cell lung cancer (NSCLC) Screening. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. *J Thorac Oncol* 2:(8 (Suppl 4)), S817. 2007.
319. Witta, S. E., Hirsch, F. R., Lapadat, R., Dziadziuszko, R., Bunn, P. A. Jr. ErbB3 expression correlates with vorinostat and gefitinib activity and its coexpression with E-cadherin restores response to gefitinib in NSCLC. 12th World Conference on Lung Cancer, September 2-6, 2007, Seoul, South Korea. *J Thorac Oncol* 2:(8 (Suppl 4)), S445-S446. 2007.
320. Hirsch, F.R., Dziadziuszko, R., Camidge, D.R., Kabbinavar, F., Richardson, K., Richardson, F, Wacker, B., Franklin, W.A., Varella-Garcia, M., Bunn, Jr., P.A. Biomarker status correlates with clinical benefit: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin/paclitaxel (ECP) in an EGFR biomarker-selected NSCLC population. Submitted, 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.
321. Camidge, D.R., Kabbinavar, F., Martins, R., Schnell, F., Witta, S., Eisen, T., Rusk, J., Wacker, B., Hirsch, F.R., Bunn, P. A. Jr. EGFR Biomarker-selected randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naïve advanced NSCLC. Submitted, 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.
322. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol, J Clin Oncol* 27: 388, 2009.
323. Hirsch FR, Dziadziuszko R, Kabbinavar F, Camidge DR, Richardson K, Rusk J, Wacker B, Franklin WA, Varella-Garcia M, Bunn PA Jr. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naive advanced NSCLC: Biomarker status correlates with clinical benefit. *Proc Am Soc Clin Oncol, J Clin Oncol* 27: 413, 2009.
324. Witta SE; Franekova V; Igolnikov I; Yoshida K; Coldren C; Frederick B; Varella-Garcia M; Bunn PA, Jr.; Hirsch FR. Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung or head and neck cancer cell lines expressing Her2. *Proc Am Soc Clin Oncol*, submitted, 2009.
325. Franekova V; Witta SE; Bunn PA, Jr.; Hirsch FR. The HDAC inhibitor SNDX-275 synergizes with erlotinib and induces mesenchymal to epithelial transition in pancreatic carcinoma. *Proc Am Assoc Cancer Res*, 2009.
326. Conner A; Helfrich B; Chan DF; Bunn PA, Jr. EGFR expression confers resistance to IGF1R inhibition in ovarian cancer cell lines. *Proc Am Assoc Cancer*, submitted, 2009.
327. Bunn PA, Jr. Signal transduction overview. *Proceeding. J Thorac Oncol* 4: S149, 2009
328. Pisters KM, Vallieres E, Bunn P, Crowley J, Chansky K, Gandara R. S9900 trial update, mature analysis. *Proceeding. J Thorac Oncol* 4, S201, 2009.
329. Peled N, Adams O, Koichi Y, Bunn P, Haick H, Hirsch FR. The unique "smell print" of NSCLC cell lines. *Proceeding. J Thorac Oncol* 4, S329, 2009
330. Keith RL, Kittelson JK, Blatchford P, Jackson M, Franklin WA, Hirsch FR, Minna J, Bunn PA, Miller YE. Oral Iloprost improves endobronchial dysplasia in former smokers. *Proceeding, J Thorac Oncol* 4: S380, 2009.

FASCO

331. Kavanagh BD, Adulrahman R, Camidge DR, Gerber DE, Bunn PA, Schiller J, Choy H, Gasper LE, Wu, J, King T, Timmerman RD. A pilot trial of erlotinib in combination with stereotactic body irradiation therapy (SBRT) for patients with recurrent non-small cell lung cancer (NSCLC). Proceeding, J Thorac Oncol 4: S590, 2009.
332. Witta SE, Girard L, Zheng D, Zhang Z, Minna J, Bunn PA, Jr., Chan D, Hirsch FR. Cetuximab activity in non-small cell lung cancer is enhanced in vivo by the HDAC inhibitor entinostat. Proceeding, J Thorac Oncol 4: S 597, 2009
333. Chan DC, Gupta M, Zhang Z, Zheng D, Sui X, Peters W, Bunn PA, Jr. Anti-tumor activity of ADH-1 in vitro and in vivo in combination with erlotinib (Tarceva) in lung cancer cell lines. Proceeding, J Thorax Oncol 4: S795, 2009.
334. Chan DC, Zheng D, Zhang Z, Sui X, Tiffany T, Sugita M, Bunn Jr. PA. Roles of natural killer-cell immunoglobulin-like receptors (KIR) in immune escape and cancer metastasis. Proceeding, J Thorax Oncol 4: S900, 2009.
335. Chan DC, Witta SE, Zheng D, Franekova V, Sui Z, Ordentlich P, Bunn PA, Jr., Hirsch FR. Characterization of the class 1 histone deacetylase inhibitor entinostat in EGFRi acquired resistance models and in combination with cetuximab in NSCLC. Proceeding AACR, April 2010.
336. Jonsson S, Moller YE, Kennedy TC, Varella-Garcia M, Skokan M, Wolf H, Feser W, Byers T, Haney J, Merrick D, Bunn PA, Jr., Keith RL, Hirsch FR, Franklin WA. Histological and molecular characteristics of twenty-nine cases of carcinoma in situ from a prospective bronchoscope cohort. Proceeding AACR, April 2010.
337. Peled N, Hakim M, Haick H, Bunn PA, Miller YE, Kennedy TC, Mitchell JD, Weyant MJ, Hirsch FR. Use of a nanoparticle-based artificial olfactory system, NaNose to distinguish malignant from benign pulmonary nodules. Proceeding, ASCO # 10521, 2010.
338. Varella-Garcia M, Cho Y, Lu X, Baron AE, Terracciano L, Camidge DR, Bunn PA, Franklin WA, Cappuzzo F, Doebele RC. ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). Proceeding, ASCO # 10533, 2010.
339. Doebele RC, Sumey C, Maxson DA, Lu X, Baron AB, Bunn PA, Varella-Garcia M, Aisner DL, Franklin WA, Camidge DR. Oncogene Status in Lung Adenocarcinomas Predicts patterns of metastatic spread. Proceeding IASLC WCLC 2011.